US20040039033A1 - (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase - Google Patents
(1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase Download PDFInfo
- Publication number
- US20040039033A1 US20040039033A1 US10/315,818 US31581802A US2004039033A1 US 20040039033 A1 US20040039033 A1 US 20040039033A1 US 31581802 A US31581802 A US 31581802A US 2004039033 A1 US2004039033 A1 US 2004039033A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- optionally substituted
- substituted
- heteroaryl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 */N=C(\NC(CC)C1=CC=CC=C1)N([2*])[3*].CC Chemical compound */N=C(\NC(CC)C1=CC=CC=C1)N([2*])[3*].CC 0.000 description 56
- RZEAFTDKXQTDJE-UHFFFAOYSA-N CC(C)C1=CC=C(Cl)C=C1Cl Chemical compound CC(C)C1=CC=C(Cl)C=C1Cl RZEAFTDKXQTDJE-UHFFFAOYSA-N 0.000 description 17
- CZTVXRSMLZRUMJ-UHFFFAOYSA-N CC(C)C1=CC=C(F)C=C1F Chemical compound CC(C)C1=CC=C(F)C=C1F CZTVXRSMLZRUMJ-UHFFFAOYSA-N 0.000 description 14
- FHBSIIZALGOVLM-UHFFFAOYSA-N CC(C)C1=CC=C(Cl)C=C1 Chemical compound CC(C)C1=CC=C(Cl)C=C1 FHBSIIZALGOVLM-UHFFFAOYSA-N 0.000 description 10
- MGVNITAKTROLJO-UHFFFAOYSA-N CC1=CC(Cl)=C(C(C)C)C=C1 Chemical compound CC1=CC(Cl)=C(C(C)C)C=C1 MGVNITAKTROLJO-UHFFFAOYSA-N 0.000 description 8
- QEJFJGSJIQQWRC-UHFFFAOYSA-N CC(C)C1(C)CC1 Chemical compound CC(C)C1(C)CC1 QEJFJGSJIQQWRC-UHFFFAOYSA-N 0.000 description 7
- FZALJWFYGLWQEO-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CC(Cl)=C1 Chemical compound CC(C)C1=CC(Cl)=CC(Cl)=C1 FZALJWFYGLWQEO-UHFFFAOYSA-N 0.000 description 7
- HPBROFGYTXOJIO-UHFFFAOYSA-N CC(C)C1CC1 Chemical compound CC(C)C1CC1 HPBROFGYTXOJIO-UHFFFAOYSA-N 0.000 description 7
- PUKYTSMWXQOQKI-UHFFFAOYSA-N CC1=C(C(C)C)C=CC(Br)=C1 Chemical compound CC1=C(C(C)C)C=CC(Br)=C1 PUKYTSMWXQOQKI-UHFFFAOYSA-N 0.000 description 7
- DQZUIRYHGMGWFY-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(Cl)C=C1 Chemical compound CC(C)C1=CC(Cl)=C(Cl)C=C1 DQZUIRYHGMGWFY-UHFFFAOYSA-N 0.000 description 6
- MCGSDKVOKTWDRB-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CC=C1 Chemical compound CC(C)C1=CC(Cl)=CC=C1 MCGSDKVOKTWDRB-UHFFFAOYSA-N 0.000 description 6
- DPUYDFJBHDYVQM-UHFFFAOYSA-N CC(C)CC1CCCC1 Chemical compound CC(C)CC1CCCC1 DPUYDFJBHDYVQM-UHFFFAOYSA-N 0.000 description 6
- ZSTKODDIHPJZBV-UHFFFAOYSA-N CC1=C(C(C)C)C=CC(Cl)=C1 Chemical compound CC1=C(C(C)C)C=CC(Cl)=C1 ZSTKODDIHPJZBV-UHFFFAOYSA-N 0.000 description 6
- AADQFNAACHHRLT-UHFFFAOYSA-N CC1=CC(C)=C(C(C)C)C=C1 Chemical compound CC1=CC(C)=C(C(C)C)C=C1 AADQFNAACHHRLT-UHFFFAOYSA-N 0.000 description 6
- ZISSAWUMDACLOM-UHFFFAOYSA-N CC(C)C(C)(C)C Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 5
- CYDHAUACPYASTO-UHFFFAOYSA-N CC(C)C1(C)CC1(Cl)Cl Chemical compound CC(C)C1(C)CC1(Cl)Cl CYDHAUACPYASTO-UHFFFAOYSA-N 0.000 description 5
- RNEMUWDQJSRDMQ-UHFFFAOYSA-N CC(C)C1=C(Cl)C=CC=C1 Chemical compound CC(C)C1=C(Cl)C=CC=C1 RNEMUWDQJSRDMQ-UHFFFAOYSA-N 0.000 description 5
- UJHIOLUOUDCINT-UHFFFAOYSA-N CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1 Chemical compound CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1 UJHIOLUOUDCINT-UHFFFAOYSA-N 0.000 description 5
- LJCXKMJVDSCHOA-UHFFFAOYSA-N CC1=C(C(C)C)C=CC(F)=C1 Chemical compound CC1=C(C(C)C)C=CC(F)=C1 LJCXKMJVDSCHOA-UHFFFAOYSA-N 0.000 description 5
- OKVWYBALHQFVFP-UHFFFAOYSA-N CCC(C)(C)C(C)C Chemical compound CCC(C)(C)C(C)C OKVWYBALHQFVFP-UHFFFAOYSA-N 0.000 description 5
- NNZRVXTXKISCGS-UHFFFAOYSA-N COC1=C(C(C)C)C=CC=C1 Chemical compound COC1=C(C(C)C)C=CC=C1 NNZRVXTXKISCGS-UHFFFAOYSA-N 0.000 description 5
- JULZQKLZSNOEEJ-UHFFFAOYSA-N COC1=CC=C(C(C)C)C=C1 Chemical compound COC1=CC=C(C(C)C)C=C1 JULZQKLZSNOEEJ-UHFFFAOYSA-N 0.000 description 5
- FAMOAJMEFGYSNY-UHFFFAOYSA-N CC(C)C(C)(C)CO Chemical compound CC(C)C(C)(C)CO FAMOAJMEFGYSNY-UHFFFAOYSA-N 0.000 description 4
- XPQDAIPCBCVWIJ-UHFFFAOYSA-N CC(C)C1=CC2=C(C=C1)CCC2 Chemical compound CC(C)C1=CC2=C(C=C1)CCC2 XPQDAIPCBCVWIJ-UHFFFAOYSA-N 0.000 description 4
- RPQZZDWFWOIRAN-UHFFFAOYSA-N CC(C)C1=CC=C(C(F)(F)F)C=C1 Chemical compound CC(C)C1=CC=C(C(F)(F)F)C=C1 RPQZZDWFWOIRAN-UHFFFAOYSA-N 0.000 description 4
- TVSBRLGQVHJIKT-UHFFFAOYSA-N CC(C)C1CCCC1 Chemical compound CC(C)C1CCCC1 TVSBRLGQVHJIKT-UHFFFAOYSA-N 0.000 description 4
- NLYSTKLGOXKUQC-UHFFFAOYSA-N CC(C)(C)C1(C)CC1(Cl)Cl Chemical compound CC(C)(C)C1(C)CC1(Cl)Cl NLYSTKLGOXKUQC-UHFFFAOYSA-N 0.000 description 3
- NQRMTOKLHZNAQH-UHFFFAOYSA-N CC(C)C(C)C1=CC=CC=C1 Chemical compound CC(C)C(C)C1=CC=CC=C1 NQRMTOKLHZNAQH-UHFFFAOYSA-N 0.000 description 3
- LLWMDTOIHHQUHQ-UHFFFAOYSA-N CC(C)C1(C2=CC=C(Cl)C=C2)CC1 Chemical compound CC(C)C1(C2=CC=C(Cl)C=C2)CC1 LLWMDTOIHHQUHQ-UHFFFAOYSA-N 0.000 description 3
- DIEDNWZQIIEMKF-UHFFFAOYSA-N CC(C)C1=C(Cl)C=CC=C1Cl Chemical compound CC(C)C1=C(Cl)C=CC=C1Cl DIEDNWZQIIEMKF-UHFFFAOYSA-N 0.000 description 3
- AUEXDQNETNFJPI-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CC=C1Cl Chemical compound CC(C)C1=CC(Cl)=CC=C1Cl AUEXDQNETNFJPI-UHFFFAOYSA-N 0.000 description 3
- ZZWJZCURFRSZPD-UHFFFAOYSA-N CC(C)C1=CC(N(C)C)=CC=C1 Chemical compound CC(C)C1=CC(N(C)C)=CC=C1 ZZWJZCURFRSZPD-UHFFFAOYSA-N 0.000 description 3
- HDFBFSAULZZLIL-UHFFFAOYSA-N CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1 Chemical compound CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1 HDFBFSAULZZLIL-UHFFFAOYSA-N 0.000 description 3
- MJRUTYCVCLZWSR-UHFFFAOYSA-N CC(C)C1=CC=C(N(C)C)C=C1 Chemical compound CC(C)C1=CC=C(N(C)C)C=C1 MJRUTYCVCLZWSR-UHFFFAOYSA-N 0.000 description 3
- LWYFMTMRWRGREZ-UHFFFAOYSA-N CC(C)C1=CC=CC(C#N)=C1 Chemical compound CC(C)C1=CC=CC(C#N)=C1 LWYFMTMRWRGREZ-UHFFFAOYSA-N 0.000 description 3
- GDHRQDYGUDOEIZ-UHFFFAOYSA-N CC(C)CN(C)C Chemical compound CC(C)CN(C)C GDHRQDYGUDOEIZ-UHFFFAOYSA-N 0.000 description 3
- QWTDNUCVQCZILF-UHFFFAOYSA-N CCC(C)C Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 3
- GKDWDNZOCKBXMO-UHFFFAOYSA-N CCOC1=CC=C(C(C)C)C=C1 Chemical compound CCOC1=CC=C(C(C)C)C=C1 GKDWDNZOCKBXMO-UHFFFAOYSA-N 0.000 description 3
- HWINBBUYLKWIBO-UHFFFAOYSA-N COC1=CC(C(C)C)=CC=C1 Chemical compound COC1=CC(C(C)C)=CC=C1 HWINBBUYLKWIBO-UHFFFAOYSA-N 0.000 description 3
- UYVGFIKOUAFDOZ-UHFFFAOYSA-N CSCC(C)C Chemical compound CSCC(C)C UYVGFIKOUAFDOZ-UHFFFAOYSA-N 0.000 description 3
- LJUPHNZVBXVDAE-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C(C)C)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C(C)C)=C1 LJUPHNZVBXVDAE-UHFFFAOYSA-N 0.000 description 3
- CFSFQKBVHOBDHG-UHFFFAOYSA-N CC(=O)NCCC1=CN(C(C)C)C=N1 Chemical compound CC(=O)NCCC1=CN(C(C)C)C=N1 CFSFQKBVHOBDHG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N CC(C)=O Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RBGVSNKHEWLESV-UHFFFAOYSA-N CC(C)C1(C#N)CC1 Chemical compound CC(C)C1(C#N)CC1 RBGVSNKHEWLESV-UHFFFAOYSA-N 0.000 description 2
- BYPOENRTPJTXAT-UHFFFAOYSA-N CC(C)C1=CC(C(F)(F)F)=CC=C1 Chemical compound CC(C)C1=CC(C(F)(F)F)=CC=C1 BYPOENRTPJTXAT-UHFFFAOYSA-N 0.000 description 2
- TVYVQNHYIHAJTD-UHFFFAOYSA-N CC(C)C1=CC2=C(C=CC=C2)C=C1 Chemical compound CC(C)C1=CC2=C(C=CC=C2)C=C1 TVYVQNHYIHAJTD-UHFFFAOYSA-N 0.000 description 2
- MOZHUOIQYVYEPN-UHFFFAOYSA-N CC(C)C1=CC=C(Br)C=C1 Chemical compound CC(C)C1=CC=C(Br)C=C1 MOZHUOIQYVYEPN-UHFFFAOYSA-N 0.000 description 2
- GTADDTOGTOQQMD-UHFFFAOYSA-N CC(C)C1=CC=C(OC(F)(F)F)C=C1 Chemical compound CC(C)C1=CC=C(OC(F)(F)F)C=C1 GTADDTOGTOQQMD-UHFFFAOYSA-N 0.000 description 2
- LOXBELRNKUFSRD-UHFFFAOYSA-N CC(C)C1=CC=CS1 Chemical compound CC(C)C1=CC=CS1 LOXBELRNKUFSRD-UHFFFAOYSA-N 0.000 description 2
- DNJROFGCOSDKIL-UHFFFAOYSA-N CC(C)C1=CN=C(Cl)C=C1 Chemical compound CC(C)C1=CN=C(Cl)C=C1 DNJROFGCOSDKIL-UHFFFAOYSA-N 0.000 description 2
- DAAARXMHBLJQPU-UHFFFAOYSA-N CC(C)C1=COC=C1 Chemical compound CC(C)C1=COC=C1 DAAARXMHBLJQPU-UHFFFAOYSA-N 0.000 description 2
- CQHUVZYXOKFEQA-UHFFFAOYSA-N CC(C)C1CC1(Cl)Cl Chemical compound CC(C)C1CC1(Cl)Cl CQHUVZYXOKFEQA-UHFFFAOYSA-N 0.000 description 2
- RFHQRRJFJJCQDJ-UHFFFAOYSA-N CC(C)C1CCC1 Chemical compound CC(C)C1CCC1 RFHQRRJFJJCQDJ-UHFFFAOYSA-N 0.000 description 2
- LRCMZPVVFRECQR-UHFFFAOYSA-N CC(C)C1CCCC2=CC=CC=C21 Chemical compound CC(C)C1CCCC2=CC=CC=C21 LRCMZPVVFRECQR-UHFFFAOYSA-N 0.000 description 2
- GWESVXSMPKAFAS-UHFFFAOYSA-N CC(C)C1CCCCC1 Chemical compound CC(C)C1CCCCC1 GWESVXSMPKAFAS-UHFFFAOYSA-N 0.000 description 2
- NDBFBUXHYZPAPI-UHFFFAOYSA-N CC(C)CC1(C2=CC=C(Cl)C=C2)CC1 Chemical compound CC(C)CC1(C2=CC=C(Cl)C=C2)CC1 NDBFBUXHYZPAPI-UHFFFAOYSA-N 0.000 description 2
- XZUSXWMBZDIECA-UHFFFAOYSA-N CC(C)CCC1=CC=C(Cl)C=C1 Chemical compound CC(C)CCC1=CC=C(Cl)C=C1 XZUSXWMBZDIECA-UHFFFAOYSA-N 0.000 description 2
- WFLMROXVKKQYNH-UHFFFAOYSA-N CC(C)CCCN(C)C1=CC=CC=C1 Chemical compound CC(C)CCCN(C)C1=CC=CC=C1 WFLMROXVKKQYNH-UHFFFAOYSA-N 0.000 description 2
- WXUKQOZEGKXDFQ-UHFFFAOYSA-N CC(C)CCSCC1=CC=CC=C1 Chemical compound CC(C)CCSCC1=CC=CC=C1 WXUKQOZEGKXDFQ-UHFFFAOYSA-N 0.000 description 2
- UMJVKPYTXOUBSB-UHFFFAOYSA-N CC(C)N1C=NC2=CC=CC=C21 Chemical compound CC(C)N1C=NC2=CC=CC=C21 UMJVKPYTXOUBSB-UHFFFAOYSA-N 0.000 description 2
- RDTUDLGSHURRHY-UHFFFAOYSA-N CC(C)N1C=NC=N1 Chemical compound CC(C)N1C=NC=N1 RDTUDLGSHURRHY-UHFFFAOYSA-N 0.000 description 2
- QAAXBCPKKJHDSF-UHFFFAOYSA-N CC(C)N1CCC(CC2=CC=CC=C2)CC1 Chemical compound CC(C)N1CCC(CC2=CC=CC=C2)CC1 QAAXBCPKKJHDSF-UHFFFAOYSA-N 0.000 description 2
- XLZMWNWNBXSZKF-UHFFFAOYSA-N CC(C)N1CCOCC1 Chemical compound CC(C)N1CCOCC1 XLZMWNWNBXSZKF-UHFFFAOYSA-N 0.000 description 2
- HGEXOWFANSIFAZ-UHFFFAOYSA-N CC(C)NC1CCCC1 Chemical compound CC(C)NC1CCCC1 HGEXOWFANSIFAZ-UHFFFAOYSA-N 0.000 description 2
- BPWXWGQISMIPCB-UHFFFAOYSA-N CC(C)NCC1=C(F)C=C(Cl)C=C1 Chemical compound CC(C)NCC1=C(F)C=C(Cl)C=C1 BPWXWGQISMIPCB-UHFFFAOYSA-N 0.000 description 2
- OUYHOSBITBAACX-UHFFFAOYSA-N CC(C)NCCC1=NC=CC=C1 Chemical compound CC(C)NCCC1=NC=CC=C1 OUYHOSBITBAACX-UHFFFAOYSA-N 0.000 description 2
- ZOMLUJGPZRNYBF-UHFFFAOYSA-N CC1=C(C(C)C)SC=C1 Chemical compound CC1=C(C(C)C)SC=C1 ZOMLUJGPZRNYBF-UHFFFAOYSA-N 0.000 description 2
- WNGLOIPFSSQUCD-UHFFFAOYSA-N CC1=C(Cl)C=CC(C(C)C)=C1 Chemical compound CC1=C(Cl)C=CC(C(C)C)=C1 WNGLOIPFSSQUCD-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N CC1=CC=C(C(C)C)C=C1 Chemical compound CC1=CC=C(C(C)C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- XRRHERXEIHMKLC-UHFFFAOYSA-N CC1=CC=C(CC(C2=CC=CC=C2)C(C)C)C=C1 Chemical compound CC1=CC=C(CC(C2=CC=CC=C2)C(C)C)C=C1 XRRHERXEIHMKLC-UHFFFAOYSA-N 0.000 description 2
- HXTKDDGTKRUJOQ-UHFFFAOYSA-N CC1=CN(C(C)C)C=N1 Chemical compound CC1=CN(C(C)C)C=N1 HXTKDDGTKRUJOQ-UHFFFAOYSA-N 0.000 description 2
- SZJLHJKGQVZRIB-UHFFFAOYSA-N CC1=NC=CN1CC(N/C(=N\C(=O)C1=CC=CC(C#N)=C1)NC1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1Cl Chemical compound CC1=NC=CN1CC(N/C(=N\C(=O)C1=CC=CC(C#N)=C1)NC1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1Cl SZJLHJKGQVZRIB-UHFFFAOYSA-N 0.000 description 2
- GWYQEAOIAZVHCH-UHFFFAOYSA-N CC1=NSC(C(C)C)=C1 Chemical compound CC1=NSC(C(C)C)=C1 GWYQEAOIAZVHCH-UHFFFAOYSA-N 0.000 description 2
- HCPCKBJUCKOZBC-UHFFFAOYSA-N CCC(CC1=CC=C(C)C(O)=C1)C(C)C Chemical compound CCC(CC1=CC=C(C)C(O)=C1)C(C)C HCPCKBJUCKOZBC-UHFFFAOYSA-N 0.000 description 2
- NOZHSQDFCDZOAH-UHFFFAOYSA-N CCN(CCC(C)C)C1=CC(C)=CC=C1 Chemical compound CCN(CCC(C)C)C1=CC(C)=CC=C1 NOZHSQDFCDZOAH-UHFFFAOYSA-N 0.000 description 2
- AHUQAEPQRQSPMC-UHFFFAOYSA-N CCOC(=O)N1CCC(C(C)C)CC1 Chemical compound CCOC(=O)N1CCC(C(C)C)CC1 AHUQAEPQRQSPMC-UHFFFAOYSA-N 0.000 description 2
- RQUBQBFVDOLUKC-UHFFFAOYSA-N CCOCC(C)C Chemical compound CCOCC(C)C RQUBQBFVDOLUKC-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N COC(C)=O Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- IGKRCEMLHDKLEE-UHFFFAOYSA-N CSC1=CC=C(C(C)C)C=C1 Chemical compound CSC1=CC=C(C(C)C)C=C1 IGKRCEMLHDKLEE-UHFFFAOYSA-N 0.000 description 2
- QCHYQQVUOOUVLM-UHFFFAOYSA-N Cl.N#CC1=CC=C(C(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 Chemical compound Cl.N#CC1=CC=C(C(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 QCHYQQVUOOUVLM-UHFFFAOYSA-N 0.000 description 2
- QTGGFCDESWTBBI-UHFFFAOYSA-N N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F Chemical compound N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F QTGGFCDESWTBBI-UHFFFAOYSA-N 0.000 description 2
- JSDNSNGMRBMINN-UHFFFAOYSA-N N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=NC=N1)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F Chemical compound N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=NC=N1)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F JSDNSNGMRBMINN-UHFFFAOYSA-N 0.000 description 2
- XTMVQYZQKNYOCC-UHFFFAOYSA-N O=C(/N=C(/NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NCC1=CC=C(Cl)C=C1 Chemical compound O=C(/N=C(/NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NCC1=CC=C(Cl)C=C1 XTMVQYZQKNYOCC-UHFFFAOYSA-N 0.000 description 2
- DUWQRUQKMFSRRT-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(C(C)C)C=C1 Chemical compound [C-]#[N+]C1=CC=C(C(C)C)C=C1 DUWQRUQKMFSRRT-UHFFFAOYSA-N 0.000 description 2
- KMPBAEGDESUVTM-UHFFFAOYSA-N [H]N(C1=C(Cl)C=C(Cl)C=C1)/C(=N\C#N)NC(CC1=NC2=C(C=CC=C2)N1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F Chemical compound [H]N(C1=C(Cl)C=C(Cl)C=C1)/C(=N\C#N)NC(CC1=NC2=C(C=CC=C2)N1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F KMPBAEGDESUVTM-UHFFFAOYSA-N 0.000 description 2
- MOMVXPYYGZAHRC-LBPRGKRZSA-N [H][C@@](CO)(CC1=CC=CC=C1)C(C)C Chemical compound [H][C@@](CO)(CC1=CC=CC=C1)C(C)C MOMVXPYYGZAHRC-LBPRGKRZSA-N 0.000 description 2
- SRBCTUXEIURYAA-OLZOCXBDSA-N [H][C@@](COC)(C(C)C)[C@@]([H])(O)C1=CC=CC=C1 Chemical compound [H][C@@](COC)(C(C)C)[C@@]([H])(O)C1=CC=CC=C1 SRBCTUXEIURYAA-OLZOCXBDSA-N 0.000 description 2
- MOMVXPYYGZAHRC-GFCCVEGCSA-N [H][C@](CO)(CC1=CC=CC=C1)C(C)C Chemical compound [H][C@](CO)(CC1=CC=CC=C1)C(C)C MOMVXPYYGZAHRC-GFCCVEGCSA-N 0.000 description 2
- WZGRUDMGVCNMSW-GFCCVEGCSA-N [H][C@](NC(C)C)(C(=O)OCC)C1=CC=CC=C1 Chemical compound [H][C@](NC(C)C)(C(=O)OCC)C1=CC=CC=C1 WZGRUDMGVCNMSW-GFCCVEGCSA-N 0.000 description 2
- CNWRIAFGYXZRJN-ZIKNSQGESA-N C/C=C/C1(CC)CCC1.CCCC1(CC)CC1 Chemical compound C/C=C/C1(CC)CCC1.CCCC1(CC)CC1 CNWRIAFGYXZRJN-ZIKNSQGESA-N 0.000 description 1
- DAEJFWMDVJJZPN-UHFFFAOYSA-N C1=CSC=N1.CC Chemical compound C1=CSC=N1.CC DAEJFWMDVJJZPN-UHFFFAOYSA-N 0.000 description 1
- PDLCCNYKIIUWHA-UHFFFAOYSA-N CC(=O)C1=CC=C(C(C)C)C=C1 Chemical compound CC(=O)C1=CC=C(C(C)C)C=C1 PDLCCNYKIIUWHA-UHFFFAOYSA-N 0.000 description 1
- MDTNHRGBSZPRNI-UHFFFAOYSA-N CC(=O)C1CC(CC(C)C)C1(C)C Chemical compound CC(=O)C1CC(CC(C)C)C1(C)C MDTNHRGBSZPRNI-UHFFFAOYSA-N 0.000 description 1
- WAGUWLSTIVCYLG-UHFFFAOYSA-N CC(=O)NC1=CC=CC(C(C)C)=C1 Chemical compound CC(=O)NC1=CC=CC(C(C)C)=C1 WAGUWLSTIVCYLG-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N CC(=O)OC(C)C Chemical compound CC(=O)OC(C)C JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- ZFHLUUHAMWNEJI-UHFFFAOYSA-N CC(C)(C)C1=CC(Cl)=CC(Cl)=C1 Chemical compound CC(C)(C)C1=CC(Cl)=CC(Cl)=C1 ZFHLUUHAMWNEJI-UHFFFAOYSA-N 0.000 description 1
- HIUJUJQGZWLWAN-UHFFFAOYSA-N CC(C)(C)C1=CC2=C(C=C1)CCC2 Chemical compound CC(C)(C)C1=CC2=C(C=C1)CCC2 HIUJUJQGZWLWAN-UHFFFAOYSA-N 0.000 description 1
- JZVUKVQULLPJCD-UHFFFAOYSA-N CC(C)(C)C1=CC=C(Cl)C=C1Br Chemical compound CC(C)(C)C1=CC=C(Cl)C=C1Br JZVUKVQULLPJCD-UHFFFAOYSA-N 0.000 description 1
- XHMMRLCYBCKKBB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(Cl)C=C1Cl Chemical compound CC(C)(C)C1=CC=C(Cl)C=C1Cl XHMMRLCYBCKKBB-UHFFFAOYSA-N 0.000 description 1
- KGUHTGQIVJNWTA-UHFFFAOYSA-N CC(C)(C)C1=CC=C(S(=O)(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1.CC(C)(C)C1=CC=C(S(=O)(=O)Cl)C=C1.CC(C)(C)C1=CC=C(S(=O)(=O)NC(=S)NC2=CC=C(Cl)C=C2)C=C1.CC(C)(C)C1=CC=C(S(N)(=O)=O)C=C1.N.NC(CN1C=CN=C1)C1=C(Cl)C=C(Cl)C=C1.O.S=C=NC1=CC=C(Cl)C=C1.[NaH] Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1.CC(C)(C)C1=CC=C(S(=O)(=O)Cl)C=C1.CC(C)(C)C1=CC=C(S(=O)(=O)NC(=S)NC2=CC=C(Cl)C=C2)C=C1.CC(C)(C)C1=CC=C(S(N)(=O)=O)C=C1.N.NC(CN1C=CN=C1)C1=C(Cl)C=C(Cl)C=C1.O.S=C=NC1=CC=C(Cl)C=C1.[NaH] KGUHTGQIVJNWTA-UHFFFAOYSA-N 0.000 description 1
- NGKNFUDRZUUCNB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(S(=O)(=O)N=C(NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)N=C(NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 NGKNFUDRZUUCNB-UHFFFAOYSA-N 0.000 description 1
- ZNSDWIACRLCNRG-UHFFFAOYSA-N CC(C)(C)C1=CC=C(S(=O)(=O)NC(=S)NC2=CC=C(Cl)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)NC(=S)NC2=CC=C(Cl)C=C2)C=C1 ZNSDWIACRLCNRG-UHFFFAOYSA-N 0.000 description 1
- ZQWHWRQRGKZTSE-UHFFFAOYSA-N CC(C)(C)C1=NC2=C(C=CC=C2)N1 Chemical compound CC(C)(C)C1=NC2=C(C=CC=C2)N1 ZQWHWRQRGKZTSE-UHFFFAOYSA-N 0.000 description 1
- WRULTDVOSNQBHM-UHFFFAOYSA-N CC(C)(C)C1CCC(N/C(=N/C(=O)C2=CC=CC(C#N)=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)CC1 Chemical compound CC(C)(C)C1CCC(N/C(=N/C(=O)C2=CC=CC(C#N)=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)CC1 WRULTDVOSNQBHM-UHFFFAOYSA-N 0.000 description 1
- QXFYJDKPZSNCBB-UHFFFAOYSA-N CC(C)=CC1C(C(C)C)C1(C)C Chemical compound CC(C)=CC1C(C(C)C)C1(C)C QXFYJDKPZSNCBB-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N CC(C)C(C)C Chemical compound CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QZBSQQAXFOJXTD-UHFFFAOYSA-N CC(C)C(C)C(=O)NC1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)C(C)C(=O)NC1=CC2=CC=CC=C2C=C1 QZBSQQAXFOJXTD-UHFFFAOYSA-N 0.000 description 1
- XOHUWXPFOCLKDT-UHFFFAOYSA-N CC(C)C(C)C(=O)NC1=CC=CC2=CC=CC=C21 Chemical compound CC(C)C(C)C(=O)NC1=CC=CC2=CC=CC=C21 XOHUWXPFOCLKDT-UHFFFAOYSA-N 0.000 description 1
- STUMXRIBJALNEO-UHFFFAOYSA-N CC(C)C(C)C1=CC=CC2=CC=CC=C21 Chemical compound CC(C)C(C)C1=CC=CC2=CC=CC=C21 STUMXRIBJALNEO-UHFFFAOYSA-N 0.000 description 1
- WYYWMBKUPQWNRU-UHFFFAOYSA-N CC(C)C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C)C(C1=CC=CC=C1)C1=CC=CC=C1 WYYWMBKUPQWNRU-UHFFFAOYSA-N 0.000 description 1
- XGJDCBYCYSDZJK-UHFFFAOYSA-N CC(C)C(CC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C)C(CC1=CC=CC=C1)C1=CC=CC=C1 XGJDCBYCYSDZJK-UHFFFAOYSA-N 0.000 description 1
- QXALUNHYJJONQH-UHFFFAOYSA-N CC(C)C(F)(F)F Chemical compound CC(C)C(F)(F)F QXALUNHYJJONQH-UHFFFAOYSA-N 0.000 description 1
- ZXVORZUKRZRPFH-UHFFFAOYSA-N CC(C)C1(NC(=O)OC(C)(C)C)CC1 Chemical compound CC(C)C1(NC(=O)OC(C)(C)C)CC1 ZXVORZUKRZRPFH-UHFFFAOYSA-N 0.000 description 1
- LRMXTWCDIPSDCW-UHFFFAOYSA-N CC(C)C1=C(C(F)(F)F)C=CC=C1 Chemical compound CC(C)C1=C(C(F)(F)F)C=CC=C1 LRMXTWCDIPSDCW-UHFFFAOYSA-N 0.000 description 1
- DQLQVCHFECTFEG-UHFFFAOYSA-N CC(C)C1=C(Cl)C=C(Cl)C=C1Cl Chemical compound CC(C)C1=C(Cl)C=C(Cl)C=C1Cl DQLQVCHFECTFEG-UHFFFAOYSA-N 0.000 description 1
- ICTCCOUARBGHFR-UHFFFAOYSA-N CC(C)C1=C(F)C=CC=C1 Chemical compound CC(C)C1=C(F)C=CC=C1 ICTCCOUARBGHFR-UHFFFAOYSA-N 0.000 description 1
- BSMKYQUHXQAVKG-UHFFFAOYSA-N CC(C)C1=C([N+](=O)[O-])C=CC=C1 Chemical compound CC(C)C1=C([N+](=O)[O-])C=CC=C1 BSMKYQUHXQAVKG-UHFFFAOYSA-N 0.000 description 1
- MXNUVOXCJHNYLV-UHFFFAOYSA-N CC(C)C1=CC(C(C)(C)C)=NO1 Chemical compound CC(C)C1=CC(C(C)(C)C)=NO1 MXNUVOXCJHNYLV-UHFFFAOYSA-N 0.000 description 1
- NENPOZZSGMXQFI-UHFFFAOYSA-N CC(C)C1=CC(C(F)(F)F)=C(Cl)C=C1 Chemical compound CC(C)C1=CC(C(F)(F)F)=C(Cl)C=C1 NENPOZZSGMXQFI-UHFFFAOYSA-N 0.000 description 1
- QLDQUTIKZDTKRB-UHFFFAOYSA-N CC(C)C1=CC(C2=CC=CC=C2)=NO1 Chemical compound CC(C)C1=CC(C2=CC=CC=C2)=NO1 QLDQUTIKZDTKRB-UHFFFAOYSA-N 0.000 description 1
- SFGKLAWTOXLADM-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(Cl)C(Cl)=C1 Chemical compound CC(C)C1=CC(Cl)=C(Cl)C(Cl)=C1 SFGKLAWTOXLADM-UHFFFAOYSA-N 0.000 description 1
- PKJUHJHUTCAWSZ-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(F)C=C1 Chemical compound CC(C)C1=CC(Cl)=C(F)C=C1 PKJUHJHUTCAWSZ-UHFFFAOYSA-N 0.000 description 1
- MRALPINBULDTKA-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CC=C1[N+](=O)[O-] Chemical compound CC(C)C1=CC(Cl)=CC=C1[N+](=O)[O-] MRALPINBULDTKA-UHFFFAOYSA-N 0.000 description 1
- NAYXHKRRAWPEKG-UHFFFAOYSA-N CC(C)C1=CC(F)=CC=C1 Chemical compound CC(C)C1=CC(F)=CC=C1 NAYXHKRRAWPEKG-UHFFFAOYSA-N 0.000 description 1
- SGPFUCRQUZMQCP-UHFFFAOYSA-N CC(C)C1=CC(S(C)(=O)=O)=CC=C1 Chemical compound CC(C)C1=CC(S(C)(=O)=O)=CC=C1 SGPFUCRQUZMQCP-UHFFFAOYSA-N 0.000 description 1
- LBMWSYKMVSBGRF-UHFFFAOYSA-N CC(C)C1=CC([N+](=O)[O-])=C(Cl)C=C1 Chemical compound CC(C)C1=CC([N+](=O)[O-])=C(Cl)C=C1 LBMWSYKMVSBGRF-UHFFFAOYSA-N 0.000 description 1
- ATIDOGVSLYMUAS-UHFFFAOYSA-N CC(C)C1=CC=C(Br)C=C1C1=CC=CC=C1 Chemical compound CC(C)C1=CC=C(Br)C=C1C1=CC=CC=C1 ATIDOGVSLYMUAS-UHFFFAOYSA-N 0.000 description 1
- YEWSCYBYXNKOTF-UHFFFAOYSA-N CC(C)C1=CC=C(C(C#N)C2=CC=CC=C2)C(Cl)=C1 Chemical compound CC(C)C1=CC=C(C(C#N)C2=CC=CC=C2)C(Cl)=C1 YEWSCYBYXNKOTF-UHFFFAOYSA-N 0.000 description 1
- VBSMBCNJCBKQFP-UHFFFAOYSA-N CC(C)C1=CC=C(C(C)(C)O)C=C1 Chemical compound CC(C)C1=CC=C(C(C)(C)O)C=C1 VBSMBCNJCBKQFP-UHFFFAOYSA-N 0.000 description 1
- SPPWGCYEYAMHDT-UHFFFAOYSA-N CC(C)C1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(C(C)C)C=C1 SPPWGCYEYAMHDT-UHFFFAOYSA-N 0.000 description 1
- LPWMXVJCBUKVQH-UHFFFAOYSA-N CC(C)C1=CC=C(C(C)O)C=C1 Chemical compound CC(C)C1=CC=C(C(C)O)C=C1 LPWMXVJCBUKVQH-UHFFFAOYSA-N 0.000 description 1
- QBSLLBRETIZNRI-UHFFFAOYSA-N CC(C)C1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1 Chemical compound CC(C)C1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1 QBSLLBRETIZNRI-UHFFFAOYSA-N 0.000 description 1
- KWSHGRJUSUJPQD-UHFFFAOYSA-N CC(C)C1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC(C)C1=CC=C(C2=CC=CC=C2)C=C1 KWSHGRJUSUJPQD-UHFFFAOYSA-N 0.000 description 1
- KXSYMLMTVWUDDP-UHFFFAOYSA-N CC(C)C1=CC=C(C2CCCCC2)C=C1 Chemical compound CC(C)C1=CC=C(C2CCCCC2)C=C1 KXSYMLMTVWUDDP-UHFFFAOYSA-N 0.000 description 1
- CUZLZNSEKVTOIM-UHFFFAOYSA-N CC(C)C1=CC=C(CC2=CC=NC=C2)C=C1 Chemical compound CC(C)C1=CC=C(CC2=CC=NC=C2)C=C1 CUZLZNSEKVTOIM-UHFFFAOYSA-N 0.000 description 1
- XZISOEPNTDOUEA-UHFFFAOYSA-N CC(C)C1=CC=C(F)C=C1 Chemical compound CC(C)C1=CC=C(F)C=C1 XZISOEPNTDOUEA-UHFFFAOYSA-N 0.000 description 1
- RYIJFWGCIXQLKT-UHFFFAOYSA-N CC(C)C1=CC=C(O)C(Cl)=C1 Chemical compound CC(C)C1=CC=C(O)C(Cl)=C1 RYIJFWGCIXQLKT-UHFFFAOYSA-N 0.000 description 1
- LTRDTHLAKOBLDW-UHFFFAOYSA-N CC(C)C1=CC=C(S(C)(=O)=O)C=C1 Chemical compound CC(C)C1=CC=C(S(C)(=O)=O)C=C1 LTRDTHLAKOBLDW-UHFFFAOYSA-N 0.000 description 1
- WVOWEROKBOQYLJ-UHFFFAOYSA-N CC(C)C1=CC=C(S(N)(=O)=O)C=C1 Chemical compound CC(C)C1=CC=C(S(N)(=O)=O)C=C1 WVOWEROKBOQYLJ-UHFFFAOYSA-N 0.000 description 1
- HAYFAWCFEINMAK-UHFFFAOYSA-N CC(C)C1=CC=C2COC(=O)C2=C1 Chemical compound CC(C)C1=CC=C2COC(=O)C2=C1 HAYFAWCFEINMAK-UHFFFAOYSA-N 0.000 description 1
- SIZCAMBYKFGFAR-UHFFFAOYSA-N CC(C)C1=CC=C2N=CSC2=C1 Chemical compound CC(C)C1=CC=C2N=CSC2=C1 SIZCAMBYKFGFAR-UHFFFAOYSA-N 0.000 description 1
- NYCKJGRASIXRFK-UHFFFAOYSA-N CC(C)C1=CC=CC(Cl)=C1Cl Chemical compound CC(C)C1=CC=CC(Cl)=C1Cl NYCKJGRASIXRFK-UHFFFAOYSA-N 0.000 description 1
- YCKRJNYTGWQAON-UHFFFAOYSA-N CC(C)C1=CC=CC(Cl)=C1F Chemical compound CC(C)C1=CC=CC(Cl)=C1F YCKRJNYTGWQAON-UHFFFAOYSA-N 0.000 description 1
- PMPBFICDXLLSRM-UHFFFAOYSA-N CC(C)C1=CC=CC2=CC=CC=C21 Chemical compound CC(C)C1=CC=CC2=CC=CC=C21 PMPBFICDXLLSRM-UHFFFAOYSA-N 0.000 description 1
- RWGFKTVRMDUZSP-UHFFFAOYSA-N CC(C)C1=CC=CC=C1 Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 1
- LWLOIGPQGSROHK-UHFFFAOYSA-N CC(C)C1=CC=CN1C Chemical compound CC(C)C1=CC=CN1C LWLOIGPQGSROHK-UHFFFAOYSA-N 0.000 description 1
- AFOPCURQYRRFRQ-UHFFFAOYSA-N CC(C)C1=CC=CO1 Chemical compound CC(C)C1=CC=CO1 AFOPCURQYRRFRQ-UHFFFAOYSA-N 0.000 description 1
- PUACTIIESPYWSI-UHFFFAOYSA-N CC(C)C1=CN=CC=C1 Chemical compound CC(C)C1=CN=CC=C1 PUACTIIESPYWSI-UHFFFAOYSA-N 0.000 description 1
- ZVUKYLSLULGIAB-UHFFFAOYSA-N CC(C)C1=NC(C2=CC=CC=C2)=NS1 Chemical compound CC(C)C1=NC(C2=CC=CC=C2)=NS1 ZVUKYLSLULGIAB-UHFFFAOYSA-N 0.000 description 1
- LBUMAFWRDUMLPD-UHFFFAOYSA-N CC(C)C1=NC2=C(CCC2)S1 Chemical compound CC(C)C1=NC2=C(CCC2)S1 LBUMAFWRDUMLPD-UHFFFAOYSA-N 0.000 description 1
- QJGAEMVYBOUKQI-UHFFFAOYSA-N CC(C)C1=NC=C(Cl)S1 Chemical compound CC(C)C1=NC=C(Cl)S1 QJGAEMVYBOUKQI-UHFFFAOYSA-N 0.000 description 1
- LONFGLKCTPTOKA-UHFFFAOYSA-N CC(C)C1=NN=C(C(F)(F)F)S1 Chemical compound CC(C)C1=NN=C(C(F)(F)F)S1 LONFGLKCTPTOKA-UHFFFAOYSA-N 0.000 description 1
- FEWZURCKMOEMGZ-UHFFFAOYSA-N CC(C)C1=NOC(C(C)(C)C)=C1 Chemical compound CC(C)C1=NOC(C(C)(C)C)=C1 FEWZURCKMOEMGZ-UHFFFAOYSA-N 0.000 description 1
- URGXPBMKGUEYAX-UHFFFAOYSA-N CC(C)C1C(C)(C)C1(C)C Chemical compound CC(C)C1C(C)(C)C1(C)C URGXPBMKGUEYAX-UHFFFAOYSA-N 0.000 description 1
- JDZVNQMEYFJAND-UHFFFAOYSA-N CC(C)C1CC1C Chemical compound CC(C)C1CC1C JDZVNQMEYFJAND-UHFFFAOYSA-N 0.000 description 1
- HOWRLXGUHZATCY-UHFFFAOYSA-N CC(C)C1CC2=CC=CC=C2C1 Chemical compound CC(C)C1CC2=CC=CC=C2C1 HOWRLXGUHZATCY-UHFFFAOYSA-N 0.000 description 1
- SPDGGMLOTGMUGR-UHFFFAOYSA-N CC(C)C1CC2CCC1C2 Chemical compound CC(C)C1CC2CCC1C2 SPDGGMLOTGMUGR-UHFFFAOYSA-N 0.000 description 1
- DAPPPBKQVCURPG-UHFFFAOYSA-N CC(C)C1CCC(C(C)(C)C)CC1 Chemical compound CC(C)C1CCC(C(C)(C)C)CC1 DAPPPBKQVCURPG-UHFFFAOYSA-N 0.000 description 1
- FLUHDWXWFRCIFJ-UHFFFAOYSA-N CC(C)C1CCC2=CC=CC=C21 Chemical compound CC(C)C1CCC2=CC=CC=C21 FLUHDWXWFRCIFJ-UHFFFAOYSA-N 0.000 description 1
- SCHUXJDKKORFPW-UHFFFAOYSA-N CC(C)C1CCCC(C)C1C Chemical compound CC(C)C1CCCC(C)C1C SCHUXJDKKORFPW-UHFFFAOYSA-N 0.000 description 1
- WKSZKSJVOTWTTG-UHFFFAOYSA-N CC(C)C1CCN(CC2=CC=CC=C2)C1 Chemical compound CC(C)C1CCN(CC2=CC=CC=C2)C1 WKSZKSJVOTWTTG-UHFFFAOYSA-N 0.000 description 1
- CNOIDYXZYNKDMI-UHFFFAOYSA-N CC(C)C1CCN(CC2=CC=CC=C2)CC1 Chemical compound CC(C)C1CCN(CC2=CC=CC=C2)CC1 CNOIDYXZYNKDMI-UHFFFAOYSA-N 0.000 description 1
- ZAZKXCPCFVOYJW-UHFFFAOYSA-N CC(C)C1CN2CCC1CC2 Chemical compound CC(C)C1CN2CCC1CC2 ZAZKXCPCFVOYJW-UHFFFAOYSA-N 0.000 description 1
- QSNQVTQNRRKXSG-UHFFFAOYSA-N CC(C)C1SC(C2=CC=C(C(F)(F)F)C=C2)=NC1C Chemical compound CC(C)C1SC(C2=CC=C(C(F)(F)F)C=C2)=NC1C QSNQVTQNRRKXSG-UHFFFAOYSA-N 0.000 description 1
- PDQCEOHPACOFEO-UHFFFAOYSA-N CC(C)CC(C)C1=CC=C(Cl)C=C1 Chemical compound CC(C)CC(C)C1=CC=C(Cl)C=C1 PDQCEOHPACOFEO-UHFFFAOYSA-N 0.000 description 1
- MAUAHKQOJAFLQH-UHFFFAOYSA-N CC(C)CC(C)C1=CC=CC=C1 Chemical compound CC(C)CC(C)C1=CC=CC=C1 MAUAHKQOJAFLQH-UHFFFAOYSA-N 0.000 description 1
- WVYWICLMDOOCFB-UHFFFAOYSA-N CC(C)CC(C)O Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 description 1
- VLMDOKCOURAQDR-UHFFFAOYSA-N CC(C)CC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C)CC(C1=CC=CC=C1)C1=CC=CC=C1 VLMDOKCOURAQDR-UHFFFAOYSA-N 0.000 description 1
- KWXSTAUVUZAMGW-UHFFFAOYSA-N CC(C)CC(O)C1=CC=CC=C1 Chemical compound CC(C)CC(O)C1=CC=CC=C1 KWXSTAUVUZAMGW-UHFFFAOYSA-N 0.000 description 1
- JPCSCXJJRXMWBA-UHFFFAOYSA-N CC(C)CC1=C(Cl)C=C(Cl)C=C1 Chemical compound CC(C)CC1=C(Cl)C=C(Cl)C=C1 JPCSCXJJRXMWBA-UHFFFAOYSA-N 0.000 description 1
- GDGIWTCMODZHAM-UHFFFAOYSA-N CC(C)CC1=C(Cl)C=CC(Cl)=C1 Chemical compound CC(C)CC1=C(Cl)C=CC(Cl)=C1 GDGIWTCMODZHAM-UHFFFAOYSA-N 0.000 description 1
- SOXCUYKWCXNSJN-UHFFFAOYSA-N CC(C)CC1=C(Cl)C=CC=C1 Chemical compound CC(C)CC1=C(Cl)C=CC=C1 SOXCUYKWCXNSJN-UHFFFAOYSA-N 0.000 description 1
- LMZINBIBRUZJON-UHFFFAOYSA-N CC(C)CC1=C(Cl)C=CC=C1OC1=CC=CC=C1 Chemical compound CC(C)CC1=C(Cl)C=CC=C1OC1=CC=CC=C1 LMZINBIBRUZJON-UHFFFAOYSA-N 0.000 description 1
- HLSPCKDFGCRDJW-UHFFFAOYSA-N CC(C)CC1=C(F)C=C(Cl)C=C1 Chemical compound CC(C)CC1=C(F)C=C(Cl)C=C1 HLSPCKDFGCRDJW-UHFFFAOYSA-N 0.000 description 1
- XQLDRIMCYVUIMT-UHFFFAOYSA-N CC(C)CC1=C(SC2=CC=CC=C2CO)C=CC=C1 Chemical compound CC(C)CC1=C(SC2=CC=CC=C2CO)C=CC=C1 XQLDRIMCYVUIMT-UHFFFAOYSA-N 0.000 description 1
- ZXDIUHDYAISCGL-UHFFFAOYSA-N CC(C)CC1=CC(Cl)=C(Cl)C=C1 Chemical compound CC(C)CC1=CC(Cl)=C(Cl)C=C1 ZXDIUHDYAISCGL-UHFFFAOYSA-N 0.000 description 1
- NPNPUGOJVKWSIF-UHFFFAOYSA-N CC(C)CC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC(C)CC1=CC(Cl)=CC(Cl)=C1 NPNPUGOJVKWSIF-UHFFFAOYSA-N 0.000 description 1
- PKKJRVCAVQMBJE-UHFFFAOYSA-N CC(C)CC1=CC(F)=CC(F)=C1 Chemical compound CC(C)CC1=CC(F)=CC(F)=C1 PKKJRVCAVQMBJE-UHFFFAOYSA-N 0.000 description 1
- WMZGKBNDKLBTAT-UHFFFAOYSA-N CC(C)CC1=CC(I)=CC=C1 Chemical compound CC(C)CC1=CC(I)=CC=C1 WMZGKBNDKLBTAT-UHFFFAOYSA-N 0.000 description 1
- PCYRHVCROYSFSX-UHFFFAOYSA-N CC(C)CC1=CC2=C(C=C1)OCO2 Chemical compound CC(C)CC1=CC2=C(C=C1)OCO2 PCYRHVCROYSFSX-UHFFFAOYSA-N 0.000 description 1
- OHLHYHRZBBMYPE-UHFFFAOYSA-N CC(C)CC1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)CC1=CC2=CC=CC=C2C=C1 OHLHYHRZBBMYPE-UHFFFAOYSA-N 0.000 description 1
- BVBHVVRVSMBCPW-UHFFFAOYSA-N CC(C)CC1=CC=C(Br)C=C1 Chemical compound CC(C)CC1=CC=C(Br)C=C1 BVBHVVRVSMBCPW-UHFFFAOYSA-N 0.000 description 1
- DASMSBKLVCOMSG-UHFFFAOYSA-N CC(C)CC1=CC=C(C2CSN=N2)C=C1 Chemical compound CC(C)CC1=CC=C(C2CSN=N2)C=C1 DASMSBKLVCOMSG-UHFFFAOYSA-N 0.000 description 1
- LSBAAZBMKRLQJZ-UHFFFAOYSA-N CC(C)CC1=CC=C(Cl)C=C1 Chemical compound CC(C)CC1=CC=C(Cl)C=C1 LSBAAZBMKRLQJZ-UHFFFAOYSA-N 0.000 description 1
- XXXRTRXRQTWRNP-UHFFFAOYSA-N CC(C)CC1=CC=CC(C(F)(F)F)=C1 Chemical compound CC(C)CC1=CC=CC(C(F)(F)F)=C1 XXXRTRXRQTWRNP-UHFFFAOYSA-N 0.000 description 1
- KXUHSQYYJYAXGZ-UHFFFAOYSA-N CC(C)CC1=CC=CC=C1 Chemical compound CC(C)CC1=CC=CC=C1 KXUHSQYYJYAXGZ-UHFFFAOYSA-N 0.000 description 1
- DEGXTCKEZCCZOP-UHFFFAOYSA-N CC(C)CC1=CN=CC=C1 Chemical compound CC(C)CC1=CN=CC=C1 DEGXTCKEZCCZOP-UHFFFAOYSA-N 0.000 description 1
- NAAQKMWATRJPAE-UHFFFAOYSA-N CC(C)CC1=CSC2=CC=CC=C12 Chemical compound CC(C)CC1=CSC2=CC=CC=C12 NAAQKMWATRJPAE-UHFFFAOYSA-N 0.000 description 1
- XIMCWSMVGVJQQN-UHFFFAOYSA-N CC(C)CC1CC1 Chemical compound CC(C)CC1CC1 XIMCWSMVGVJQQN-UHFFFAOYSA-N 0.000 description 1
- YPDGHBILOUMNMC-UHFFFAOYSA-N CC(C)CC1COC2=CC=CC=C2O1 Chemical compound CC(C)CC1COC2=CC=CC=C2O1 YPDGHBILOUMNMC-UHFFFAOYSA-N 0.000 description 1
- LVAQAVMTGMJWJG-UHFFFAOYSA-N CC(C)CCC1=C(Cl)C=C(Cl)C=C1 Chemical compound CC(C)CCC1=C(Cl)C=C(Cl)C=C1 LVAQAVMTGMJWJG-UHFFFAOYSA-N 0.000 description 1
- JRIPTFISENCJRO-UHFFFAOYSA-N CC(C)CCC1=CC(Cl)=CC=C1 Chemical compound CC(C)CCC1=CC(Cl)=CC=C1 JRIPTFISENCJRO-UHFFFAOYSA-N 0.000 description 1
- VMYCBRCROUQELU-UHFFFAOYSA-N CC(C)CCC1=CC(OCC2=CC=CC=C2)=C(OCC2=CC=CC=C2)C=C1 Chemical compound CC(C)CCC1=CC(OCC2=CC=CC=C2)=C(OCC2=CC=CC=C2)C=C1 VMYCBRCROUQELU-UHFFFAOYSA-N 0.000 description 1
- CRKOOBBDUSAJFV-UHFFFAOYSA-N CC(C)CCC1=CC=C(Br)C=C1 Chemical compound CC(C)CCC1=CC=C(Br)C=C1 CRKOOBBDUSAJFV-UHFFFAOYSA-N 0.000 description 1
- INVDVZUTHBLQOD-UHFFFAOYSA-N CC(C)CCC1=CC=C(OC2=CC=CC=C2)C=C1 Chemical compound CC(C)CCC1=CC=C(OC2=CC=CC=C2)C=C1 INVDVZUTHBLQOD-UHFFFAOYSA-N 0.000 description 1
- XNXIYYFOYIUJIW-UHFFFAOYSA-N CC(C)CCC1=CC=CC=C1 Chemical compound CC(C)CCC1=CC=CC=C1 XNXIYYFOYIUJIW-UHFFFAOYSA-N 0.000 description 1
- VTFSAOVBFNTODP-UHFFFAOYSA-N CC(C)CCC1=CNC2=CC=C(OCC3=CC=CC=C3)C=C12 Chemical compound CC(C)CCC1=CNC2=CC=C(OCC3=CC=CC=C3)C=C12 VTFSAOVBFNTODP-UHFFFAOYSA-N 0.000 description 1
- RIQHEIKMKGOIQN-UHFFFAOYSA-N CC(C)CCC1=CNC2=CC=CC=C12 Chemical compound CC(C)CCC1=CNC2=CC=CC=C12 RIQHEIKMKGOIQN-UHFFFAOYSA-N 0.000 description 1
- SUMOGCZUNXXYRP-UHFFFAOYSA-N CC(C)CCCC1=CC=CC=C1 Chemical compound CC(C)CCCC1=CC=CC=C1 SUMOGCZUNXXYRP-UHFFFAOYSA-N 0.000 description 1
- DWPOQXHQARBRER-UHFFFAOYSA-N CC(C)CCCN1CCCC1=O Chemical compound CC(C)CCCN1CCCC1=O DWPOQXHQARBRER-UHFFFAOYSA-N 0.000 description 1
- YIYSIMLIWDXTER-UHFFFAOYSA-N CC(C)CCCN1CCOCC1 Chemical compound CC(C)CCCN1CCOCC1 YIYSIMLIWDXTER-UHFFFAOYSA-N 0.000 description 1
- KOOQJINBDNZUTB-UHFFFAOYSA-N CC(C)CCN(C)C Chemical compound CC(C)CCN(C)C KOOQJINBDNZUTB-UHFFFAOYSA-N 0.000 description 1
- PWMYYGYCTJRBBX-UHFFFAOYSA-N CC(C)CCN1CCCCC1 Chemical compound CC(C)CCN1CCCCC1 PWMYYGYCTJRBBX-UHFFFAOYSA-N 0.000 description 1
- XTIWDQSGPGJYNH-UHFFFAOYSA-N CC(C)CCNC1=CC=CC2=C1C=CC=C2 Chemical compound CC(C)CCNC1=CC=CC2=C1C=CC=C2 XTIWDQSGPGJYNH-UHFFFAOYSA-N 0.000 description 1
- OCZBPNBIXHLBFM-UHFFFAOYSA-N CC(C)N(C(C)C)C1CCCCC1 Chemical compound CC(C)N(C(C)C)C1CCCCC1 OCZBPNBIXHLBFM-UHFFFAOYSA-N 0.000 description 1
- NFOIDBSVEXPOOU-UHFFFAOYSA-N CC(C)N(C)C1CCN(C)CC1 Chemical compound CC(C)N(C)C1CCN(C)CC1 NFOIDBSVEXPOOU-UHFFFAOYSA-N 0.000 description 1
- ZULJJRIKBVTCFO-UHFFFAOYSA-N CC(C)N(C)CC1=C2C=CC=CC2=CC2=CC=CC=C21 Chemical compound CC(C)N(C)CC1=C2C=CC=CC2=CC2=CC=CC=C21 ZULJJRIKBVTCFO-UHFFFAOYSA-N 0.000 description 1
- BXNMPLQBRJFVDG-UHFFFAOYSA-N CC(C)N(C)CC1=CC(Cl)=C(Cl)C=C1 Chemical compound CC(C)N(C)CC1=CC(Cl)=C(Cl)C=C1 BXNMPLQBRJFVDG-UHFFFAOYSA-N 0.000 description 1
- WFMUJLWWGDJDBF-UHFFFAOYSA-N CC(C)N(C)CC1=CC=CC=C1 Chemical compound CC(C)N(C)CC1=CC=CC=C1 WFMUJLWWGDJDBF-UHFFFAOYSA-N 0.000 description 1
- HLJOCCQVHGRQPB-UHFFFAOYSA-N CC(C)N(CC1=CC=CC=C1)CC1=CC=CC=C1 Chemical compound CC(C)N(CC1=CC=CC=C1)CC1=CC=CC=C1 HLJOCCQVHGRQPB-UHFFFAOYSA-N 0.000 description 1
- NWEGNBKTAWAGNQ-UHFFFAOYSA-N CC(C)N1CC=C(C2=CC=C(Cl)C=C2)CC1 Chemical compound CC(C)N1CC=C(C2=CC=C(Cl)C=C2)CC1 NWEGNBKTAWAGNQ-UHFFFAOYSA-N 0.000 description 1
- XCNAPBRWCDLTKB-UHFFFAOYSA-N CC(C)N1CC=CCC1 Chemical compound CC(C)N1CC=CCC1 XCNAPBRWCDLTKB-UHFFFAOYSA-N 0.000 description 1
- NFANQYWJYLBRCH-UHFFFAOYSA-N CC(C)N1CCC(N2C(=O)NC3=C2C=CC=C3)CC1 Chemical compound CC(C)N1CCC(N2C(=O)NC3=C2C=CC=C3)CC1 NFANQYWJYLBRCH-UHFFFAOYSA-N 0.000 description 1
- MBYWLQNDKOBVEL-UHFFFAOYSA-N CC(C)N1CCC2(CC1)C(=O)NCN2C1=CC=CC=C1 Chemical compound CC(C)N1CCC2(CC1)C(=O)NCN2C1=CC=CC=C1 MBYWLQNDKOBVEL-UHFFFAOYSA-N 0.000 description 1
- NHNYSSNFWPFZRG-UHFFFAOYSA-N CC(C)N1CCCC2CCCCC21 Chemical compound CC(C)N1CCCC2CCCCC21 NHNYSSNFWPFZRG-UHFFFAOYSA-N 0.000 description 1
- ODIQTOYGORNLPE-UHFFFAOYSA-N CC(C)N1CCN(C)CC1 Chemical compound CC(C)N1CCN(C)CC1 ODIQTOYGORNLPE-UHFFFAOYSA-N 0.000 description 1
- LYXXHMOCQTVBIM-UHFFFAOYSA-N CC(C)N1CCN(CC2=CC=CC=C2)CC1 Chemical compound CC(C)N1CCN(CC2=CC=CC=C2)CC1 LYXXHMOCQTVBIM-UHFFFAOYSA-N 0.000 description 1
- LUYUTLBVIHVLHY-UHFFFAOYSA-N CC(C)NC(C)C(=O)NC1=CC2=C(C=CC=C2)C=C1 Chemical compound CC(C)NC(C)C(=O)NC1=CC2=C(C=CC=C2)C=C1 LUYUTLBVIHVLHY-UHFFFAOYSA-N 0.000 description 1
- JBXRACPHHNWKBE-UHFFFAOYSA-N CC(C)NC(C)C1=CC=CC2=C1C=CC=C2 Chemical compound CC(C)NC(C)C1=CC=CC2=C1C=CC=C2 JBXRACPHHNWKBE-UHFFFAOYSA-N 0.000 description 1
- RPGLUMRDPMBBBQ-UHFFFAOYSA-N CC(C)NC1CC2=CC=CC=C2C1 Chemical compound CC(C)NC1CC2=CC=CC=C2C1 RPGLUMRDPMBBBQ-UHFFFAOYSA-N 0.000 description 1
- IGEFUZDZFLHZRZ-UHFFFAOYSA-N CC(C)NC1CCCCNC1=O Chemical compound CC(C)NC1CCCCNC1=O IGEFUZDZFLHZRZ-UHFFFAOYSA-N 0.000 description 1
- ZZRSCWSJSHLFSI-UHFFFAOYSA-N CC(C)NCC(C)C1=CC=CC=C1 Chemical compound CC(C)NCC(C)C1=CC=CC=C1 ZZRSCWSJSHLFSI-UHFFFAOYSA-N 0.000 description 1
- JUNZDHUVFTUYIP-UHFFFAOYSA-N CC(C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C)NCC(C1=CC=CC=C1)C1=CC=CC=C1 JUNZDHUVFTUYIP-UHFFFAOYSA-N 0.000 description 1
- AHXJNCOFVXXIAS-UHFFFAOYSA-N CC(C)NCC1=C(Cl)C=CC=C1 Chemical compound CC(C)NCC1=C(Cl)C=CC=C1 AHXJNCOFVXXIAS-UHFFFAOYSA-N 0.000 description 1
- KECOIFWUUTVTTN-UHFFFAOYSA-N CC(C)NCC1=C(F)C=CC=C1 Chemical compound CC(C)NCC1=C(F)C=CC=C1 KECOIFWUUTVTTN-UHFFFAOYSA-N 0.000 description 1
- QFYRNLXBQZHPTK-UHFFFAOYSA-N CC(C)NCC1=C(F)C=CC=C1F Chemical compound CC(C)NCC1=C(F)C=CC=C1F QFYRNLXBQZHPTK-UHFFFAOYSA-N 0.000 description 1
- LMZQLDWKPXNCJR-UHFFFAOYSA-N CC(C)NCC1=C(N)C=CC=C1 Chemical compound CC(C)NCC1=C(N)C=CC=C1 LMZQLDWKPXNCJR-UHFFFAOYSA-N 0.000 description 1
- MUMHEZLVUWADEU-UHFFFAOYSA-N CC(C)NCC1=CC=C(C2=CSN=N2)C=C1 Chemical compound CC(C)NCC1=CC=C(C2=CSN=N2)C=C1 MUMHEZLVUWADEU-UHFFFAOYSA-N 0.000 description 1
- LYBKPDDZTNUNNM-UHFFFAOYSA-N CC(C)NCC1=CC=CC=C1 Chemical compound CC(C)NCC1=CC=CC=C1 LYBKPDDZTNUNNM-UHFFFAOYSA-N 0.000 description 1
- PDJPWMFBBIDZPM-UHFFFAOYSA-N CC(C)NCC1=NC2=CC=CC=C2N1 Chemical compound CC(C)NCC1=NC2=CC=CC=C2N1 PDJPWMFBBIDZPM-UHFFFAOYSA-N 0.000 description 1
- OXJLOUANFUGVCS-UHFFFAOYSA-N CC(C)NCC1CCCCC1 Chemical compound CC(C)NCC1CCCCC1 OXJLOUANFUGVCS-UHFFFAOYSA-N 0.000 description 1
- PELLLKANMONICH-UHFFFAOYSA-N CC(C)NCC1CCCO1 Chemical compound CC(C)NCC1CCCO1 PELLLKANMONICH-UHFFFAOYSA-N 0.000 description 1
- FLHXVAAMWGYJOY-UHFFFAOYSA-N CC(C)NCCC1=CC=C(Cl)C=C1Cl Chemical compound CC(C)NCCC1=CC=C(Cl)C=C1Cl FLHXVAAMWGYJOY-UHFFFAOYSA-N 0.000 description 1
- AHRWZWDTIPQTMC-UHFFFAOYSA-N CC(C)NCCC1=CC=CN=C1 Chemical compound CC(C)NCCC1=CC=CN=C1 AHRWZWDTIPQTMC-UHFFFAOYSA-N 0.000 description 1
- TYQJCPFOIMPJLQ-UHFFFAOYSA-N CC(C)NCCC1=CC=NC=C1 Chemical compound CC(C)NCCC1=CC=NC=C1 TYQJCPFOIMPJLQ-UHFFFAOYSA-N 0.000 description 1
- HORYKTKRJOTORI-UHFFFAOYSA-N CC(C)NCCC1=CCCCC1 Chemical compound CC(C)NCCC1=CCCCC1 HORYKTKRJOTORI-UHFFFAOYSA-N 0.000 description 1
- AGDHSWAZTKYTNX-UHFFFAOYSA-N CC(C)NCCCC1=CC=CC=C1 Chemical compound CC(C)NCCCC1=CC=CC=C1 AGDHSWAZTKYTNX-UHFFFAOYSA-N 0.000 description 1
- ILIYRATYFZOQKO-UHFFFAOYSA-N CC(C)NCCCCCCN(C)C Chemical compound CC(C)NCCCCCCN(C)C ILIYRATYFZOQKO-UHFFFAOYSA-N 0.000 description 1
- IPLWOCGPIGUXOR-UHFFFAOYSA-N CC(C)NCCCCO Chemical compound CC(C)NCCCCO IPLWOCGPIGUXOR-UHFFFAOYSA-N 0.000 description 1
- HMRQTTHUJRVTFY-UHFFFAOYSA-N CC(C)NCCCN(C)C1=CC=CC=C1 Chemical compound CC(C)NCCCN(C)C1=CC=CC=C1 HMRQTTHUJRVTFY-UHFFFAOYSA-N 0.000 description 1
- ZHNRSWUGZCPKGQ-UHFFFAOYSA-N CC(C)NCCCN1C=CN=C1 Chemical compound CC(C)NCCCN1C=CN=C1 ZHNRSWUGZCPKGQ-UHFFFAOYSA-N 0.000 description 1
- GMZRCPRHCXBZQB-UHFFFAOYSA-N CC(C)NCCCN1CCCC1=O Chemical compound CC(C)NCCCN1CCCC1=O GMZRCPRHCXBZQB-UHFFFAOYSA-N 0.000 description 1
- QXPRMANJAMOFLQ-UHFFFAOYSA-N CC(C)NCCN(C)C Chemical compound CC(C)NCCN(C)C QXPRMANJAMOFLQ-UHFFFAOYSA-N 0.000 description 1
- JDWJVQSOLXSDDY-UHFFFAOYSA-N CC(C)NC[SH]1C=CC=C1 Chemical compound CC(C)NC[SH]1C=CC=C1 JDWJVQSOLXSDDY-UHFFFAOYSA-N 0.000 description 1
- CTEJGMPMLDPYEL-UHFFFAOYSA-N CC(C)S(=O)(=O)/N=C(\NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl Chemical compound CC(C)S(=O)(=O)/N=C(\NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl CTEJGMPMLDPYEL-UHFFFAOYSA-N 0.000 description 1
- CCCUGOPASHXRII-RPCGPGEBSA-N CC(C)[C@H]1C2=CC(C(O)C(C)(C)C)=CC=C2OC(C)(C)[C@@H]1O Chemical compound CC(C)[C@H]1C2=CC(C(O)C(C)(C)C)=CC=C2OC(C)(C)[C@@H]1O CCCUGOPASHXRII-RPCGPGEBSA-N 0.000 description 1
- DEAHMVWYDKFNCG-UHFFFAOYSA-N CC(CCSS)c1c(C)cc(C)cc1C Chemical compound CC(CCSS)c1c(C)cc(C)cc1C DEAHMVWYDKFNCG-UHFFFAOYSA-N 0.000 description 1
- CZAOZQNBRFSTCY-UHFFFAOYSA-N CC1=C(Br)C=CC=C1C(C)C Chemical compound CC1=C(Br)C=CC=C1C(C)C CZAOZQNBRFSTCY-UHFFFAOYSA-N 0.000 description 1
- WWRCMNKATXZARA-UHFFFAOYSA-N CC1=C(C(C)C)C=CC=C1 Chemical compound CC1=C(C(C)C)C=CC=C1 WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 1
- FXKKMFUANDYYNP-UHFFFAOYSA-N CC1=C(C(C)C)C=CC=C1Cl Chemical compound CC1=C(C(C)C)C=CC=C1Cl FXKKMFUANDYYNP-UHFFFAOYSA-N 0.000 description 1
- KOUNJAXXZNPHOB-UHFFFAOYSA-N CC1=C(CNC(C)C)C(Cl)=CC=C1 Chemical compound CC1=C(CNC(C)C)C(Cl)=CC=C1 KOUNJAXXZNPHOB-UHFFFAOYSA-N 0.000 description 1
- KATHLXKCQHBUSQ-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=CC(C)=C1C(C)C Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1C(C)C KATHLXKCQHBUSQ-UHFFFAOYSA-N 0.000 description 1
- OBSKMRWMGXHFRO-UHFFFAOYSA-N CC1=CC(C)=C(C(C)C)C(C)=C1 Chemical compound CC1=CC(C)=C(C(C)C)C(C)=C1 OBSKMRWMGXHFRO-UHFFFAOYSA-N 0.000 description 1
- VYALSSNVODXUNL-UHFFFAOYSA-N CC1=CC(CNC(C)C)=CC=C1 Chemical compound CC1=CC(CNC(C)C)=CC=C1 VYALSSNVODXUNL-UHFFFAOYSA-N 0.000 description 1
- WYUIWKFIFOJVKW-UHFFFAOYSA-N CC1=CC(Cl)=C(Cl)C=C1 Chemical compound CC1=CC(Cl)=C(Cl)C=C1 WYUIWKFIFOJVKW-UHFFFAOYSA-N 0.000 description 1
- ZBMAUAGBSVTTLA-UHFFFAOYSA-N CC1=CC=C(CCC(C)C)C=C1 Chemical compound CC1=CC=C(CCC(C)C)C=C1 ZBMAUAGBSVTTLA-UHFFFAOYSA-N 0.000 description 1
- CFKQPTKTRWCBLX-UHFFFAOYSA-N CC1=CC=C(CCNC(C)C)C=C1 Chemical compound CC1=CC=C(CCNC(C)C)C=C1 CFKQPTKTRWCBLX-UHFFFAOYSA-N 0.000 description 1
- MLJWSCJPKNQKOG-UHFFFAOYSA-N CC1=CC=C(CNC(C)C)O1 Chemical compound CC1=CC=C(CNC(C)C)O1 MLJWSCJPKNQKOG-UHFFFAOYSA-N 0.000 description 1
- XCYJPXQACVEIOS-UHFFFAOYSA-N CC1=CC=CC(C(C)C)=C1 Chemical compound CC1=CC=CC(C(C)C)=C1 XCYJPXQACVEIOS-UHFFFAOYSA-N 0.000 description 1
- WFOPYVSELPBWBS-UHFFFAOYSA-N CC1=CC=CC(N2CCN(C(C)C)CC2)=C1C Chemical compound CC1=CC=CC(N2CCN(C(C)C)CC2)=C1C WFOPYVSELPBWBS-UHFFFAOYSA-N 0.000 description 1
- HZWUDKOCFXQWBF-UHFFFAOYSA-N CC1=NC2=CC(C(C)C)=CC=C2S1 Chemical compound CC1=NC2=CC(C(C)C)=CC=C2S1 HZWUDKOCFXQWBF-UHFFFAOYSA-N 0.000 description 1
- HOUYLTUYPPSVIN-UHFFFAOYSA-N CC1=NOC(C(C)C)=C1 Chemical compound CC1=NOC(C(C)C)=C1 HOUYLTUYPPSVIN-UHFFFAOYSA-N 0.000 description 1
- LYABPLVJRRVRLN-UHFFFAOYSA-N CC1=NOC(C(C)C)=C1C Chemical compound CC1=NOC(C(C)C)=C1C LYABPLVJRRVRLN-UHFFFAOYSA-N 0.000 description 1
- PPBHENIBPZBCHK-UHFFFAOYSA-N CC1=NOC(C(C)C)=C1[N+](=O)[O-] Chemical compound CC1=NOC(C(C)C)=C1[N+](=O)[O-] PPBHENIBPZBCHK-UHFFFAOYSA-N 0.000 description 1
- BDFDLCNMQVKYIP-UHFFFAOYSA-N CC1=NOC(NS(=O)(=O)C2=CC=C(C(C)C)C=C2)=C1C Chemical compound CC1=NOC(NS(=O)(=O)C2=CC=C(C(C)C)C=C2)=C1C BDFDLCNMQVKYIP-UHFFFAOYSA-N 0.000 description 1
- YGVBOLZJGVSPLT-UHFFFAOYSA-N CC1CC(C)CN(C(C)C)C1 Chemical compound CC1CC(C)CN(C(C)C)C1 YGVBOLZJGVSPLT-UHFFFAOYSA-N 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N CC1CCC(C(C)C)CC1 Chemical compound CC1CCC(C(C)C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- ORTAXXZJVCPZJF-UHFFFAOYSA-N CC1CCCN(C(C)C)C1 Chemical compound CC1CCCN(C(C)C)C1 ORTAXXZJVCPZJF-UHFFFAOYSA-N 0.000 description 1
- IJUOMCMYAFYRGH-UHFFFAOYSA-N CC1CN(C(C)C)CC(C)O1 Chemical compound CC1CN(C(C)C)CC(C)O1 IJUOMCMYAFYRGH-UHFFFAOYSA-N 0.000 description 1
- NVABDGKPMALTEY-UHFFFAOYSA-N CCC(CCC1=CC=C(C)C(O)=C1)C(C)C Chemical compound CCC(CCC1=CC=C(C)C(O)=C1)C(C)C NVABDGKPMALTEY-UHFFFAOYSA-N 0.000 description 1
- XUIGMCWFQYRAEK-UHFFFAOYSA-N CCC(N/C(=N\C(=O)C1=CC=CC(C#N)=C1)NC1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1Cl Chemical compound CCC(N/C(=N\C(=O)C1=CC=CC(C#N)=C1)NC1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1Cl XUIGMCWFQYRAEK-UHFFFAOYSA-N 0.000 description 1
- GUUDUUDWUWUTPD-UHFFFAOYSA-N CCC1=CC=C(C(C)C)C=C1 Chemical compound CCC1=CC=C(C(C)C)C=C1 GUUDUUDWUWUTPD-UHFFFAOYSA-N 0.000 description 1
- TZFHULPHJCPHCR-UHFFFAOYSA-N CCC1=CC=C(CCC(C)C)C=C1 Chemical compound CCC1=CC=C(CCC(C)C)C=C1 TZFHULPHJCPHCR-UHFFFAOYSA-N 0.000 description 1
- FRGDRCOOSXPXDK-UHFFFAOYSA-N CCCC1=CC=C(C(C)C)C=C1 Chemical compound CCCC1=CC=C(C(C)C)C=C1 FRGDRCOOSXPXDK-UHFFFAOYSA-N 0.000 description 1
- GORHWOUACWIXSD-UHFFFAOYSA-N CCCCCC(C)NC(C)C Chemical compound CCCCCC(C)NC(C)C GORHWOUACWIXSD-UHFFFAOYSA-N 0.000 description 1
- LMJDMESPXVAQQY-UHFFFAOYSA-N CCCCCCNC(C)C Chemical compound CCCCCCNC(C)C LMJDMESPXVAQQY-UHFFFAOYSA-N 0.000 description 1
- KNWYQHPPUVZOHX-UHFFFAOYSA-N CCCCNC(=O)/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl Chemical compound CCCCNC(=O)/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl KNWYQHPPUVZOHX-UHFFFAOYSA-N 0.000 description 1
- WZTARFPHRJQHFI-UHFFFAOYSA-N CCCN(CC1=CC=C([N+](=O)[O-])C=C1)C(C)C Chemical compound CCCN(CC1=CC=C([N+](=O)[O-])C=C1)C(C)C WZTARFPHRJQHFI-UHFFFAOYSA-N 0.000 description 1
- VTVMQXSYOIPNJH-UHFFFAOYSA-N CCCN(CC1CC1)C(C)C Chemical compound CCCN(CC1CC1)C(C)C VTVMQXSYOIPNJH-UHFFFAOYSA-N 0.000 description 1
- VXEXNSLAVSWNKX-UHFFFAOYSA-N CCCN(CCC1=NC=CC=C1)C(C)C Chemical compound CCCN(CCC1=NC=CC=C1)C(C)C VXEXNSLAVSWNKX-UHFFFAOYSA-N 0.000 description 1
- ZDMMLJIKRKJSGM-UHFFFAOYSA-N CCN(CC)C(=O)C1CCCN(C(C)C)C1 Chemical compound CCN(CC)C(=O)C1CCCN(C(C)C)C1 ZDMMLJIKRKJSGM-UHFFFAOYSA-N 0.000 description 1
- VYTWUHNMPKVLKM-UHFFFAOYSA-N CCN(CCN(C)C)C(C)C Chemical compound CCN(CCN(C)C)C(C)C VYTWUHNMPKVLKM-UHFFFAOYSA-N 0.000 description 1
- MRPHWAQVODJEPJ-UHFFFAOYSA-N CCN(CCNC(C)C)C1=CC=CC(C)=C1 Chemical compound CCN(CCNC(C)C)C1=CC=CC(C)=C1 MRPHWAQVODJEPJ-UHFFFAOYSA-N 0.000 description 1
- PZDVAGQYGYPLRJ-UHFFFAOYSA-N CCN1C2=CC=C(C(C)C)C=C2N=C1C Chemical compound CCN1C2=CC=C(C(C)C)C=C2N=C1C PZDVAGQYGYPLRJ-UHFFFAOYSA-N 0.000 description 1
- CBQOEYAQFVRTNV-UHFFFAOYSA-N CCOC(=O)C1=CNN=C1C(C)C Chemical compound CCOC(=O)C1=CNN=C1C(C)C CBQOEYAQFVRTNV-UHFFFAOYSA-N 0.000 description 1
- SWVREOJHXVLZRP-UHFFFAOYSA-N CCOC(=O)C1=NOC(C(C)C)=C1C#N Chemical compound CCOC(=O)C1=NOC(C(C)C)=C1C#N SWVREOJHXVLZRP-UHFFFAOYSA-N 0.000 description 1
- ILEWGMFFMZYVCG-UHFFFAOYSA-N CCOC(=O)C1CCCN(C(C)C)C1 Chemical compound CCOC(=O)C1CCCN(C(C)C)C1 ILEWGMFFMZYVCG-UHFFFAOYSA-N 0.000 description 1
- WBOKRIJKCMYJJM-UHFFFAOYSA-N CCOC(=O)CC1=CSC(C(C)C)=N1 Chemical compound CCOC(=O)CC1=CSC(C(C)C)=N1 WBOKRIJKCMYJJM-UHFFFAOYSA-N 0.000 description 1
- ZDESYVHBWFEARS-UHFFFAOYSA-N CCOC(=O)CCCNC(C)C Chemical compound CCOC(=O)CCCNC(C)C ZDESYVHBWFEARS-UHFFFAOYSA-N 0.000 description 1
- AFJPXRUUGZHLTI-UHFFFAOYSA-N CCOC(=O)CN(C)C(C)C Chemical compound CCOC(=O)CN(C)C(C)C AFJPXRUUGZHLTI-UHFFFAOYSA-N 0.000 description 1
- YQTFNXBVTDBPHT-UHFFFAOYSA-N CCOC(=O)N1CCC(NC(C)C)CC1 Chemical compound CCOC(=O)N1CCC(NC(C)C)CC1 YQTFNXBVTDBPHT-UHFFFAOYSA-N 0.000 description 1
- XSJVWZAETSBXKU-UHFFFAOYSA-N CCOC(C)C Chemical compound CCOC(C)C XSJVWZAETSBXKU-UHFFFAOYSA-N 0.000 description 1
- WLJATEFRGGYAPN-UHFFFAOYSA-N CCSC1=NN=C(C(C)C)S1 Chemical compound CCSC1=NN=C(C(C)C)S1 WLJATEFRGGYAPN-UHFFFAOYSA-N 0.000 description 1
- UFSAHJAFXSJPDB-UHFFFAOYSA-N CCc1nnc(C(F)(F)F)[s]1 Chemical compound CCc1nnc(C(F)(F)F)[s]1 UFSAHJAFXSJPDB-UHFFFAOYSA-N 0.000 description 1
- JGUGHKDCZBQDAH-UHFFFAOYSA-N CN(C)C(=O)/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl Chemical compound CN(C)C(=O)/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl JGUGHKDCZBQDAH-UHFFFAOYSA-N 0.000 description 1
- JCMWSVNNSPUNER-UHFFFAOYSA-N CNCCc(cc1)ccc1OC Chemical compound CNCCc(cc1)ccc1OC JCMWSVNNSPUNER-UHFFFAOYSA-N 0.000 description 1
- IPIVTJSCIHXKOE-UHFFFAOYSA-N COC(=O)C1=CC=C(C(C)C)C=C1 Chemical compound COC(=O)C1=CC=C(C(C)C)C=C1 IPIVTJSCIHXKOE-UHFFFAOYSA-N 0.000 description 1
- FDXFTILZIXUGKL-UHFFFAOYSA-N COC(=O)C1=CC=CC(C(C)C)=C1 Chemical compound COC(=O)C1=CC=CC(C(C)C)=C1 FDXFTILZIXUGKL-UHFFFAOYSA-N 0.000 description 1
- UMHOMPHRASIYBE-UHFFFAOYSA-N COC1=C(CCNC(C)C)C=CC=C1 Chemical compound COC1=C(CCNC(C)C)C=CC=C1 UMHOMPHRASIYBE-UHFFFAOYSA-N 0.000 description 1
- KRLRXJANBUGNSF-UHFFFAOYSA-N COC1=C(OC)C=C(C(C)C)C=C1 Chemical compound COC1=C(OC)C=C(C(C)C)C=C1 KRLRXJANBUGNSF-UHFFFAOYSA-N 0.000 description 1
- RDUSBVGIKPQXGH-UHFFFAOYSA-N COC1=C(OC)C=C(C(CC2=CC=CC=C2)NC(C)C)C=C1 Chemical compound COC1=C(OC)C=C(C(CC2=CC=CC=C2)NC(C)C)C=C1 RDUSBVGIKPQXGH-UHFFFAOYSA-N 0.000 description 1
- BIZDXHFVERDHHG-UHFFFAOYSA-N COC1=C(OC)C=C(CCC(C)C)C=C1 Chemical compound COC1=C(OC)C=C(CCC(C)C)C=C1 BIZDXHFVERDHHG-UHFFFAOYSA-N 0.000 description 1
- YVBQRDJJQXIWDB-UHFFFAOYSA-N COC1=C(OC)C=C2CN(C(C)C)CCC2=C1 Chemical compound COC1=C(OC)C=C2CN(C(C)C)CCC2=C1 YVBQRDJJQXIWDB-UHFFFAOYSA-N 0.000 description 1
- LPUQSKPTDQDLCE-UHFFFAOYSA-N COC1=CC(CC(C)C)=CC(OC)=C1 Chemical compound COC1=CC(CC(C)C)=CC(OC)=C1 LPUQSKPTDQDLCE-UHFFFAOYSA-N 0.000 description 1
- KSAIXMUSQQWFQM-UHFFFAOYSA-N COC1=CC(CC(C)C)=CC(OC)=C1OC Chemical compound COC1=CC(CC(C)C)=CC(OC)=C1OC KSAIXMUSQQWFQM-UHFFFAOYSA-N 0.000 description 1
- PQJWLYTVVDVQLY-UHFFFAOYSA-N COC1=CC(CC(C)C)=CC=C1O Chemical compound COC1=CC(CC(C)C)=CC=C1O PQJWLYTVVDVQLY-UHFFFAOYSA-N 0.000 description 1
- PZMKBAWPMWYNOP-UHFFFAOYSA-N COC1=CC(CCNC(C)C)=CC=C1 Chemical compound COC1=CC(CCNC(C)C)=CC=C1 PZMKBAWPMWYNOP-UHFFFAOYSA-N 0.000 description 1
- AIUUGWAHNHLTBD-UHFFFAOYSA-N COC1=CC(NC(=O)CCC(C)C)=CC2=CC=CC=C21 Chemical compound COC1=CC(NC(=O)CCC(C)C)=CC2=CC=CC=C21 AIUUGWAHNHLTBD-UHFFFAOYSA-N 0.000 description 1
- NWFXUMSRVKPBTK-UHFFFAOYSA-N COC1=CC(NC(=O)CCNC(C)C)=CC2=CC=CC=C21 Chemical compound COC1=CC(NC(=O)CCNC(C)C)=CC2=CC=CC=C21 NWFXUMSRVKPBTK-UHFFFAOYSA-N 0.000 description 1
- WKVJISDVJWJDAC-UHFFFAOYSA-N COC1=CC=C(C(C)C)C=N1 Chemical compound COC1=CC=C(C(C)C)C=N1 WKVJISDVJWJDAC-UHFFFAOYSA-N 0.000 description 1
- AAIMXWKRWRKLOT-UHFFFAOYSA-N COC1=CC=C(C(C2=CC=C(OC)C=C2)C(C)C)C=C1 Chemical compound COC1=CC=C(C(C2=CC=C(OC)C=C2)C(C)C)C=C1 AAIMXWKRWRKLOT-UHFFFAOYSA-N 0.000 description 1
- KMDFYMFGCLEPPB-UHFFFAOYSA-N COC1=CC=C(C(NC(C)C)C2CC2)C=C1 Chemical compound COC1=CC=C(C(NC(C)C)C2CC2)C=C1 KMDFYMFGCLEPPB-UHFFFAOYSA-N 0.000 description 1
- HLKLJTIAXKHOKZ-UHFFFAOYSA-N COC1=CC=C(CCC(C)C)C=C1 Chemical compound COC1=CC=C(CCC(C)C)C=C1 HLKLJTIAXKHOKZ-UHFFFAOYSA-N 0.000 description 1
- RUFDGSSUOBSVBG-UHFFFAOYSA-N COC1=CC=C(CCNC(C)C)C=C1 Chemical compound COC1=CC=C(CCNC(C)C)C=C1 RUFDGSSUOBSVBG-UHFFFAOYSA-N 0.000 description 1
- VPKKHCIAXQNSKH-UHFFFAOYSA-N COC1=CC=C(N2CCN(C(C)C)CC2C)C=C1 Chemical compound COC1=CC=C(N2CCN(C(C)C)CC2C)C=C1 VPKKHCIAXQNSKH-UHFFFAOYSA-N 0.000 description 1
- QQZJNZJNPDORBO-UHFFFAOYSA-N COC1=CC=C2NC=C(CCNC(C)C)C2=C1 Chemical compound COC1=CC=C2NC=C(CCNC(C)C)C2=C1 QQZJNZJNPDORBO-UHFFFAOYSA-N 0.000 description 1
- GRACVHPLBOMWNY-UHFFFAOYSA-N COC1=CC=CC(OC)=C1CNC(C)C Chemical compound COC1=CC=CC(OC)=C1CNC(C)C GRACVHPLBOMWNY-UHFFFAOYSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N COCC(C)C Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- VTLAOFNWLFSDLF-UHFFFAOYSA-N COCCN(CCOC)C(C)C Chemical compound COCCN(CCOC)C(C)C VTLAOFNWLFSDLF-UHFFFAOYSA-N 0.000 description 1
- IJYVYLOMHABWGB-UHFFFAOYSA-N Cl.Cl.O=C(/N=C(/NC1=CC=C(C(F)(F)F)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NC1=CN=CC=C1 Chemical compound Cl.Cl.O=C(/N=C(/NC1=CC=C(C(F)(F)F)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NC1=CN=CC=C1 IJYVYLOMHABWGB-UHFFFAOYSA-N 0.000 description 1
- VFVJVPONKVEZFO-UHFFFAOYSA-N Cl.ClC1=CC=C(C(CN2C=CN=C2)NC(=NC2=NC=CS2)NC(C2=CC=CC=C2)C2=CC=CC=C2)C(Cl)=C1 Chemical compound Cl.ClC1=CC=C(C(CN2C=CN=C2)NC(=NC2=NC=CS2)NC(C2=CC=CC=C2)C2=CC=CC=C2)C(Cl)=C1 VFVJVPONKVEZFO-UHFFFAOYSA-N 0.000 description 1
- YYTUVUFQDHTNFQ-UHFFFAOYSA-N Cl.N#CC1=CC(C(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)=CC=C1 Chemical compound Cl.N#CC1=CC(C(=O)/N=C(/NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)=CC=C1 YYTUVUFQDHTNFQ-UHFFFAOYSA-N 0.000 description 1
- JVBUHQBMWZUPJK-UHFFFAOYSA-N Cl.O=C(/N=C(\NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1 Chemical compound Cl.O=C(/N=C(\NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)NC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1 JVBUHQBMWZUPJK-UHFFFAOYSA-N 0.000 description 1
- LWBLQPPLHLHOIK-UHFFFAOYSA-N N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1Cl Chemical compound N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1Cl LWBLQPPLHLHOIK-UHFFFAOYSA-N 0.000 description 1
- UBDSUHWJFNHOFP-UHFFFAOYSA-N N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(Cl)=CC=C1Cl Chemical compound N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC(Cl)=CC=C1Cl UBDSUHWJFNHOFP-UHFFFAOYSA-N 0.000 description 1
- CMYKFXHXERJCER-UHFFFAOYSA-N N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl Chemical compound N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl CMYKFXHXERJCER-UHFFFAOYSA-N 0.000 description 1
- LYLKBSFAQQNCEC-UHFFFAOYSA-N N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=CC=C1Cl Chemical compound N#C/N=C(/NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=CC=C1Cl LYLKBSFAQQNCEC-UHFFFAOYSA-N 0.000 description 1
- XWFNXSAWRGLALK-UHFFFAOYSA-N N#C/N=C(/NCCCC1=CC=CC=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl Chemical compound N#C/N=C(/NCCCC1=CC=CC=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl XWFNXSAWRGLALK-UHFFFAOYSA-N 0.000 description 1
- FRCFQYVNOIRLGK-UHFFFAOYSA-N N#C/N=C(\NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)NC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound N#C/N=C(\NC(CN1C=CN=C1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)NC(C1=CC=CC=C1)C1=CC=CC=C1 FRCFQYVNOIRLGK-UHFFFAOYSA-N 0.000 description 1
- SOBMSGXOIOSHQX-UHFFFAOYSA-N N#C/N=C(\NC1=CC(Cl)=C(Cl)C=C1)NC(CN1C=NC2=C1C=CC=C2)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F Chemical compound N#C/N=C(\NC1=CC(Cl)=C(Cl)C=C1)NC(CN1C=NC2=C1C=CC=C2)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F SOBMSGXOIOSHQX-UHFFFAOYSA-N 0.000 description 1
- BJCKVMPZZAXNSK-UHFFFAOYSA-N N#C/N=C(\NC1=CC2=C(C=C1)CCC2)NC(CN1C=NC2=C1C=CC=C2)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F Chemical compound N#C/N=C(\NC1=CC2=C(C=C1)CCC2)NC(CN1C=NC2=C1C=CC=C2)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F BJCKVMPZZAXNSK-UHFFFAOYSA-N 0.000 description 1
- UOZQNOFQBOHGDS-UHFFFAOYSA-N N#C/N=C(\NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=CC(Cl)=C1Cl Chemical compound N#C/N=C(\NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=CC(Cl)=C1Cl UOZQNOFQBOHGDS-UHFFFAOYSA-N 0.000 description 1
- NDWDEEVIGSPANI-UHFFFAOYSA-N N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F Chemical compound N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=CN=C1)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F NDWDEEVIGSPANI-UHFFFAOYSA-N 0.000 description 1
- KENIZJBTWIVOBO-UHFFFAOYSA-N N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=NC2=C1C=CC=C2)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F Chemical compound N#C/N=C(\NC1=CC=C(Cl)C=C1Cl)NC(CN1C=NC2=C1C=CC=C2)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F KENIZJBTWIVOBO-UHFFFAOYSA-N 0.000 description 1
- RVOCWEDLXPWLAZ-UHFFFAOYSA-N O=C(/N=C(/NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)C1=CC=NC=C1 Chemical compound O=C(/N=C(/NC1=CC=C(Cl)C=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)C1=CC=NC=C1 RVOCWEDLXPWLAZ-UHFFFAOYSA-N 0.000 description 1
- BXWSPLIPEQPRPE-UHFFFAOYSA-N O=C(/N=C(/NC1=CC=CC=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)C1=CC=CC=C1 Chemical compound O=C(/N=C(/NC1=CC=CC=C1)NC(CN1C=CN=C1)C1=CC=C(Cl)C=C1Cl)C1=CC=CC=C1 BXWSPLIPEQPRPE-UHFFFAOYSA-N 0.000 description 1
- NBHDTKVZAZFKKN-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(S(=O)(=O)N=C(NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 Chemical compound O=[N+]([O-])C1=CC=C(S(=O)(=O)N=C(NC2=CC=C(Cl)C=C2)NC(CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 NBHDTKVZAZFKKN-UHFFFAOYSA-N 0.000 description 1
- IBCHXZWXPDFZDZ-UHFFFAOYSA-N [C-]#[N+]C1=CC(Cl)=C(C(C)C)C=C1 Chemical compound [C-]#[N+]C1=CC(Cl)=C(C(C)C)C=C1 IBCHXZWXPDFZDZ-UHFFFAOYSA-N 0.000 description 1
- OBOFZHBRWRLFMT-UHFFFAOYSA-N [C-]#[N+]CC1=CC=C(C(C)C)C=C1 Chemical compound [C-]#[N+]CC1=CC=C(C(C)C)C=C1 OBOFZHBRWRLFMT-UHFFFAOYSA-N 0.000 description 1
- GJFLSNYQEXQQHB-UHFFFAOYSA-N [H]N(C1=CC=C(Cl)C=C1)/C(=N\C#N)NC(CC1=NC2=C(C=CC=C2)N1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F Chemical compound [H]N(C1=CC=C(Cl)C=C1)/C(=N\C#N)NC(CC1=NC2=C(C=CC=C2)N1)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F GJFLSNYQEXQQHB-UHFFFAOYSA-N 0.000 description 1
- CFBBCIIDENOGQU-NSHDSACASA-N [H][C@@](CO)(C1=CC=CC=C1)C(C)C Chemical compound [H][C@@](CO)(C1=CC=CC=C1)C(C)C CFBBCIIDENOGQU-NSHDSACASA-N 0.000 description 1
- MBHMDDAPBVALMF-ZDUSSCGKSA-N [H][C@@](CO)(CC1=CC=CC=C1)CC(C)C Chemical compound [H][C@@](CO)(CC1=CC=CC=C1)CC(C)C MBHMDDAPBVALMF-ZDUSSCGKSA-N 0.000 description 1
- FPSDOPVFMZNTLA-CYBMUJFWSA-N [H][C@@](CO)(CSCC1=CC=CC=C1)C(C)C Chemical compound [H][C@@](CO)(CSCC1=CC=CC=C1)C(C)C FPSDOPVFMZNTLA-CYBMUJFWSA-N 0.000 description 1
- OGNARDLBSBXJSE-HNNXBMFYSA-N [H][C@@]1(CNC2=C(C)C=CC=C2C)CCCN1C(C)C Chemical compound [H][C@@]1(CNC2=C(C)C=CC=C2C)CCCN1C(C)C OGNARDLBSBXJSE-HNNXBMFYSA-N 0.000 description 1
- CFBBCIIDENOGQU-LLVKDONJSA-N [H][C@](CO)(C1=CC=CC=C1)C(C)C Chemical compound [H][C@](CO)(C1=CC=CC=C1)C(C)C CFBBCIIDENOGQU-LLVKDONJSA-N 0.000 description 1
- NOOYNMCECTVYMI-CYBMUJFWSA-N [H][C@](COC)(CC1=CC=CC=C1)C(C)C Chemical compound [H][C@](COC)(CC1=CC=CC=C1)C(C)C NOOYNMCECTVYMI-CYBMUJFWSA-N 0.000 description 1
- ACABZBGQXFLDAB-VXGBXAGGSA-N [H][C@]1(C2=CC=CC=C2)C[C@]1([H])C(C)C Chemical compound [H][C@]1(C2=CC=CC=C2)C[C@]1([H])C(C)C ACABZBGQXFLDAB-VXGBXAGGSA-N 0.000 description 1
- PYIRNPXAVPQEQR-NEPJUHHUSA-N [H][C@]1(NC(C)C)C[C@]1([H])C1=CC=CC=C1 Chemical compound [H][C@]1(NC(C)C)C[C@]1([H])C1=CC=CC=C1 PYIRNPXAVPQEQR-NEPJUHHUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to compounds that inhibit nitochondrial F 1 F 0 ATP hydrolase and are useful for treating ischemia-related diseases.
- the invention further pertains to methods of treating conditions associated with depleted levels of adenosine triphosphate (ATP) due to hydrolysis by mitochondrial F 1 F 0 ATPase.
- ATP adenosine triphosphate
- Ischemic heart disease is a common and serious health problem. Every year, large numbers of patients die from ischemic heart disease and its complications. Many others experience acute myocardial infarcation, congestive heart failure, cardiac arrhythmias, or other disorders.
- Myocardial ischemia exists when the heart tissue experiences a demand for oxygen and substrates that exceed the supply. Imbalances between oxygen supply and demand span a large range, and thus, there are various syndromes and biochemical pathways involved in the pathogenesis of ischemia, e.g., from low-grade to severe ischemic conditions.
- chronic stable angina pectoris is a low-grade condition, in which the resting coronary blood flood may be normal but the blood flow reserve is insufficient to meet an increased energy demand.
- the ischemic muscle can develop an impaired contractile function and potential to generate arrhythmias.
- Major consequences of myocardial ischemia include mechanical and electrical dysfunction, muscle cell damage, and development of necrosis. Acute ischemic events may develop where there is coronary atherosclerosis. Ultimately, if the ischemia is sufficiently severe there will be an immediate reduction (or cessation) of contractile function in the heart.
- ATP adenosine triphosphate
- ATPases adenosine triphosphatases
- ATPases are enzymes that typically catalyze the hydrolysis of ATP, the main energy currency in cells, to adenosine monophosphate (AMP) or adenosine diphosphate (ADP), plus phosphate ions and energy.
- AMP adenosine monophosphate
- ADP adenosine diphosphate
- the contractile function of the heart is regulated by the transport of calcium, sodium, and potassium ions, which in turn is modulated by ATP and ATPases.
- intracellular ATP is split by Na + ,K + ATPase, an enzyme that is responsible for maintaining a gradient of sodium and potassium ions across the cell membrane.
- the splitting of ATP by Na + ,K + ATPase releases the energy needed to transport K+ and Na + ions against concentration gradients. This enables the existence of a resting potential in the membrane (i.e, Na + out, K + in) which initiates the contractile response.
- Contraction is triggered by Na/Ca exchange and Ca 2+ transport, the energy for which is generated by the hydrolysis of ATP by Ca 2+ ATPase.
- the cells' supply of ATP must be replenished as it is consumed (e.g., with muscle contraction).
- the rate of ATP synthesis needs to be closely matched to its rate of consumption.
- the most important ATPase is the mitochondrial F 1 F 0 -ATPase.
- the F 1 F 0 -ATPase has both hydrolytic and synthetic states.
- ATP synthase the mitochondrial F 1 F 0 -ATPase catalyzes the production of ATP via oxidative phosphorylation of ADP and P i .
- F 1 F 0 -ATPase is responsible for producing the cell's main energy source, ATP.
- mitochondrial F 1 F 0 -ATPase modulates this ATP production via its two units, the F 1 and F 0 complexes.
- F 0 is the inner membrane domain
- F 1 is a catalytic domain consisting of five subunits (( ⁇ -the catalytic site is on the ⁇ unit), that protrude from the F 0 domain into the mitochondrial matrix.
- This proton/electron transport creates an electrochemical proton gradient across the mitochondrial membrane and through the F 0 domain which drives the F 1 domain to synthesize ATP.
- IF 1 inhibitor protein may be bound to the F 1 unit under ischemic conditions to inhibit the ATP hydrolase activity of the enzyme; however, IF 1 is highly pH dependent and in severe conditions can provide only a modicum of control.
- the conversion of F 1 F 0 -ATP synthase to F 1 F 0 -ATP hydrolase is reversible, as addition of substrate and oxygen to the mitochondria of ischemic muscle can reactivate the F 1 F 0 -ATPase and ATP levels to control levels.
- F 1 F 0 -ATPase produces a futile cycling and waste of ATP. It is believed that this depletion of ATP and/or ATP synthase may suppress the Na + K + pump to increase cardiac contractility, vasoconstriction, sensitivity to vasoactive agents, and arterial blood pressure.
- Several inhibitors of F 1 F 0 -ATPase have been described, including efrapeptin, oligomycin, autovertin B, and azide. Oligomycin targets F 0 and reportedly postpones cell injury by preserving ATP during ischemia.
- the only known inhibitors of F 1 F 0 -ATPase are large proteins or peptides which are not orally bioavailable.
- the instant invention provides N-substituted-N′-(1-phenyl-2-heteraryl)ethyl-guanidine compounds including cyanoguanidine and benzoylguanidine compounds that are potent and selective inhibitors of F 1 F 0 -ATP hydrolase.
- the compounds of the present invention are useful in treating or preventing conditions associated with ischemia, particularly myocardial ischemia and associated conditions, such as muscle cell damage, necrosis, and cardiac arrhythmias. Also, in view of their inhibitory activity, the inventive compounds may be used to treat cancer and tumor growth.
- Cyano-guanidine based compounds for treating various other indications are disclosed in Shimada et al, “Synthesis and Gastric Antisecretory Activity of N - Cyano - N′ ( phenyl - pyridinylmethyl ) guanidine Derivatives,” Chem. Pharm. Bull ., Vol. 32(12), (1984), at pp. 4893-4906; WO 00/35449 , “N - Ureidoalkyl - Piperidines as Modulators of Chemokine Receptor Activity ,” to Du Pont Pharmaceuticals Co.; U.S. Pat. No.
- R 1 is cyano, —SO 2 R 8 , —C( ⁇ O)R 9 , or heteroaryl;
- R 2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R 3 forms a heterocyclo;
- R 3 is (i) independently alkyl, substituted alkyl, alkylthio, aminoalkyl, carbamyl, A-aryl, A-heterocyclo, A-heteroaryl, or A-cycloalkyl, or (ii) taken together with R 2 forms a heterocyclo;
- Z is heteroaryl provided that when R 1 is cyano, Z is not 2-pyridinyl;
- A is a bond, C 1-4 alkylene, C 2-4 alkenylene, substituted C 1-4 alkylene, substituted C 2-4 alkenylene, —C( ⁇ O)NR 19 —, —C 1-4 alkylene-C( ⁇ O)NR 19 —, or substituted C 1-4 alkylene-C( ⁇ O)NR 19 —;
- R 4 at each occurrence is selected independently of each other R 4 from the group consisting of halogen, alkyl, haloalkyl, nitro, cyano, haloalkoxy, OR 25 , SR 25 , NR 25 R 26 , NR 25 SO 2 R 27 , SO 2 R 27 , SO 2 NR 25 R 26 , CO 2 R 26 , C( ⁇ O)R 26 , C( ⁇ O)NR 25 R 26 , OC( ⁇ O)R 25 , —OC( ⁇ O)NR 25 R 26 , NR 25 C( ⁇ O)R 26 , NR 25 CO 2 R 26 , aryl, heteroaryl, heterocyclo and cycloalkyl;
- R 8 is alkyl, substituted alkyl, aryl, or heteroaryl
- R 9 is —NR 10 R 11 , alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO 2 R 12 ;
- R 10 and R 11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R 12 and R 19 are hydrogen or alkyl
- R 25 and R 26 are independently selected from hydrogen, alkyl, or substituted alkyl, or taken together form a heterocyclo or heteroaryl ring;
- R 27 is alkyl or substituted alkyl
- q is 0, 1, 2, or 3.
- compositions comprising one or compounds of formula (I), and methods of treating ischemic conditions and/or conditions associated with depleted levels of adenosine triphosphate (ATP) and/or the activity of mitochondrial F 1 F 0 ATPase.
- ATP adenosine triphosphate
- methods of treating ischemic conditions and/or conditions associated with depleted levels of adenosine triphosphate (ATP) and/or the activity of mitochondrial F 1 F 0 ATPase comprise administering an effective amount of at least one compound of formula (I) to a patient in need thereof.
- F 1 F 0 -ATP hydrolase can be selectively inhibited via use of a small organic molecule, i.e., a non-peptidic organic compound having less than 1000 molecular weight, and this invention is also claimed herein.
- alkyl refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred.
- substituted alkyl refers to an alkyl group as defined above having one, two, three, or four substituents selected from the group consisting of halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OR a , SR a , NR a R b , NR a SO 2 , NR a SO 2 R c , SO 2 R c , SO 2 NR a R b , CO 2 R a , C( ⁇ O)R a , C( ⁇ O)NR a R b , OC( ⁇ O)R a , —OC( ⁇ O)NR a R b , NR a C( ⁇ O)R b , NR a CO 2 R b , ⁇ N—OH, ⁇ N—O-alkyl, aryl, heteroaryl, heterocyclo and cycloalkyl, wherein R
- a substituted alkyl includes an aryl, heterocyclo, heteroaryl, or cycloalkyl substituent
- said ringed systems are as defined below and thus may in turn have zero to four substituents (preferably 0-2 substituents), also as defined below.
- R a , R b or R c When either R a , R b or R c is an alkyl, said alkyl may optionally be substituted with 1-2 of halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH 2 , NH(alkyl), N(alkyl) 2 , NHSO 2 , NHSO 2 (alkyl), SO 2 (alkyl), SO 2 NH 2 , SO 2 NH(alkyl), CO 2 H, CO 2 (alkyl), C( ⁇ O)H, C( ⁇ O)alkyl, C( ⁇ O)NH 2 , C( ⁇ O)NH(alkyl), C( ⁇ O)N(alkyl) 2 , OC( ⁇ O)alkyl, —OC( ⁇ O)NH 2 , —OC( ⁇ O)
- Alkyl when used in conjunction with another group such as in arylalkyl refers to a substituted alkyl in which at least one of the substituents is the specifically-named group.
- arylalkyl includes benzyl, or any other straight or branched chain alkyl having at least one aryl group attached at any point of the alkyl chain.
- carbamylalkyl includes the group —(CH 2 ) n —NH—C( ⁇ O)alkyl, wherein n is 1 to 12.
- alkenyl refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups of 2 to 6 carbon atoms and having one double bond are most preferred.
- alkynyl refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred.
- alkylene refers to bivalent straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, e.g., ⁇ —CH 2 — ⁇ n , wherein n is 1 to 12, preferably 1-8. Lower alkylene groups, that is, alkylene groups of 1 to 4 carbon atoms, are most preferred.
- alkenylene and alkynylene refer to bivalent radicals of alkenyl and alknyl groups, respectively, as defined above.
- substituted alkylene, alkenylene, or alkynylene group these groups are substituted with one to four substitutents as defined above for alkyl groups.
- a substituted alkylene, alkenylene, or alkynylene may have a ringed substituent attached in a spiro fashion as in
- alkoxy refers to an alkyl or substituted alkyl group as defined above having one, two or three oxygen atoms (—O—) in the alkyl chain.
- alkoxy includes the groups —O—C 1-12 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, —C 1-4 alkylene-O-phenyl, and so forth.
- thioalkyl refers to an alkyl or substituted alkyl group as defined above having one or more sulfur (—S—) atoms in the alkyl chain.
- thioalkyl or “alkylthio” includes the groups —(CH 2 ) n —S—CH 2 aryl, —(CH 2 ) n —S-aryl, etc.
- aminoalkyl refers to an alkyl or substituted alkyl group as defined above having one or more nitrogen (—NR′—) atoms in the alkyl chain.
- aminoalkyl includes the groups —NR′—C 1-12 alkyl and —CH 2 —NR′-aryl, etc. (where R′ is hydrogen, alkyl or substituted alkyl as defined above.)
- Amino refers to the group —NH 2 .
- a subscript refers to the number of carbon atoms the group may contin.
- Zero when used in a subscript denotes a bond, e.g., C 0-4 alkyl refers to a bond or an alkyl of 1 to 4 carbon atoms.
- a subscript refers to the number of carbon atoms that the group may contain in addition to heteroatoms. Thus, for example, monovalent.
- C, 2 aminoalkyl includes the groups —CH 2 —NH 2 , —NH—CH 3 , —(CH 2 ) 2 —NH 2 , —NH—CH 2 —CH 3 , —CH 2 —NH 2 —CH 3 , and —N—(CH 3 ) 2 .
- a lower aminoalkyl comprises an aminoalkyl having one to four carbon atoms.
- the alkoxy, thioalkyl, or aminoalkyl groups may be monovalent or bivalent.
- monovalent it is meant that the group has a valency (i.e., power to combine with another group), of one
- bivalent it is meant that the group has a valency of two.
- a monovalent alkoxy includes groups such as —O—C 1-12 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, etc.
- a bivalent alkoxy includes groups such as —O—C 1-2 alkylene-, —C 1-6 alkylene-O—C 1-6 alkylene-, etc.
- acyl refers to a carbonyl
- R d may be selected from alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, heterocyclo, cycloalkyl, or heteroaryl, as defined herein.
- alkoxycarbonyl refers to a group having a carboxy or ester group
- R d is as defined above for acyl.
- carbamyl refers to a functional group in which a nitrogen atom is directly bonded to a carbonyl, i.e., as in —NR e C( ⁇ O)R f or —C( ⁇ O)NR e R f , wherein R e and R f can be hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, cycloalkyl, aryl, heterocyclo, or heteroaryl, or they may join to form a ring.
- sulfonyl refers to a sulphoxide group (i.e., —S(O) 1-2 ) linked to an organic radical R c , as defined above.
- sulfonamide or “sulfonamido” refers to the group —S(O) 2 NR e R f , wherein R e and R f are as defined above.
- R e and R f are optionally substituted heteroaryl or heterocycle (as defined below), the other of R e and R f is hydrogen or alkyl.
- cycloalkyl refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms.
- the term “cycloalkyl” includes such rings having zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halogen, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, keto, OR d , SR d NR d R e NR c SO 2 , NR c SO 2 R e , C( ⁇ O)H, acyl, —CO 2 H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC( ⁇ O)R d , ⁇ N—OH, ⁇ N—O-alkyl, aryl, heteroaryl, heterocyclo, a 4 to 7 membered carb
- cycloalkyl also includes such rings having a phenyl ring fused thereto or having a carbon-carbon bridge of 3 to 4 carbon atoms. Additionally, when a cycloalkyl is substituted with a further ring, i.e., aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo, heterocycloalkyl, cycloalkylalkyl, or a further cycloalkyl ring, such ring in turn may be substituted with one to two of C 0-4 alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH 2 , NH(alkyl), N(alkyl) 2 , NHSO 2 , NHSO 2 (alkyl), SO 2 (alkyl),
- halo or “halogen” refers to chloro, bromo, fluoro and iodo.
- haloalkyl means a substituted alkyl having one or more halo substituents.
- haloalkyl includes mono, bi, and trifluoromethyl.
- haloalkoxy means an alkoxy group having one or more halo substituents.
- haloalkoxy includes OCF 3 .
- aryl refers to phenyl, biphenyl, 1-naphthyl, 2-naphthyl, and anthracenyl, with phenyl being preferred.
- aryl includes such rings having zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, OR d , SR d , NR d R e , NR d SO 2 , NR d SO 2 R c , C( ⁇ O)H, acyl, —CO 2 H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC( ⁇ O)R d , heteroaryl, heterocyclo, cycloalkyl, phenyl,
- two substituents attached to an aryl may join to form a further ring such as a fused or spiro-ring, e.g., cyclopentyl or cyclohexyl or fused heterocycle or heteroaryl.
- such ring in turn may be substituted with one to two of CO 4 alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH 2 , NH(alkyl), N(alkyl) 2 , NHSO 2 , NHSO 2 (alkyl), SO 2 (alkyl), SO 2 NH 2 , SO 2 NH(alkyl), CO 2 H, CO 2 (alkyl), C( ⁇ O)H, C( ⁇ O)alkyl, C( ⁇ O)NH 2 , C( ⁇ O)NH(alkyl), C( ⁇ O)N(alkyl) 2 , OC( ⁇ O)alkyl, —OC( ⁇ O)NH 2 , —OC( ⁇ O)NH(alkyl), NHC
- heterocyclo refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N).
- Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom.
- the fused rings completing bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
- the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
- the heterocyclo group may be attached at any available nitrogen or carbon atom.
- the heterocyclo ring may contain zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, keto, OR d , SR d , NR d R e , NR d SO 2 , NR d SO 2 R c , SO 2 R d , C( ⁇ O)H, acyl, —CO 2 H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC( ⁇ O)R d , ⁇ N—OH, ⁇ N—O-alkyl, aryl,
- heterocyclo also includes such rings having a phenyl ring fused thereto or having a carbon-carbon bridge of 3 to 4 carbon atoms.
- a heterocyclo when a heterocyclo is substituted with a further ring, i.e., aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or a further heterocyclo ring, such ring in turn may be substituted with one to two of C 0-4 alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH 2 , NH(alkyl), N(alkyl) 2 , NHSO 2 , NHSO 2 (alkyl), SO 2 (alkyl), SO 2 (
- Exemplary monocyclic groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like.
- Exemplary bicyclic heterocyclo groups include quinuclidinyl,
- heteroaryl refers to substituted and unsubstituted aromatic 5 to 7 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings.
- Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
- the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
- the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
- Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
- the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
- the heteroaryl ring system may contain zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, OR d , SR d , NR d R e , NR d SO 2 , NR d SO 1 2 R c , SO 2 R d , C( ⁇ O)H, acyl, —CO 2 H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC( ⁇ O)R d , heterocyclo, cycloalkyl, aryl, or a monocyclic 4 to 7 membered aromatic ring having one to four heteroatoms, including phenylethyl, phenyloxy, and phenylthio, wherein R c , R
- a heteroaryl when a heteroaryl is substituted with a further ring, i.e., aryl, arylalkyl, heterocyclo, heterocycloalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or a further heteroaryl ring, such ring in turn may be substituted with one to two of C 0-4 alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto ( ⁇ O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH 2 , NH(alkyl), N(alkyl) 2 , NHSO 2 , NHSO 2 (alkyl),n SO 2 (alkyl), SO 2 NH 2 , SO 2 NH(alkyl), CO 2 H, CO 2 (alkyl), C( ⁇ O)H, C( ⁇ O)alky
- Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl (i.e.,
- thiadiazolyl isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.
- Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxaxolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
- Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- the compounds of formula I form salts which are also within the scope of this invention.
- Reference to a compound of the formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
- the term “salt(s)”, as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases.
- zwitterions inner salts may be formed and are included within the term “salt(s)” as used herein.
- Salts of the compounds of the formula I may be formed, for example, by reacting a compound of the formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- the compounds of formula I which contain a basic moiety may form salts with a variety of organic and inorganic acids.
- Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobrom
- the compounds of formula I which contain an acidic moiety may form salts with a variety of organic and inorganic bases.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines [formed with N,N-bis(dehydro-abietyl)ethylenediamine], N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
- lower alkyl halides e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates
- All stereoisomers of the present compounds such as those, for example, which may exist due to asymmetric carbons, including enantiomeric forms (which may exist even in the absence of asynmmetric carbons) and diastereomeric forms, are contemplated and within the scope of this invention.
- Individual stereoisomers of the compounds of this invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- compounds of the formulas I may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., a compound of formula I) is a prodrug within the scope and spirit of the invention.
- pro-drug compounds of the formulas I may be carboxylate ester moieties.
- a carboxylate ester may be conveniently formed by esterifying any of the carboxylic acid functionalities found on the disclosed ring structure(s).
- prodrug derivatives are well known in the art.
- prodrug derivatives see:
- solvates e.g., hydrates
- Methods of solvation are generally known in the art.
- Preferred compounds of the present invention are those having the following formula, or salts, hydrates, and prodrugs thereof,
- Z is triazolyl optionally substituted with one to two R 7 or imidazolyl optionally substituted with one to two R 7 and/or having fused thereto a benzene ring in turn optionally substituted with one to two R 7 ;
- R 1 is cyano or —C( ⁇ O)R 9 ;
- R 2 is hydrogen, alkyl, or benzyl
- R 3 is aryl or arylalkyl optionally substituted with alkyl, halogen, trifluoromethyl, OCF 3 , cyano, nitro, amino, hydroxy, or methoxy;
- R 4 is halogen, alkyl, trifluoromethyl, or OCF 3 ;
- R 7 is alkyl, carbamyl or carbamylC 1-4 alkyl
- R 9 is —NR 10 R 11 , alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO 2 R 12 ;
- R 10 and R 11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R 12 is hydrogen or alkyl
- q is 0, 1, 2, or 3.
- Y is N or CR 7c ;
- R 1 is cyano or —C( ⁇ O)R 9 ;
- R 2 is hydrogen or C 1-4 alkyl
- R 4 is halogen, C 1-4 alkyl, trifluoromethyl, or OCF 3 ;
- R 7a , R 7b and R 7c are alkyl, carbamyl or carbamylC 1-4 alkyl, or R 7a and R 7c join to form an optionally substituted fused phenyl ring;
- R 9 is —NR 10 R 11 , alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO 2 R 12 ;
- R 10 and R 11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R 12 is hydrogen or alkyl
- R 23 is hydrogen, alkyl, hydroxyalkyl, or phenyl
- R 24 is alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF 3 , methoxy, phenyloxy, benzyloxy, cyano, or acyl, or two R 24 groups join to form a fused cycloalkyl or benzene ring;
- q is 1 or 2;
- x is 0, 1, or 2;
- y is 0, 1, 2, or 3.
- R 1 is cyano or —C( ⁇ O)R 9 ;
- R 4 is halogen, C 1-4 alkyl, trifluoromethyl, or OCF 3 ;
- R 7 and R 7 join to form a fused benzene ring optionally substituted with C 1-4 alkyl or —(CH 2 ) 1-2 —NHC( ⁇ O)C 1-4 alkyl
- R 7b is hydrogen, C 1-4 alkyl, or —(CH 2 ) 1-2 —NHC( ⁇ O)C 1-4 alkyl
- R 9 is a) —NR 10 R 11;
- cycloalkyl optionally substituted with one to two of C( ⁇ O)H, C 1-4 acyl, alkenyl, carbamyl, and/or phenyl in turn optionally substituted with halogen;
- phenyl or napthyl optionally substituted with one to two of halogen, nitro, amino, alkyl, hydroxy, C 1-4 alkoxy, or having fused thereto a five or six membered heterocyclo;
- cycloalkyl optionally having up to four substituents selected from alkyl, halogen, cyano, alkenyl, acyl, alkylthio, carbamyl, and/or phenyl in turn optionally substituted with halogen; or having an aryl fused thereto;
- phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C 1-4 alkoxy, haloalkoxy, C 1-6 alkyl, CO 2 alkyl, SO 2 alkyl, SO 2 NH 2 , amino, NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , NHC( ⁇ O)alkyl, C( ⁇ O)alkyl, and/or C 1-4 alkyl in turn optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto;
- R 10 is hydrogen, alkyl, or alkoxy
- R 11 is alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, or heteroaryl; or
- R 10 and R 11 taken together form a heterocyclo or heteroaryl
- R 23 is hydrogen, alkyl, hydroxyalkyl, or phenyl
- R 24 is alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF 3 , methoxy, phenyloxy, benzyloxy, cyano, or acyl, or two R 24 groups join to form a fused cycloalkyl or benzene ring;
- q is 0, 1, or 2;
- x is 0 or 1
- y is 0, 1, or 2.
- R1 is cyano or —C( ⁇ O)R 9 ;
- R 9 is optionally substituted phenyl or phenyl C 1-4 alkyl;
- x is 0 or 1; and
- q and y are 1 or 2.
- the compounds of this invention by inhibiting F 1 F 0 -ATPase may be used to help conserve ATP under conditions of oxygen deprivation.
- the compounds may be useful in treating or preventing any condition associated with depleted levels of ATP and/or tissue ischeria (from mild to acute or severe).
- the terms “treating” or “treatment” encompass both responsive and prophylaxis measures designed to inhibit or delay the onset of the disease or disorder, or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms.
- the inventive compounds are useful in treating cardiovascular diseases including, without limitation, congestive heart failure, cardiac arrhythmias, unstable angina, and high blood pressure.
- the compounds also are useful to treat ischemia, including ischemia resulting from vascular occlusion, cerebral infarction, stroke and related cerebral vascular diseases (including cerebrovascular accident and transient ischemic attack), and accurate coronary syndromes such as myocardial infarction, coronary artery disease, unstable angina, and non-Q wave MI.
- the compounds are useful in treating or preventing symptoms or consequences occurring from thrombosis and/or the formation of atherosclerotic plaques, atherosclerosis, peripheral arterial disease, coagulation syndromes, and intermittent claudication.
- the compounds may be used to treat thrombotic or thromboembolic conditions such as thromboembolic stroke (including that resulting from atrial fibrillation 10 or from ventricular mural thrombus); venous thrombosis (including deep vein thrombosis); arterial thrombosis; cerebral thrombosis; pulmonary embolism; cerebral embolism; peripheral occlusive arterial disease (e.g., peripheral arterial disease, intermittent claudication, critical leg ischemia, prevention of amputation, prevention of cardiovascular morbidity such as MI, stroke or death); thromboembolic consequenses of surgery, interventional cardiology or immobility; thromboembolic consequenses of medication (such as oral contraceptives, hormome replacement and
- Compounds of the present invention may be useful for maintaining blood vessel patency in conjunction with vascular surgery including bypass grafting, arterial reconstruction, atherectomy, vascular graft and stent patency, organ, tissue and cell implantation and transplantation.
- the compounds of the present invention may be useful for maintaining blood vessel patency in conjunction with interventional cardiology or vascular surgery including bypass grafting, arterial reconstruction, atherectomy, vascular graft and stent patency, organ, tissue and cell implantation and transplantation.
- the compounds may be used for preservation of tissue as related to organ transplantation.
- inventive compounds also are useful in treating diseases or disorders in other tissues or muscles that are associated with ischemic conditions.
- the compounds may be used to treat muscle cell damage and necrosis.
- the inventive compounds may be useful as anti-cancer and/or anti-tumor agents. It is reported that inhibitors of mitochondrial FIF 0 -ATPase selectively kill metabolically active tumor cells that do not exhibit the Warburg effect, i.e., cells that do not maintain a high level of anaerobic carbon metabolism even in the presence of oxygen. See Salomon et al., “ Understanding and Exploiting the Mechanistic Basis for Selecivity of Polyketide Inhibitors of F 1 F 0 - ATPase,” Proc. Natl. Acad. Sci . Vol. 97 (26) (2000), at pp. 14766-14771. Accordingly, the compounds of the present invention are useful in treating tumor growth, as an adjunct to chemotherapy, and for treating cancer, more particularly, cancer of the lung, prostate, colon, breast, ovaries, and bone.
- inventive compounds may also be used in combination with other F 1 F 0 -ATPase inhibitors such as efrapeptin, oligomycin, autovertin B, and azide, and/or in combination with other cardiovascular drugs. Additionally, the compounds may be used in combination with other therapeutic agents such as potassium channel openers, calcium channel blockers, sodium hydrogen exchanger inhibitors, anti-arrhythmic agents, thrombin inhibitors, platelet aggregation inhibitors or anti-platelet agents, fibrinogen antatagonists, diuretics, anti-hypertensive agents, mineralocorticoid receptor antagonists; phospodiesterase inhibitors; cholesterol/lipid lowering agents and lipid profile therapies; anti-diabetic agents; anti-depressants; anti-inflammatory agents (steroidal and non-steroidal); anti-oxidant agents; angiogenesis modulators; anti-osteoporosis agents; hormone replacement therapies; oral contraceptives; anti-coagulants; anti-obesity agents; anti-anxiety agents
- inventive compounds may be used in combination with aspirin, clopidogrel, ticlopidine or CS-747, warfarin, and low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin).
- suitable therapeutic agents in combination with which the inventive compounds may be used include:
- anti-arrhythmic agents including Class I agents (such as propafenone); Class II agents (propranolol); Class III agents (such as sotalol, dofetilide, amiodarone, azimilide and ibutilide); Class IV agents (such as ditiazem and verapamil); K + channel openers such as IAch inhibitors, and IKur inhibitors (e.g., compounds such as those disclosed in U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000;
- alpha- or beta- adrenergic blockers such as propranolol, nadolol and carvedilol
- - ⁇ -adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, and/or fenoterol
- angiotensin-II receptor antagonists e.g., irbesartan, losartan or valsartan
- anticholinergics such as ipratropium bromide
- anti-diabetic agents such as biguamides (e.g. metformin); glucosidase inhibitors (e.g. acarbose); insulins (including insulin secretagogues or insulin sensitizers); meglitinides (e.g. repaglinide); sulfonylureas (e.g., glimepiride, glyburide and glipizide); biguamide/glyburide combinations (e.g., glucovance), thiozolidinediones (e.g.
- biguamides e.g. metformin
- glucosidase inhibitors e.g. acarbose
- insulins including insulin secretagogues or insulin sensitizers
- meglitinides e.g. repaglinide
- sulfonylureas e.g., glimepiride, glyburide and glipizide
- troglitazone rosiglitazone and pioglitazone
- PPAR-alpha agonists PPAR-gamma agonists
- PPAR alpha/gamma dual agonists SGLT2 inhibitors
- inhibitors of fatty acid binding protein (aP2) such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000 and assigned to the present assignee, glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase IV (DP4) inhibitors;
- anti-depressant or anti-anxiety agents such as nefazodone, sertraline, diazepam, lorazepam, buspirone, and hydroxyzine pamoate;
- anti-diabetic agents such as biguamides (e.g. metformin); glucosidase inhibitors (e.g. acarbose); insulins (including insulin secretagogues or insulin sensitizers); meglitinides (e.g. repaglinide); sulfonylureas (e.g., glimepiride, glyburide and glipizide); biguamide/glyburide combinations (e.g., glucovance), thiozolidinediones (e.g.
- biguamides e.g. metformin
- glucosidase inhibitors e.g. acarbose
- insulins including insulin secretagogues or insulin sensitizers
- meglitinides e.g. repaglinide
- sulfonylureas e.g., glimepiride, glyburide and glipizide
- troglitazone rosiglitazone and pioglitazone
- PPAR-alpha agonists PPAR-gamma agonists
- PPAR alpha/gamma dual agonists SGLT2 inhibitors
- inhibitors of fatty acid binding protein (aP2) such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000 and assigned to the present assignee, glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase IV (DP4) inhibitors;
- anti-hypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril, lisinopril, zofenopril, ramipril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril), vasopeptidase inhibitors, i.e., dual ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan); ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265); Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389); neutral endopeptidase (NEP
- anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and/or pranleukast or cortiocosteroids including beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone; prednisone; dexamethasone; enbrel; protien tyrosine kinase (PTK) inhibitors; cyclooxygenase inhibitors (including NSAIDs, and COX-1 and/or COX-2 inhibitors); aspirin; or indomethacin; lipoxygenase inhibitors; chemokine receptor modulators (including CCR1, CCR2, CCR3, CXCR2 receptor antagonists); secretory and cytosolic phospholipase A2 inhibitors; VLA4 antagonists; cytokine modulators (e.g. T
- angiogenesis modulators such as endostatin
- anti-oxidant agents and/or lipid peroxidation inhibitors such as probucol, BO-653, Vitamin A, Vitamin E, AGI-1067;
- anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, tirofiban); P2Y 12 antagonists (e.g., clopidogrel, ticlopidine, CS-747); or thromboxane receptor antagonists (e.g., ifetroban);
- GPIIb/GPIIIa blockers e.g., abciximab, eptifibatide, tirofiban
- P2Y 12 antagonists e.g., clopidogrel, ticlopidine, CS-747
- thromboxane receptor antagonists e.g., ifetroban
- anti-osteoporosis agents including alendronate and raloxifene.
- anti-obesity agents including orlistat and aP2 inhibitors (such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000);
- anti-proliferative agents for use in combination with the compounds of the present invention include cyclosporin A, paclitaxel, FK 506, and adriamycin;
- anti-ulcer and gastroesophageal reflux disease agents including famotidine, ranitidine, and omeprazole;
- NHE-1 (NHE-1) inhibitors such as cariporide
- calcium channel blocking agents such as verapamil, nifedipine, diltiazem, amlodipine and mybefradil;
- cardiac glycosides such as digitalis and ouabain;
- diuretics such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetamide, triamtrenene, amiloride;
- hormone replacement therapies including estrogen (e.g., congugated estrogens) and estradiol;
- lipid profile modulators including HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin [Nissan/Kowa]), ZD-4522 (a.k.a.
- HMG-CoA reductase inhibitors e.g., pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin [Nissan/Kowa]
- ZD-4522 a.k.a.
- mineralocorticoid receptor antagonists such as spironolactone and eplirinone.
- microsomal triglyceride transport protein inhibitors such as disclosed in U.S. Pat. Nos. 5,739,135, 5,712,279 and 5,760,246);
- PDE phosphodiesterase
- PDE inhibitors including dipyridamole, cilostazol, or sildenafil, or PDE inhibitors in combination with aspirin, ifetroban, picotamide, ketanserin, clopidogrel, and/or thromboxane receptor antagonists or thromboxane A synthetase inhibitors (such as picotamide);
- serotonin-2-receptor antagonists such as ketanserin
- fibrinogen receptor antagonists such as ketanserin
- thrombolytic agents such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, tenecteplase (TNK), lanoteplase (nPA), anisolated,streptokinase plasminogen activator complex (ASPAC), factor VIIa inhibitors, factor Xa inhibitors, thrombin inhibitors (such as hirudin and argatroban), animal salivary gland plasminogen activators, PAI-1 inhibitors such as XR-330 and T-686, and inhibitors of ⁇ -2-antiplasmin such as anti- ⁇ -2-antiplasmin antibody, prostacyclin mimetics.
- tissue plasminogen activator natural or recombinant
- streptokinase reteplase
- activase lanoteplase
- urokinase prourokina
- inventive compounds may also be useful in combination with other anticancer strategies and chemotherapies such as taxol and/or cisplatin.
- the compounds may be used in conjunction with anti-tumor agents such as paclitaxel, adriamycin, epithilones, cisplatin, and carboplatin.
- the compounds of the present invention may act in a synergistic fashion with one or more of the above agents to allow for increased efficacy and/or reduced doses of any of the above agents and therefore minimize potential hemorrhagic side-effects.
- the compounds of formula I may be administered by any means suitable for the condition to be treated.
- Systematic treatment is typically preferred for cancerous conditions, although other modes of delivery are contemplated.
- the compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; sublingually; bucally; transdermally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; rectally such as in the form of suppositories; or liposomally.
- Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered.
- the compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.
- compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.
- the inventive compounds may be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets.
- compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins.
- fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins.
- high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (e.g., GANTREZ®); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934®).
- Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
- compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
- compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
- suitable non-irritating excipients such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
- the effective amount of a compound of the present invention may be determined by one of ordinary skill in the art.
- the specific dose level and frequency of dosage for any particular subject may vary and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
- An exemplary effective amount of compounds of formula I may be within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.
- Mitochondria were isolated from bovine hearts and purified through a Percoll gradient, sonicated to generate sub mitochondrial particles (SMP), centrifuged, and stored at ⁇ 80° C. See Gasnier F. et al, “Use of Percoll Gradients for Isolation of Human Placenta Mitochondria Suitable for Investigating Outer Membrane Proteins,” Anal. Biochem ., Vol 212(1) (1993) at pp. 173-178; and Matsuno-Yagi A et al, “ Studies on the Mechanism of Oxidative Phosphorylation: Effects of Specific F 0 Modifiers on Ligand - Induced Conformation Changes of F 1 ,” Proc.
- ATP hydrolyase activity was determined using SMP and the well-characterized coupled enzyme system in which ATP hydrolysis and subsequent ADP generation is coupled through pyruvate kinase and lactate dehydrogenase to NAD+generation which was monitored by a decrease in absorbance at 340 nm (see Pullman, M. E. et al, “ Partial Resolution of the Enzymes Catalyzing Oxidative Phosphorylation,” J. Biol. Chem. Vol. 235 (1960), at pp.
- DIP-Cl B-chlorodiisopinocampheylborane
- NaHCO 3 sodium bicarbonate
- KCNS potassium isothiocyanate
- Ph 3 P triphenylphosphine
- TEA triethylamine or Et 3 N
- TFA trifluoroacetic acid
- Inventive compounds that are inhibitors of mitochondrial F 1 F 0 ATP hydrolase may be prepared by methods illustrated in the following Schemes I to IX. Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art using known methods.
- the groups R 1 -R 4 are as described above for a compound of Formula I and X is halogen, unless otherwise indicated.
- the group “Z” as used in these schemes corresponds to the group NR 5 R 6 , as described for a compound of Formula I, unless indicated otherwise.
- Groups designated generally as “R” are selected from substituents as set forth in the above definitions.
- HSA High Speed Analoging
- N-Arylcyanoguanidines of formula (Ia) were prepared by coupling 1-aryl-2-heteroaryl ethylamines 1 with N-aryl-N′-cyanothiourea in the presence of N-dimethylaminopropyl-N′-ethylcarbodiimide in solvent such as DMF.
- Ethylamines 1 may be prepared as described below in Schemes VI and VIII.
- Cyanoguanidines of formula (Ib) were prepared by reacting 1-Aryl-2-heteroaryl ethylamines 1 (Schemes VI-VIII) with diphenylcyanoimidate to give compound 2. Subsequent reaction of 2 with amine R 3 —NH 2 in a solvent such as acetonitrile at temperatures at around 80° C. gave cyanoguanidine (Ib). This synthetic scheme is advantageous for nucleophilic amines (R—NH 2 ), such as benzylamine.
- Acyl guanidines (Ic) were prepared by two methods: (i) first reacting the corresponding acids (R 9 —CO 2 H) with CDI to produce intermediates, and then reacting the intermediates with guanidine 4, and (ii) reacting amines R′R′′NH with CDI to produce mixed ureas, and then reacting the mixed ureas with guanidine 4.
- Ureidoguanidines of formula (Id) were prepared by first reacting guanidine 4 with CDI, and then reacting the intermediate with amine (R 10 R 11 NH).
- Acylguanidines of formula (If) were prepared by first converting acyl chloride 7 to acylisothiocyanate 8 by reaction with an isothiocyanate such as potassium isothiocyanate. Treatment of 8 with 1-aryl-2-heteroaryl ethylamine 1 gave acylthiourea 9. Treatment of 9 with TEA and a metal salt such as HgCl 2 in acetonitrile gave compounds (If).
- 1-Aryl-2-heteroaryl ethylamines 1 (used in Schemes I-V) were prepared from aroylchlorides 10 and directly from acetophenones 11. Aroylchlorides 10 were reacted with methlymagnesium bromide in the presence of tributylphosphine in THF to give substituted acetophenone 11. Halogentation of acetophenones such as by bromination (Br 2 /CH 2 Cl 2 ), gave haloacetophenones 12. Displacement of the halogen in 12 with nucleophilic heteroaryls, such imidazole, benzimidazole, or triazole, in solvent, such as acetonitrile, gave compound 13.
- ketone 13 Reduction of ketone 13 with a reducing agent, such as sodium borohydride, in a solvent such as EtOH, gave substituted 1-aryl-2-heteroaryl ethanol 12.
- Alcohol 12 was converted to amine 1 by reaction with an azide such as DPPA and DBU, followed by reduction with reducing agents such as Ph 3 P and water in a solvent such as THF.
- 1-Aryl-2-heteroaryl ethanols 14 were also prepared by treating an arylaldehyde 15 under epoxidizing conditions, such as trimethylsulfonium iodide and KOH in acetonitrile to give epoxide 16. Reaction of the epoxide 16 with heteroaryls, such as imidazole, benzimidazole, triazole, in the presence of NaH in a solvent such as DMF produced 1-aryl-2-heteroaryl ethanol 14. The ethanol 14 can then be converted to 1-Aryl-2-heteroaryl ethylamines 1 by reaction with an azide as shown in Scheme VI.
- epoxidizing conditions such as trimethylsulfonium iodide and KOH in acetonitrile
- heteroaryls such as imidazole, benzimidazole, triazole
- [0227] can also be prepared by reacting arylaldehydes 15 with LiHMDS in THF and then with TMSCl to produce compounds 17.
- N-(Aryl)sulphonylguanidines can be prepared by treatment of arylsulphonyl chlorides 1 with ammonium hydroxide to produce arylsulphonamines 2, which yield thioureas 3 upon treatment with isothiocyanates and a base, such as sodium hydride. Reaction of these N-aryl-N′-arylsulphonylthioureas with a benzylic amine such as 4, in the presence of HgCl 2 and a base, such as DIPEA, yields N-(aryl)sulphonylguanidines 5.
- Example 82 The general procedure described in Example 1 (Steps C-F) was followed to synthesize Example 82; however, in Step C, trichloroacetophenone was used instead of 1-bromomethylcarbonyl-2,5-bistrifluoromethylbenzene to produce the intermediate 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethylamine as a white solid, and then this intermediate was used in step F instead of 1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylamine, to provide Example 82 as a solid.
- Example 12 The procedure described for Example 12 was followed, except 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethylamine was used in Step A to produce the intermediate N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(3-phenylpropyl)-N′′-cyanoguanidine, and then that intermediate was used in Step B with 3-phenylpropylamine (instead of diphenylmethylamine) to produce Example 105.
- Step A 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethylamine was used in Step A to produce the intermediate N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(3-phenylpropyl)-N′′-cyanoguanidine, and then that intermediate was
- Steps B to E of Example 1 were followed, starting with 2,5-dichlorophenylmethyl-carbonylbenzene in Step B, to produce after Step E the intermediate 1-(2,5-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine; and then this amine was used as Compound E in Step F of Example 1 to obtain the titled compound as a solid.
- Example 1 The procedure of Example 1 was followed, except in Step B, 2-chlorophenylmethylketone was used as Compound A (instead of 2,5-bistrifluoromethyl-1-methylcarbonylbenzene), to produce after Step E 1-(2-Chlorophenyl)-2-(imidazol-1-yl)ethylamine. Then in Step F, this ethylamine was used to obtain Example 136 as a solid. MS (ES): m/z 433 [M+H] + .
- Example 148 The procedure of Example 1 was followed, except 2,3-Dichlorophenylmethylketone was used in Step B instead of 2,5-bistrifluoromethyl-1-methylcarbonylbenzene, to produce after Step E 1-(2,3-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine, and then step F was followed with this ethylamine to obtain Example 148 as a solid.
- Example 1 The procedure of Example 1 was followed, except 2,4-bistrifluoromethyl-phenylmethylketone was used as Compound A in Step B to produce 1-(2,4-Bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylamine (after Step E), and then Step F was followed with this ethylamine to obtain Example 155 as a solid.
- Example 172 was synthesized following the procedure described for Example 155, except triazole was used instead of imidazole (i.e., as per Example 1, Step C), to produce 1-(2,4-Bistrifluoromethylphenyt)-2-[1-(1,2,4-triazolyl)]ethylamine, and this ethylamine was used in the last step to make the titled compound as a solid.
- Example 172 The procedure described for Example 172 was followed using benzimidazole instead of triazole to produce 1-(2,4-Bistrifluoromethylphenyl)-2-(benzimidazol-1-yl)ethylamine, and then this ethylamine was used in the last step to make Example 176.
- Example 177 was prepared in the same manner as for Example 176, except N-(indan-7-yl)-N′-cyanothiourea was used in the last step. MS (ES): m/z 556 [M+H] + .
- Example 272 was prepared by following the procedure of Example 190, except 3-cyanobenzoyl chloride was used instead of 4-chlorobenzoyl chloride in Step A to obtain N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(3-cyanophenyl)carbonyl thiourea, and tert-butylcyclohexylamine was used in Step B instead of diphenylmethylamine to obtain the titled compound.
- Step A 2,5-bistrifluoromethylbenzadehyde was used to give 2,5-Bistrifluoromethylphenylethylene oxide.
- Step B gave bistrifuoromethylphenyl)-2-(benzimidazol-1-yl)ethanol, which was used in Step C to give 1-(2-Chloro-5-trifuoromethylphenyl)-2-(benzimidazol-1-yl)ethylamine and Example 308.
- Example 49 To a stirred solution of compound B (1.91 g, 5 mmol) in DMF was added 1-(2,4-dichlorophenyl)-2-imidazol-1-yl)ethylamine (1.35 g, 5 mmol, 1 equiv), followed by 1 mL diisopropylethylamine. The mixture was allowed to stir at rt for 15 min, and then HgCl 2 was added (2 g, 7.5 mmol, 1.5 equiv). After stirring at rt for 20 h, the mixture was poured into 1N HCl solution, and then filtered by Buchner funnel.
- Example 491 was neutralized to pH 9-10, extracted with EtOAc, and then purified using preparative HPLC, giving 2.0 g (63%) of Example 491 as a white solid.
- Example 492 The same procedure of Example 491 was followed, except in step A, t-butyl sulfonyl chloride was used in place of 4-(t-butyl)phenyl sulfonyl chloride to give 50% yield of Example 492 as a white solid.
- This compound was prepared from 1-[2,5-bis(trifluromethyl)phenyl]-2-(benzimidazol-2-yl)-ethylamine and N-cyano-N′-(2,4-dichlorophenyl)thiourea in a manner similar to that previously described for Example 1.
- HPLC 99% at 1.75 min (retention time) (YMC S5 ODS column 4.6 ⁇ 33 mm eluting with 10-90% aqueous MeOH over 2 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm)
- Example 494 was prepared from 1-[2,5-bis(trifluromethyl)phenyl]-2-(benzimidazol-2-yl)-ethylamine and N-cyano-N′-(4-chlorophenyl)thiourea in a manner similar to that previously described for Example 1, providing the desired cyanoguanidine as an off-white solid.
- HPLC 99% at 3.16 min (retention time) (YMC ODSA column 4.6 ⁇ 50 mm eluting with 10-90% aqueous MeOH over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 60/339,108 filed Dec. 10, 2001.
- This invention relates to compounds that inhibit nitochondrial F1F0 ATP hydrolase and are useful for treating ischemia-related diseases. The invention further pertains to methods of treating conditions associated with depleted levels of adenosine triphosphate (ATP) due to hydrolysis by mitochondrial F1F0 ATPase.
- Ischemic heart disease is a common and serious health problem. Every year, large numbers of patients die from ischemic heart disease and its complications. Many others experience acute myocardial infarcation, congestive heart failure, cardiac arrhythmias, or other disorders.
- Myocardial ischemia exists when the heart tissue experiences a demand for oxygen and substrates that exceed the supply. Imbalances between oxygen supply and demand span a large range, and thus, there are various syndromes and biochemical pathways involved in the pathogenesis of ischemia, e.g., from low-grade to severe ischemic conditions. For example, chronic stable angina pectoris is a low-grade condition, in which the resting coronary blood flood may be normal but the blood flow reserve is insufficient to meet an increased energy demand. In more extreme situations, the ischemic muscle can develop an impaired contractile function and potential to generate arrhythmias. Major consequences of myocardial ischemia include mechanical and electrical dysfunction, muscle cell damage, and development of necrosis. Acute ischemic events may develop where there is coronary atherosclerosis. Ultimately, if the ischemia is sufficiently severe there will be an immediate reduction (or cessation) of contractile function in the heart.
- The impairment of contractile function in ischemic muscle is associated with mitochondrial levels of adenosine triphosphate (ATP) and adenosine triphosphatases (ATPases). ATPases are enzymes that typically catalyze the hydrolysis of ATP, the main energy currency in cells, to adenosine monophosphate (AMP) or adenosine diphosphate (ADP), plus phosphate ions and energy. The contractile function of the heart is regulated by the transport of calcium, sodium, and potassium ions, which in turn is modulated by ATP and ATPases. More particularly, intracellular ATP is split by Na+,K+ ATPase, an enzyme that is responsible for maintaining a gradient of sodium and potassium ions across the cell membrane. The splitting of ATP by Na+,K+ ATPase releases the energy needed to transport K+ and Na+ ions against concentration gradients. This enables the existence of a resting potential in the membrane (i.e, Na+ out, K+ in) which initiates the contractile response. Contraction is triggered by Na/Ca exchange and Ca2+ transport, the energy for which is generated by the hydrolysis of ATP by Ca2+ ATPase.
- To maintain homeostasis, the cells' supply of ATP must be replenished as it is consumed (e.g., with muscle contraction). During the steady state, the rate of ATP synthesis needs to be closely matched to its rate of consumption. Arguably, the most important ATPase is the mitochondrial F1F0-ATPase. Unlike other ATPases which function typically to hydrolyze ATP and release energy, the F1F0-ATPase has both hydrolytic and synthetic states. As “ATP synthase”, the mitochondrial F1F0-ATPase catalyzes the production of ATP via oxidative phosphorylation of ADP and Pi. Thus, F1F0-ATPase is responsible for producing the cell's main energy source, ATP. In normoxic conditions, mitochondrial F1F0-ATPase modulates this ATP production via its two units, the F1 and F0 complexes. F0 is the inner membrane domain, and F1 is a catalytic domain consisting of five subunits ((αβχδε-the catalytic site is on the β unit), that protrude from the F0 domain into the mitochondrial matrix. When sufficient levels of oxygen are present, electrons from ATPase substrates are transferred to oxygen, and protons are transported out of the mithcondrial matrix. This proton/electron transport creates an electrochemical proton gradient across the mitochondrial membrane and through the F0 domain which drives the F1 domain to synthesize ATP.
- In ischemic conditions, however, this electrochemical gradient collapses, and F1F0-ATPase switches to its hydrolytic state. This hydrolysis of ATP seems to serve no useful purpose. Also, as F1F0-ATPase operates in its hydrolytic state there is a down-regulation of F1F0-ATP synthase. F1F0-ATP synthase activities in vesicles from ischemic muscle typically are substantially (up to 50-80%) less than those of control muscle. A native peptide called IF1 inhibitor protein (or IF1) may be bound to the F1 unit under ischemic conditions to inhibit the ATP hydrolase activity of the enzyme; however, IF1 is highly pH dependent and in severe conditions can provide only a modicum of control. The conversion of F1F0-ATP synthase to F1F0-ATP hydrolase is reversible, as addition of substrate and oxygen to the mitochondria of ischemic muscle can reactivate the F1F0-ATPase and ATP levels to control levels.
- As may be appreciated, in ischemic conditions the activity of F1F0-ATPase produces a futile cycling and waste of ATP. It is believed that this depletion of ATP and/or ATP synthase may suppress the Na+ K+ pump to increase cardiac contractility, vasoconstriction, sensitivity to vasoactive agents, and arterial blood pressure. Several inhibitors of F1F0-ATPase have been described, including efrapeptin, oligomycin, autovertin B, and azide. Oligomycin targets F0 and reportedly postpones cell injury by preserving ATP during ischemia. However, the only known inhibitors of F1F0-ATPase are large proteins or peptides which are not orally bioavailable.
- The instant invention provides N-substituted-N′-(1-phenyl-2-heteraryl)ethyl-guanidine compounds including cyanoguanidine and benzoylguanidine compounds that are potent and selective inhibitors of F1F0-ATP hydrolase. The compounds of the present invention are useful in treating or preventing conditions associated with ischemia, particularly myocardial ischemia and associated conditions, such as muscle cell damage, necrosis, and cardiac arrhythmias. Also, in view of their inhibitory activity, the inventive compounds may be used to treat cancer and tumor growth. Cyano-guanidine based compounds for treating various other indications (e.g., diseases relating to the CNS-system, gastric secretion, inflammation, HIV, etc.) are disclosed in Shimada et al, “Synthesis and Gastric Antisecretory Activity of N-Cyano-N′(phenyl-pyridinylmethyl)guanidine Derivatives,” Chem. Pharm. Bull., Vol. 32(12), (1984), at pp. 4893-4906; WO 00/35449, “N-Ureidoalkyl-Piperidines as Modulators of Chemokine Receptor Activity,” to Du Pont Pharmaceuticals Co.; U.S. Pat. No. 5,478,845, “Piperidine Derivatives,” issued Dec. 26, 1995 and assigned to Novo Nordisk A/S; WO-93/05026, “Peptide Isoters Containing a Heterocycle as H.L V. Inhibitors,” to Smith-Kline Beecham Corp.; and WO 00/43415, “Compounds which Inhibit Leukocyte Adhesion Mediated by VLA-4,” to Elan Pharmaceuticals, Inc. Cyano-guanidine compounds useful for lowering blood pressure or treating thrombotic or platelet aggregating conditions are disclosed in U.S. Pat. No. 5,521,177, U.S. Pat. No. 5,482,948, and WO 96/23771.
- Each of the patents, patent applications and publications referred to in this application are incorporated herein by reference.
-
- or a pharmaceutically-acceptable salt, hydrate, or prodrug thereof, wherein:
- R1 is cyano, —SO2R8, —C(═O)R9, or heteroaryl;
- R2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R3 forms a heterocyclo;
- R3 is (i) independently alkyl, substituted alkyl, alkylthio, aminoalkyl, carbamyl, A-aryl, A-heterocyclo, A-heteroaryl, or A-cycloalkyl, or (ii) taken together with R2 forms a heterocyclo;
- Z is heteroaryl provided that when R1 is cyano, Z is not 2-pyridinyl;
- A is a bond, C1-4alkylene, C2-4alkenylene, substituted C1-4alkylene, substituted C2-4alkenylene, —C(═O)NR19—, —C1-4alkylene-C(═O)NR19—, or substituted C1-4alkylene-C(═O)NR19—;
- R4 at each occurrence is selected independently of each other R4 from the group consisting of halogen, alkyl, haloalkyl, nitro, cyano, haloalkoxy, OR25, SR25, NR25R26, NR25SO2R27, SO2R27, SO2NR25R26, CO2R26, C(═O)R26, C(═O)NR25R26, OC(═O)R25, —OC(═O)NR25R26, NR25C(═O)R26, NR25CO2R26, aryl, heteroaryl, heterocyclo and cycloalkyl;
- R8 is alkyl, substituted alkyl, aryl, or heteroaryl;
- R9 is —NR10R11, alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO2R12;
- R10 and R11, are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R12 and R19 are hydrogen or alkyl;
- R25 and R26 are independently selected from hydrogen, alkyl, or substituted alkyl, or taken together form a heterocyclo or heteroaryl ring;
- R27 is alkyl or substituted alkyl, and
- q is 0, 1, 2, or 3.
- Also included within the scope of the invention are pharmaceutical compositions comprising one or compounds of formula (I), and methods of treating ischemic conditions and/or conditions associated with depleted levels of adenosine triphosphate (ATP) and/or the activity of mitochondrial F1F0 ATPase. These methods comprise administering an effective amount of at least one compound of formula (I) to a patient in need thereof. Additionally, applicants have discovered that F1F0-ATP hydrolase can be selectively inhibited via use of a small organic molecule, i.e., a non-peptidic organic compound having less than 1000 molecular weight, and this invention is also claimed herein.
- The following are definitions of terms used in this specification. The initial definition provided for a group or term herein applies to that group or term throughout the present specification, individually or as part of another group, unless otherwise indicated.
- The term “alkyl” refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred.
- The term “substituted alkyl” refers to an alkyl group as defined above having one, two, three, or four substituents selected from the group consisting of halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), ORa, SRa, NRaRb, NRaSO2, NRaSO2Rc, SO2Rc, SO2NRaRb, CO2Ra, C(═O)Ra, C(═O)NRaRb, OC(═O)Ra, —OC(═O)NRaRb, NRaC(═O)Rb, NRaCO2Rb, ═N—OH, ═N—O-alkyl, aryl, heteroaryl, heterocyclo and cycloalkyl, wherein Ra and Rb are selected from hydrogen, alkyl, alkenyl, cycloalkyl, heterocyclo, aryl, and heteroaryl, and Rc is selected from hydrogen, alkyl, cycloalkyl, heterocyclo aryl and heteroaryl. When a substituted alkyl includes an aryl, heterocyclo, heteroaryl, or cycloalkyl substituent, said ringed systems are as defined below and thus may in turn have zero to four substituents (preferably 0-2 substituents), also as defined below. When either Ra, Rb or Rc is an alkyl, said alkyl may optionally be substituted with 1-2 of halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH2, NH(alkyl), N(alkyl)2, NHSO2, NHSO2(alkyl), SO2(alkyl), SO2NH2, SO2NH(alkyl), CO2H, CO2(alkyl), C(═O)H, C(═O)alkyl, C(═O)NH2, C(═O)NH(alkyl), C(═O)N(alkyl)2, OC(═O)alkyl, —OC(═O)NH2, —OC(═O)NH(alkyl), NHC(═O)alkyl, and/or NHCO2(alkyl). “Alkyl” when used in conjunction with another group such as in arylalkyl refers to a substituted alkyl in which at least one of the substituents is the specifically-named group. For example, the term arylalkyl includes benzyl, or any other straight or branched chain alkyl having at least one aryl group attached at any point of the alkyl chain. As a further example, the term carbamylalkyl includes the group —(CH2)n—NH—C(═O)alkyl, wherein n is 1 to 12.
- The term “alkenyl” refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups of 2 to 6 carbon atoms and having one double bond are most preferred.
- The term “alkynyl” refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred.
- The term “alkylene” refers to bivalent straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, e.g., {—CH2—}n, wherein n is 1 to 12, preferably 1-8. Lower alkylene groups, that is, alkylene groups of 1 to 4 carbon atoms, are most preferred. The terms “alkenylene” and “alkynylene” refer to bivalent radicals of alkenyl and alknyl groups, respectively, as defined above.
-
- and so forth.
- The term “alkoxy” refers to an alkyl or substituted alkyl group as defined above having one, two or three oxygen atoms (—O—) in the alkyl chain. For example, the term “alkoxy” includes the groups —O—C1-12alkyl, —C1-6alkylene-O—C1-6alkyl, —C1-4alkylene-O-phenyl, and so forth.
- The term “thioalkyl” or “alkylthio” refers to an alkyl or substituted alkyl group as defined above having one or more sulfur (—S—) atoms in the alkyl chain. For example, the term “thioalkyl” or “alkylthio” includes the groups —(CH2)n—S—CH2aryl, —(CH2)n—S-aryl, etc.
- The term “aminoalkyl” refers to an alkyl or substituted alkyl group as defined above having one or more nitrogen (—NR′—) atoms in the alkyl chain. For example, the term “aminoalkyl” includes the groups —NR′—C1-12alkyl and —CH2—NR′-aryl, etc. (where R′ is hydrogen, alkyl or substituted alkyl as defined above.) “Amino” refers to the group —NH2.
- When a subscript is used as in C1-8alkyl, the subscript refers to the number of carbon atoms the group may contin. Zero when used in a subscript denotes a bond, e.g., C0-4alkyl refers to a bond or an alkyl of 1 to 4 carbon atoms. When used with alkoxy, thioalkyl or aminoalkyl, a subscript refers to the number of carbon atoms that the group may contain in addition to heteroatoms. Thus, for example, monovalent. C,2aminoalkyl includes the groups —CH2—NH2, —NH—CH3, —(CH2)2—NH2, —NH—CH2—CH3, —CH2—NH2—CH3, and —N—(CH3)2. A lower aminoalkyl comprises an aminoalkyl having one to four carbon atoms.
- The alkoxy, thioalkyl, or aminoalkyl groups may be monovalent or bivalent. By “monovalent” it is meant that the group has a valency (i.e., power to combine with another group), of one, and by “bivalent” it is meant that the group has a valency of two. For example, a monovalent alkoxy includes groups such as —O—C1-12alkyl, —C1-6alkylene-O—C1-6alkyl, etc., whereas a bivalent alkoxy includes groups such as —O—C1-2alkylene-, —C1-6alkylene-O—C1-6alkylene-, etc.
-
-
- wherein Rd may be selected from alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, heterocyclo, cycloalkyl, or heteroaryl, as defined herein.
-
-
- wherein Rd is as defined above for acyl.
- The term “carbamyl” refers to a functional group in which a nitrogen atom is directly bonded to a carbonyl, i.e., as in —NReC(═O)Rf or —C(═O)NReRf, wherein Re and Rf can be hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, cycloalkyl, aryl, heterocyclo, or heteroaryl, or they may join to form a ring.
- The term “sulfonyl” refers to a sulphoxide group (i.e., —S(O)1-2) linked to an organic radical Rc, as defined above.
- The term “sulfonamide” or “sulfonamido” refers to the group —S(O)2NReRf, wherein Re and Rf are as defined above. Preferably when one of Re and Rf is optionally substituted heteroaryl or heterocycle (as defined below), the other of Re and Rf is hydrogen or alkyl.
- The term “cycloalkyl” refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms. The term “cycloalkyl” includes such rings having zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halogen, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, keto, ORd, SRd NRdRe NRcSO2, NRcSO2Re, C(═O)H, acyl, —CO2H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC(═O)Rd, ═N—OH, ═N—O-alkyl, aryl, heteroaryl, heterocyclo, a 4 to 7 membered carbocyclic ring, and a five or six membered ketal, e.g., 1,3-dioxolane or 1,3-dioxane, wherein Rc, Rd and Re are defined as above. The term “cycloalkyl” also includes such rings having a phenyl ring fused thereto or having a carbon-carbon bridge of 3 to 4 carbon atoms. Additionally, when a cycloalkyl is substituted with a further ring, i.e., aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo, heterocycloalkyl, cycloalkylalkyl, or a further cycloalkyl ring, such ring in turn may be substituted with one to two of C0-4alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH2, NH(alkyl), N(alkyl)2, NHSO2, NHSO2(alkyl), SO2(alkyl), SO2NH2, SO2NH(alkyl), CO2H, CO2(alkyl), C(═O)H, C(═O)alkyl, C(═O)NH2, C(═O)NH(alkyl), C(═O)N(alkyl)2, OC(═O)alkyl, —OC(═O)NH2, —OC(═O)NH(alkyl), NHC(═O)alkyl, and NHCO2(alkyl).
- The term “halo” or “halogen” refers to chloro, bromo, fluoro and iodo.
- The term “haloalkyl” means a substituted alkyl having one or more halo substituents. For example, “haloalkyl” includes mono, bi, and trifluoromethyl.
- The term “haloalkoxy” means an alkoxy group having one or more halo substituents. For example, “haloalkoxy” includes OCF3.
- The term “aryl” refers to phenyl, biphenyl, 1-naphthyl, 2-naphthyl, and anthracenyl, with phenyl being preferred. The term “aryl” includes such rings having zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, ORd, SRd, NRdRe, NRdSO2, NRdSO2Rc, C(═O)H, acyl, —CO2H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC(═O)Rd, heteroaryl, heterocyclo, cycloalkyl, phenyl, benzyl, napthyl, including phenylethyl, phenyloxy, and phenylthio, wherein Rc, Rd and Re are defined as above. Additionally, two substituents attached to an aryl, particularly a phenyl group, may join to form a further ring such as a fused or spiro-ring, e.g., cyclopentyl or cyclohexyl or fused heterocycle or heteroaryl. When an aryl is substituted with a further ring, such ring in turn may be substituted with one to two of CO 4alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH2, NH(alkyl), N(alkyl)2, NHSO2, NHSO2(alkyl), SO2(alkyl), SO2NH2, SO2NH(alkyl), CO2H, CO2(alkyl), C(═O)H, C(═O)alkyl, C(═O)NH2, C(═O)NH(alkyl), C(═O)N(alkyl)2, OC(═O)alkyl, —OC(═O)NH2, —OC(═O)NH(alkyl), NHC(═O)alkyl, and NHCO2(alkyl).
- The term “heterocyclo” refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N). Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The fused rings completing bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The heterocyclo group may be attached at any available nitrogen or carbon atom. The heterocyclo ring may contain zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, keto, ORd, SRd, NRdRe, NRdSO2, NRdSO2Rc, SO2Rd, C(═O)H, acyl, —CO2H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC(═O)Rd, ═N—OH, ═N—O-alkyl, aryl, heteroaryl, cycloalkyl, a five or six membered ketal, e.g., 1,3-dioxolane or 1,3-dioxane, or a monocyclic 4 to 7 membered non-aromatic ring having one to four heteroatoms, wherein Rc, Rd and Re are defined as above. The term “heterocyclo” also includes such rings having a phenyl ring fused thereto or having a carbon-carbon bridge of 3 to 4 carbon atoms. Additionally, when a heterocyclo is substituted with a further ring, i.e., aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or a further heterocyclo ring, such ring in turn may be substituted with one to two of C0-4alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH2, NH(alkyl), N(alkyl)2, NHSO2, NHSO2(alkyl), SO2(alkyl), SO2NH2, SO2NH(alkyl), CO2H, CO2(alkyl), C(═O)H, C(═O)alkyl, C(═O)NH2, C(═O)NH(alkyl), C(═O)N(alkyl)2, OC(═O)alkyl, —OC(═O)NH2, —OC(═O)NH(alkyl), NHC(═O)alkyl, and NHCO2(alkyl).
- Exemplary monocyclic groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic heterocyclo groups include quinuclidinyl.
- The term “heteroaryl” refers to substituted and unsubstituted aromatic 5 to 7 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may contain zero to four substituents (preferably 0-2 substituents), selected from the group consisting of halo, alkyl, substituted alkyl (e.g., trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, ORd, SRd, NRdRe, NRdSO2, NRdSO1 2Rc, SO2Rd, C(═O)H, acyl, —CO2H, alkoxycarbonyl, carbamyl, sulfonyl, sulfonamide, —OC(═O)Rd, heterocyclo, cycloalkyl, aryl, or a monocyclic 4 to 7 membered aromatic ring having one to four heteroatoms, including phenylethyl, phenyloxy, and phenylthio, wherein Rc, Rd and Re are defined as above. Additionally, when a heteroaryl is substituted with a further ring, i.e., aryl, arylalkyl, heterocyclo, heterocycloalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or a further heteroaryl ring, such ring in turn may be substituted with one to two of C0-4alkyl optionally substituted with halogen, trifluoromethyl, alkenyl, alkynyl, nitro, cyano, keto (═O), OH, O(alkyl), phenyloxy, benzyloxy, SH, S(alkyl), NH2, NH(alkyl), N(alkyl)2, NHSO2, NHSO2(alkyl),n SO2(alkyl), SO2NH2, SO2NH(alkyl), CO2H, CO2(alkyl), C(═O)H, C(═O)alkyl, C(═O)NH2, C(═O)NH(alkyl), C(═O)N(alkyl)2, OC(═O)alkyl, —OC(═O)NH2, —OC(═O)NH(alkyl), NHC(═O)alkyl, and NHCO2(alkyl).
-
- ), thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.
- Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxaxolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
- Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds.
- The compounds of formula I form salts which are also within the scope of this invention. Reference to a compound of the formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, when a compound of formula I contains both a basic moiety, such as, but not limited to an amine or a pyridine or imidazole ring, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, e.g., in isolation or purification steps which may be employed during preparation. Salts of the compounds of the formula I may be formed, for example, by reacting a compound of the formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- The compounds of formula I which contain a basic moiety, such as, but not limited to an amine or a pyridine or imidazole ring, may form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.
- The compounds of formula I which contain an acidic moiety, such as, but not limited to a carboxylic acid, may form salts with a variety of organic and inorganic bases. Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines [formed with N,N-bis(dehydro-abietyl)ethylenediamine], N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
- Compounds of the formula I, and salts thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
- All stereoisomers of the present compounds, such as those, for example, which may exist due to asymmetric carbons, including enantiomeric forms (which may exist even in the absence of asynmmetric carbons) and diastereomeric forms, are contemplated and within the scope of this invention. Individual stereoisomers of the compounds of this invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- In addition, compounds of the formulas I may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., a compound of formula I) is a prodrug within the scope and spirit of the invention.
- For example, pro-drug compounds of the formulas I may be carboxylate ester moieties. A carboxylate ester may be conveniently formed by esterifying any of the carboxylic acid functionalities found on the disclosed ring structure(s).
- Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:
- a)Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985), and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et. al. (Academic Press, 1985);
- b)A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, “Design and Application of Prodrugs,” by H.
- Bundgaard, p. 113-191 (1991);
- c) H. Bundgaard,Advanced Drug Delivery Reviews, Vol. 8, p. 1-38 (1992);
- d) H. Bundgaard, et al.,Journal of Pharmaceutical Sciences, Vol. 77, p. 285 (1988); and
- e) N. Kakeya, et. al.,Chem Phar Bull, Vol. 32, p. 692 (1984).
- It should further be understood that solvates (e.g., hydrates) of the compounds of formula I are also with the scope of the present invention. Methods of solvation are generally known in the art.
-
- in which:
- Z is triazolyl optionally substituted with one to two R7 or imidazolyl optionally substituted with one to two R7 and/or having fused thereto a benzene ring in turn optionally substituted with one to two R7;
- R1 is cyano or —C(═O)R9;
- R2 is hydrogen, alkyl, or benzyl;
- R3 is aryl or arylalkyl optionally substituted with alkyl, halogen, trifluoromethyl, OCF3, cyano, nitro, amino, hydroxy, or methoxy;
- R4 is halogen, alkyl, trifluoromethyl, or OCF3;
- R7 is alkyl, carbamyl or carbamylC1-4alkyl;
- R9 is —NR10R11, alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO2R12;
- R10 and R11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R12 is hydrogen or alkyl; and
- q is 0, 1, 2, or 3.
-
-
- Y is N or CR7c;
- R1 is cyano or —C(═O)R9;
- R2 is hydrogen or C1-4alkyl;
- R4 is halogen, C1-4alkyl, trifluoromethyl, or OCF3;
- R7a, R7b and R7c are alkyl, carbamyl or carbamylC1-4alkyl, or R7a and R7c join to form an optionally substituted fused phenyl ring;
- R9 is —NR10R11, alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO2R12;
- R10 and R11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; or (ii) taken together form a heterocyclo or heteroaryl;
- R12 is hydrogen or alkyl;
- R23 is hydrogen, alkyl, hydroxyalkyl, or phenyl;
- R24 is alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF3, methoxy, phenyloxy, benzyloxy, cyano, or acyl, or two R24 groups join to form a fused cycloalkyl or benzene ring;
- q is 1 or 2;
- x is 0, 1, or 2; and
- y is 0, 1, 2, or 3.
-
- R1 is cyano or —C(═O)R9;
- R4 is halogen, C1-4alkyl, trifluoromethyl, or OCF3;
- R7 and R7, join to form a fused benzene ring optionally substituted with C1-4alkyl or —(CH2)1-2—NHC(═O)C1-4alkyl, R7b is hydrogen, C1-4alkyl, or —(CH2)1-2—NHC(═O)C1-4alkyl;
- R9 is a) —NR10R11;
- b) C1-8alkyl optionally substituted with one to two of:
- i) SR13, OR13, NR13aR13b, halogen, trifluoromethyl, CO2R13a, and C(═O)NR13aR13b;
- ii) cycloalkyl optionally substituted with one to two of C(═O)H, C1-4acyl, alkenyl, carbamyl, and/or phenyl in turn optionally substituted with halogen;
- iii) phenyl or napthyl optionally substituted with one to two of halogen, nitro, amino, alkyl, hydroxy, C1-4alkoxy, or having fused thereto a five or six membered heterocyclo;
- iv) pyridinyl, thiophenyl, furanyl, tetrahydrofuranyl, or azepinyl, optionally substituted with alkyl or having fused thereto a five to six membered carbocyclic ring optionally substituted with keto or C1-4alkoxy;
- c) C1-4alkoxy;
- d) C1-4alkylthio;
- e) CO2alkyl;
- f) 3 to 6 membered cycloalkyl optionally having up to four substituents selected from alkyl, halogen, cyano, alkenyl, acyl, alkylthio, carbamyl, and/or phenyl in turn optionally substituted with halogen; or having an aryl fused thereto;
- g) phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C1-4alkoxy, haloalkoxy, C1-6alkyl, CO2alkyl, SO2alkyl, SO2NH2, amino, NH(C1-4alkyl), N(C1-4alkyl)2, NHC(═O)alkyl, C(═O)alkyl, and/or C1-4alkyl in turn optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto;
- h) pyridinyl, thiazolyl, furanyl, thiophenyl, and pyrrolyl optionally substituted with one to two of halogen, alkyl, and phenyl in turn optionally substituted with halogen or trifluoromethyl;
- R10 is hydrogen, alkyl, or alkoxy;
- R11 is alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, or heteroaryl; or
- R10 and R11, taken together form a heterocyclo or heteroaryl;
- R23 is hydrogen, alkyl, hydroxyalkyl, or phenyl;
- R24 is alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF3, methoxy, phenyloxy, benzyloxy, cyano, or acyl, or two R24 groups join to form a fused cycloalkyl or benzene ring;
- q is 0, 1, or 2;
- x is 0 or 1; and
- y is 0, 1, or 2.
- Most preferred are compounds as immediately defined above wherein R1 is cyano or —C(═O)R9; R9 is optionally substituted phenyl or phenyl C1-4alkyl; x is 0 or 1; and q and y are 1 or 2.
- The compounds of this invention by inhibiting F1F0-ATPase may be used to help conserve ATP under conditions of oxygen deprivation. Thus, the compounds may be useful in treating or preventing any condition associated with depleted levels of ATP and/or tissue ischeria (from mild to acute or severe). As used herein with reference to the utilities described below, the terms “treating” or “treatment” encompass both responsive and prophylaxis measures designed to inhibit or delay the onset of the disease or disorder, or to alleviate, ameliorate, lessen, or cure the disease or disorder and/or its symptoms.
- In view of their F1F0-ATPase inhibitory activity, the inventive compounds are useful in treating cardiovascular diseases including, without limitation, congestive heart failure, cardiac arrhythmias, unstable angina, and high blood pressure. The compounds also are useful to treat ischemia, including ischemia resulting from vascular occlusion, cerebral infarction, stroke and related cerebral vascular diseases (including cerebrovascular accident and transient ischemic attack), and accurate coronary syndromes such as myocardial infarction, coronary artery disease, unstable angina, and non-Q wave MI.
- Additionally, the compounds are useful in treating or preventing symptoms or consequences occurring from thrombosis and/or the formation of atherosclerotic plaques, atherosclerosis, peripheral arterial disease, coagulation syndromes, and intermittent claudication. The compounds may be used to treat thrombotic or thromboembolic conditions such as thromboembolic stroke (including that resulting from atrial fibrillation 10 or from ventricular mural thrombus); venous thrombosis (including deep vein thrombosis); arterial thrombosis; cerebral thrombosis; pulmonary embolism; cerebral embolism; peripheral occlusive arterial disease (e.g., peripheral arterial disease, intermittent claudication, critical leg ischemia, prevention of amputation, prevention of cardiovascular morbidity such as MI, stroke or death); thromboembolic consequenses of surgery, interventional cardiology or immobility; thromboembolic consequenses of medication (such as oral contraceptives, hormome replacement and heparin); thrombotic consequenses of atherosclerotic vascular disease and atherosclerotic plaque rupture leading to tissue ischemia; prevention of atherosclerotic plaque formation; transplant atherosclerosis; thromboembolic complications of pregancy including fetal loss; thromboembolic consequences of thrombophilia (e.g., Factor V Leiden, and homocystinenimia); prothrombotic consequences and/or complications of cancer; prevention of thrombosis on artificial surfaces (such as stents, blood oxygenators, shunts, vascular access ports, vascular grafts, artificial valves, etc.); coagulopathies (e.g., disseminated intravascular coagulation); coagulation syndromes; vascular remodeling atherosclerosis, restenosis and systemic infection; prevention of metastesis and tumor implantation; diabetic complications including retinopathy, nephropathy and neuropathy; inflammation; Kasabach-Merritt syndrome; atrial fibrillation; ventricular enlargement (including dilated cardiac myopathy and heart failure); restenosis (e.g., following arterial injury-induced either endogenously or exogenously). Compounds of the present invention may be useful for maintaining blood vessel patency in conjunction with vascular surgery including bypass grafting, arterial reconstruction, atherectomy, vascular graft and stent patency, organ, tissue and cell implantation and transplantation. In addition, the compounds of the present invention may be useful for maintaining blood vessel patency in conjunction with interventional cardiology or vascular surgery including bypass grafting, arterial reconstruction, atherectomy, vascular graft and stent patency, organ, tissue and cell implantation and transplantation. Additionally, the compounds may be used for preservation of tissue as related to organ transplantation.
- The inventive compounds also are useful in treating diseases or disorders in other tissues or muscles that are associated with ischemic conditions. For example, the compounds may be used to treat muscle cell damage and necrosis.
- Additionally, the inventive compounds may be useful as anti-cancer and/or anti-tumor agents. It is reported that inhibitors of mitochondrial FIF0-ATPase selectively kill metabolically active tumor cells that do not exhibit the Warburg effect, i.e., cells that do not maintain a high level of anaerobic carbon metabolism even in the presence of oxygen. See Salomon et al., “Understanding and Exploiting the Mechanistic Basis for Selecivity of Polyketide Inhibitors of F 1 F 0-ATPase,” Proc. Natl. Acad. Sci. Vol. 97 (26) (2000), at pp. 14766-14771. Accordingly, the compounds of the present invention are useful in treating tumor growth, as an adjunct to chemotherapy, and for treating cancer, more particularly, cancer of the lung, prostate, colon, breast, ovaries, and bone.
- The inventive compounds may also be used in combination with other F1F0-ATPase inhibitors such as efrapeptin, oligomycin, autovertin B, and azide, and/or in combination with other cardiovascular drugs. Additionally, the compounds may be used in combination with other therapeutic agents such as potassium channel openers, calcium channel blockers, sodium hydrogen exchanger inhibitors, anti-arrhythmic agents, thrombin inhibitors, platelet aggregation inhibitors or anti-platelet agents, fibrinogen antatagonists, diuretics, anti-hypertensive agents, mineralocorticoid receptor antagonists; phospodiesterase inhibitors; cholesterol/lipid lowering agents and lipid profile therapies; anti-diabetic agents; anti-depressants; anti-inflammatory agents (steroidal and non-steroidal); anti-oxidant agents; angiogenesis modulators; anti-osteoporosis agents; hormone replacement therapies; oral contraceptives; anti-coagulants; anti-obesity agents; anti-anxiety agents; anti-proliferative agents; anti-tumor agents; anti-ulcer and gastroesophageal reflux disease agents; growth hormone and/or growth hormone secretagogues; thyroid mimetics (including thyroid receptor antagonist); anti-infective agents; anti-viral agents; anti-bacterial agents; and anti-fungal agents.
- For example, the inventive compounds may be used in combination with aspirin, clopidogrel, ticlopidine or CS-747, warfarin, and low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin). Other suitable therapeutic agents in combination with which the inventive compounds may be used include:
- anti-arrhythmic agents including Class I agents (such as propafenone); Class II agents (propranolol); Class III agents (such as sotalol, dofetilide, amiodarone, azimilide and ibutilide); Class IV agents (such as ditiazem and verapamil); K+ channel openers such as IAch inhibitors, and IKur inhibitors (e.g., compounds such as those disclosed in U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000;
- alpha- or beta- adrenergic blockers (such as propranolol, nadolol and carvedilol), or -β-adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, and/or fenoterol;
- angiotensin-II receptor antagonists (e.g., irbesartan, losartan or valsartan);
- anticholinergics such as ipratropium bromide;
- anti-diabetic agents such as biguamides (e.g. metformin); glucosidase inhibitors (e.g. acarbose); insulins (including insulin secretagogues or insulin sensitizers); meglitinides (e.g. repaglinide); sulfonylureas (e.g., glimepiride, glyburide and glipizide); biguamide/glyburide combinations (e.g., glucovance), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, SGLT2 inhibitors, inhibitors of fatty acid binding protein (aP2) such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000 and assigned to the present assignee, glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase IV (DP4) inhibitors;
- anti-depressant or anti-anxiety agents such as nefazodone, sertraline, diazepam, lorazepam, buspirone, and hydroxyzine pamoate;
- anti-diabetic agents such as biguamides (e.g. metformin); glucosidase inhibitors (e.g. acarbose); insulins (including insulin secretagogues or insulin sensitizers); meglitinides (e.g. repaglinide); sulfonylureas (e.g., glimepiride, glyburide and glipizide); biguamide/glyburide combinations (e.g., glucovance), thiozolidinediones (e.g. troglitazone, rosiglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, SGLT2 inhibitors, inhibitors of fatty acid binding protein (aP2) such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000 and assigned to the present assignee, glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase IV (DP4) inhibitors;
- anti-hypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril, lisinopril, zofenopril, ramipril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril), vasopeptidase inhibitors, i.e., dual ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan); ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265); Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389); neutral endopeptidase (NEP) inhibitors;
- anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and/or pranleukast or cortiocosteroids including beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone; prednisone; dexamethasone; enbrel; protien tyrosine kinase (PTK) inhibitors; cyclooxygenase inhibitors (including NSAIDs, and COX-1 and/or COX-2 inhibitors); aspirin; or indomethacin; lipoxygenase inhibitors; chemokine receptor modulators (including CCR1, CCR2, CCR3, CXCR2 receptor antagonists); secretory and cytosolic phospholipase A2 inhibitors; VLA4 antagonists; cytokine modulators (e.g. TNF-alpha converting enzyme (TACE) inhibitors, Interleukin-1 converting enzyme (ICE) inhibitors, Interleukin-1 receptor antagonists);
- angiogenesis modulators such as endostatin;
- anti-oxidant agents and/or lipid peroxidation inhibitors such as probucol, BO-653, Vitamin A, Vitamin E, AGI-1067;
- anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, tirofiban); P2Y12 antagonists (e.g., clopidogrel, ticlopidine, CS-747); or thromboxane receptor antagonists (e.g., ifetroban);
- anti-osteoporosis agents including alendronate and raloxifene.
- anti-obesity agents including orlistat and aP2 inhibitors (such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000);
- anti-proliferative agents for use in combination with the compounds of the present invention include cyclosporin A, paclitaxel, FK 506, and adriamycin;
- anti-ulcer and gastroesophageal reflux disease agents including famotidine, ranitidine, and omeprazole;
- sodium hydrogen exchanger-1 (NHE-1) inhibitors such as cariporide;
- calcium channel blocking agents such as verapamil, nifedipine, diltiazem, amlodipine and mybefradil;
- cardiac glycosides such as digitalis and ouabain;
- diuretics such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetamide, triamtrenene, amiloride;
- hormone replacement therapies including estrogen (e.g., congugated estrogens) and estradiol;
- lipid profile modulators including HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin [Nissan/Kowa]), ZD-4522 (a.k.a. rosuvastatin, or atavastatin or visastatin)); squalene synthetase inhibitors; fibrates; bile acid sequestrants (such as questran); ACAT1 inhibitors; ACAT2 inhibitors; dual ACAT1/2 inhibitors; MTP inhibitors; cholesterol absorption inhibitors; and cholesterol ester transfer protein inhibitors (e.g., CP-529414); PPAR-delta agonists; PPAR-alpha agonists; dual PPAR-alpha/delta agonists; LXR-alpha agonists; LXR-beta agonists; LXR dual alpha/beta agonists;
- mineralocorticoid receptor antagonists such as spironolactone and eplirinone.
- microsomal triglyceride transport protein inhibitors (such as disclosed in U.S. Pat. Nos. 5,739,135, 5,712,279 and 5,760,246);
- phosphodiesterase (PDE) inhibitors including dipyridamole, cilostazol, or sildenafil, or PDE inhibitors in combination with aspirin, ifetroban, picotamide, ketanserin, clopidogrel, and/or thromboxane receptor antagonists or thromboxane A synthetase inhibitors (such as picotamide);
- serotonin-2-receptor antagonists (such as ketanserin), fibrinogen receptor antagonists, and
- thrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, tenecteplase (TNK), lanoteplase (nPA), anisolated,streptokinase plasminogen activator complex (ASPAC), factor VIIa inhibitors, factor Xa inhibitors, thrombin inhibitors (such as hirudin and argatroban), animal salivary gland plasminogen activators, PAI-1 inhibitors such as XR-330 and T-686, and inhibitors of α-2-antiplasmin such as anti-α-2-antiplasmin antibody, prostacyclin mimetics.
- The inventive compounds may also be useful in combination with other anticancer strategies and chemotherapies such as taxol and/or cisplatin. The compounds may be used in conjunction with anti-tumor agents such as paclitaxel, adriamycin, epithilones, cisplatin, and carboplatin.
- The various other therapeutic agents described above may be employed in the same dosage form with the compound of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.
- The compounds of the present invention may act in a synergistic fashion with one or more of the above agents to allow for increased efficacy and/or reduced doses of any of the above agents and therefore minimize potential hemorrhagic side-effects.
- The compounds of formula I may be administered by any means suitable for the condition to be treated. Systematic treatment is typically preferred for cancerous conditions, although other modes of delivery are contemplated. The compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; sublingually; bucally; transdermally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; rectally such as in the form of suppositories; or liposomally. Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered. The compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.
- Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds may be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets. Exemplary compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (e.g., GANTREZ®); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934®). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
- Exemplary compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
- Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- Exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
- The effective amount of a compound of the present invention may be determined by one of ordinary skill in the art. The specific dose level and frequency of dosage for any particular subject may vary and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. An exemplary effective amount of compounds of formula I may be within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.
- Assay
- Mitochondria were isolated from bovine hearts and purified through a Percoll gradient, sonicated to generate sub mitochondrial particles (SMP), centrifuged, and stored at −80° C. See Gasnier F. et al,“Use of Percoll Gradients for Isolation of Human Placenta Mitochondria Suitable for Investigating Outer Membrane Proteins,” Anal. Biochem., Vol 212(1) (1993) at pp. 173-178; and Matsuno-Yagi A et al, “Studies on the Mechanism of Oxidative Phosphorylation: Effects of Specific F 0 Modifiers on Ligand-Induced Conformation Changes of F 1 ,” Proc. Nat'l Acad. Sci. USA, Vol. 82(22) (1985), at pp. 7550-7554.) ATP hydrolyase activity was determined using SMP and the well-characterized coupled enzyme system in which ATP hydrolysis and subsequent ADP generation is coupled through pyruvate kinase and lactate dehydrogenase to NAD+generation which was monitored by a decrease in absorbance at 340 nm (see Pullman, M. E. et al, “Partial Resolution of the Enzymes Catalyzing Oxidative Phosphorylation,” J. Biol. Chem. Vol. 235 (1960), at pp. 3322-3329.) Similarly, compound effects on ATP synthase activity were determined using SMP in the well-characterized coupled enzyme assay in which ATP generation is coupled to NADPH synthesis through the hexokinase and glucose-6-phosphate dehydrogenase pathway (Cross & Kohlbrenner, “The Mode of Inhibition of Oxidative Phosphorylation by Efrapeptin (A23871). Evidence for an Alternating Site Mechanism for ATP Synthesis,” J. Biol. Chem., Vol. 253 (1978) at pp. 4865-4873.) NADPH increase was monitored spectrophotometrically by an increase in absorbance at 340 nm. Compounds were dissolved in 100% dimethyl sulfoxide and tested at increasing concentrations for enzyme inhibition. The concentration of compound causing 50% inhibition of the enzyme (IC50) was calculated after the data was fitted using the Levenburg Marquardt algorithm and Microsoft Excel.
- Compounds of formula (I), and more particularly, the compounds of Examples 1 through 494 hereof, were tested in this assay and found to have a measurable level of activity for inhibiting F1FO-ATP hydrolase. Each of the compounds of Examples 1-494 is a non-peptidic small organic compound with less than 1000 molecular weight, with preferred compounds having less than 750 molecular weight.
- The following abbreviations are employed in the Examples and elsewhere herein:
- Ph=phenyl
- Bn=benzyl
- Me=methyl
- Et=ethyl
- MeOH=methanol
- EtOH=ethanol
- Pr=propyl
- Bu=butyl
- AcOH=acetic acid
- DBU=1,8-diazabicyclo[5,4,0]undec-7-ene
- DIP-Cl=B-chlorodiisopinocampheylborane
- DMF=N,N-dimethylformamide
- DPPA=Diphenylphosphoryl azide
- EDC═N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
- EtOAc=ethyl acetate
- NaBH4=sodium borohydride
- NaHCO3=sodium bicarbonate
- KCNS=potassium isothiocyanate
- Pd/C=palladium on carbon
- PtO2=platinum oxide
- Ph3P=triphenylphosphine
- TEA=triethylamine or Et3N
- THF=tetrahydrofuran
- TFA=trifluoroacetic acid
- min=minute(s)
- h or hr=hour(s)
- L=liter
- mL=milliliter
- μL=microliter
- g=gram(s)
- mg=milligram(s)
- mol=mole(s)
- mmol=millimole(s)
- meq=milliequivalent
- rt=room temperature
- sat or sat'd=saturated
- aq.=aqueous
- TLC=thin layer chromatography
- LC/MS=high performance liquid chromatography/mass spectrometry
- MS or Mass Spec=mass spectrometry
- mp=melting point
- Inventive compounds that are inhibitors of mitochondrial F1F0 ATP hydrolase may be prepared by methods illustrated in the following Schemes I to IX. Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art using known methods. For all of the schemes and compounds, the groups R1-R4 are as described above for a compound of Formula I and X is halogen, unless otherwise indicated. The group “Z” as used in these schemes corresponds to the group NR5R6, as described for a compound of Formula I, unless indicated otherwise. Groups designated generally as “R” are selected from substituents as set forth in the above definitions.
- Solvents, temperatures, pressures, and other reaction conditions may readily be selected by one of ordinary skill in the art. High Speed Analoging (HSA) may be employed in the preparation of compounds, for example, where the intermediates possess a carboxylic acid or amino group. For ease of reference, abbreviations listed above are used in these schemes.
-
-
-
-
- Acylguanidines of formula (If) were prepared by first converting acyl chloride 7 to acylisothiocyanate 8 by reaction with an isothiocyanate such as potassium isothiocyanate. Treatment of 8 with 1-aryl-2-heteroaryl ethylamine 1 gave acylthiourea 9. Treatment of 9 with TEA and a metal salt such as HgCl2 in acetonitrile gave compounds (If).
- 1-Aryl-2-heteroaryl ethylamines 1 (used in Schemes I-V) were prepared from aroylchlorides 10 and directly from acetophenones 11. Aroylchlorides 10 were reacted with methlymagnesium bromide in the presence of tributylphosphine in THF to give substituted acetophenone 11. Halogentation of acetophenones such as by bromination (Br2/CH2Cl2), gave haloacetophenones 12. Displacement of the halogen in 12 with nucleophilic heteroaryls, such imidazole, benzimidazole, or triazole, in solvent, such as acetonitrile, gave compound 13. Reduction of ketone 13 with a reducing agent, such as sodium borohydride, in a solvent such as EtOH, gave substituted 1-aryl-2-heteroaryl ethanol 12. Alcohol 12 was converted to amine 1 by reaction with an azide such as DPPA and DBU, followed by reduction with reducing agents such as Ph3P and water in a solvent such as THF.
- 1-Aryl-2-heteroaryl ethanols 14 were also prepared by treating an arylaldehyde 15 under epoxidizing conditions, such as trimethylsulfonium iodide and KOH in acetonitrile to give epoxide 16. Reaction of the epoxide 16 with heteroaryls, such as imidazole, benzimidazole, triazole, in the presence of NaH in a solvent such as DMF produced 1-aryl-2-heteroaryl ethanol 14. The ethanol 14 can then be converted to 1-Aryl-2-heteroaryl ethylamines 1 by reaction with an azide as shown in Scheme VI.
-
-
- N-(Aryl)sulphonylguanidines can be prepared by treatment of arylsulphonyl chlorides 1 with ammonium hydroxide to produce arylsulphonamines 2, which yield thioureas 3 upon treatment with isothiocyanates and a base, such as sodium hydride. Reaction of these N-aryl-N′-arylsulphonylthioureas with a benzylic amine such as 4, in the presence of HgCl2 and a base, such as DIPEA, yields N-(aryl)sulphonylguanidines 5.
- The invention will now be further described by the following working examples, which are illustrative rather than limiting. All temperatures are in degrees Celsius (° C.) unless otherwise indicated.
-
- A. 2,5-Bistrifluoromethyl-1-methylcarbonylbenzene.
- To a stirred solution of 2,5-trifluoromethylbenzoyl chloride (10 g, 36 mmol) in THF (150 mL) at −20° C., was added tributylphosphine (10 mL, 40 mmol) over 5 min. After stirring for 20 min, a solution of methylmagnesium bromide (3M, 12 mL) in THF was added rapidly (1 min). After addition, the reaction mixture was allowed to stir for 30 min, 1N HCl solution (20 mL) was added, and the mixture was concentrated in vacuo. The residue was partitioned between ether and 1N HCl solution. The aqueous solution was extracted with ether, the combined organic layers were dried and concentrated, and the residue was purified by silica gel column chromatography (5% EtOAc in hexanes) to give 5.1 g (56%) of Compound A as an oil.
- B. T-Bromomethylcarbonyl-2,5-bistrifluoromethylbenzene.
- To a stirred solution of Compound A (5.1 g, 20 mmol) in CH2Cl2 at rt was added a solution of Br (1.03 g) in CH2Cl2. The mixture was allowed to stir for 6 h and then washed with saturated NaHCO3. The organic layer was dried and concentrated to give Compound B as a yellow oil (6.5 g, 97%).
- C. 2,5-Bistrifluoromethyl-1-(imidazol-1-yl)methylcarbonyl)benzene.
- To a stirred solution of Compound B (6.5 g, 19.5 mmol) in CH2Cl2 (100 mL) was added imidazole (3.32 g, 48.7 mmol), and the mixture was allowed to stir at rt for 18 h. The solvent was removed, and the residue was partitioned between EtOAc (200 mL) and water. The organic layer was washed with ammonium chloride solution, dried, and concentrated to give Compound C as a solid, which was directly used in next step without further purification.
- D. 1-(2,5-Bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethanol.
- To a stirred solution of Compound C (4.2 g, 13.5 mmol) in EtOH at 0° C. was added NaBH4 (260 mg, 6.8 mmol) in one portion. This was allowed to stir at 0° C. for 2 h. The solvent was removed, and the residue was partitioned between EtOAc and NaHCO3 solution. The organic layer was separated, dried, and concentrated to give Compound D as a solid (4.1 g, 94%).
- E. 1-(2,5-Bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylaamine.
- To a stirred suspension of Compound D (4.0 g, 12.3 mmol) in toluene (40 mL) at 0° C., was added DPPA (2.9 mL, 13.6 mmol), followed by addition of DBU (2.2 mL, 14.8 mmol). The stirred reaction mixture was allowed to heat at 60° C. for 18 h. The mixture was allowed to cool and was then partitioned between EtOAc and water. The organic layer was washed with brine (3×50 mL), dried, concentrated, and re-dissolved in acetonitrile. Water (1.0 mL) was added to the solution, followed by Ph3P (4 g, 15.1 mmol), and the mixture was allowed to heat at reflux for 18 h. The solution was cooled and concentrated. The residue was partitioned between EtOAc and 10% HCl solution. The aqueous solution was extracted with EtOAc and basified (pH 12) with ION NaOH solution at 0° C. The aqueous solution was extracted with EtOAc, and combined extracts were dried (Na2SO4) and concentrated to give Compound E as a solid.
- F. N-(2,4-Dichlorophenyl)-N′-[1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)-ethyl]-N″-cyanoguanidine. To a stirred solution of Compound E (1.1 g, 3.4 mmol) in DMF at rt was added N-cyano-N′-(2,4-dichlorophenyl)thiourea (1.1 g, 4.1 mmol), followed by EDC (800 mg, 4.1 mmol). The mixture was allowed to stir at rt for 18 h and then partitioned between EtOAc and saturated ammonium chloride solution. The organic layer was separated and washed with saturated ammonium chloride solution (3×50 mL). The organic layer was dried, concentrated, and the residue was purified by silica gel column chromatography (EtOAc, MeOH, NR4OH; 95:5:0.1) to give Example 1 as a solid (350 mg). MS (ES): m/z 535 [M+H]+.
-
-
-
- A. N-[1-(2,5-Bistrifluoromethylphenyl)-2-(imidazol-1-yl)-ethyl]-N′-cyano-phenylureanate. To a stirred solution of 1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylamine (220 mg, 0.68 mmol) in acetonitrile (5 mL) at rt was added diphenyl cyanocarbonimidate (178 mg, 71 mmol). The reaction mixture was allowed to stir at rt for 18 h. The solvent was removed, and the residue was purified by silica gel column chromatography (EtOAc, MeOH; 9:1) to give 160 mg (55%) of Compound A.
- B. N-(Diphenylmethyl)-N′-[1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)-ethyl]-N″-cyanoguanidine. To a stirred solution of Compound A (10 mg) in acetonitrile (2 mL) at rt was added diphenylmethylamine (20 mg). The reaction mixture was heated at reflux for 18 h. The mixture was then concentrated and the residue purified by silica gel column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give Example 12 (5 mg). MS (ES): m/z 556 [M+H]+.
-
- Compounds having the formula (Ih), wherein R3 has the values listed in Table 2 were prepared by following the same or similar procedure described for Example 12, except in Step B, different amines were used.
TABLE 2 Example # R3 Data 13 MS 480 [M + H]+ 14 MS 548 [M + H]+ 14 MS 559 [M + H]+ 15 MS 559 [M + H]+ 16 MS 549 [M + H]+ 17 MS 559 [M + H]+ 18 MS 549 [M + H]+ 19 MS 530 [M + H]+ 20 MS 549 [M + H]+ 21 MS 514 [M + H]+ 22 MS 570 [M + H]+ 23 MS 572 [M + H]+ 24 MS 540 [M + H]+ 25 MS 524 [M + H]+ 26 MS 536 [M + H]+ 27 MS 516 [M + H]+ 28 MS 606 [M + H]+ 29 MS 524 [M + H]+ 30 MS 540 [M + H]+ 31 MS 537 [M + H]+ 32 MS 551 [M + H]+ 33 MS 515 [M + H]+ 34 MS 617 [M + H]+ 35 MS 606 [M + H]+ 36 MS 564 [M + H]+ 37 MS 544 [M + H]+ 38 MS 639 [M + H]+ 39 MS 563 [M + H]+ 40 MS 570 [M + H]+ 41 MS 545 [M + H]+ 42 MS 506 [M + H]+ 43 MS 524 [M + H]+ 44 MS 559 [M + H]+ 45 MS 508 [M + H]+ 46 MS 486 [M + H]+ 47 MS 500 [M + H]+ 48 MS 549 [M + H]+ 49 MS 528 [M + H]+ 50 MS 533 [M + H]+ 51 MS 501 [M + H]+ 52 MS 517 [M + H]+ 53 MS 554 [M + H]+ 54 MS 706 [M + H]+ 55 MS 506 [M + H]+ 56 MS 554 [M + H]+ 57 MS 520 [M + H]+ 58 MS 524 [M + H]+ 59 MS 494 [M + H]+ 60 MS 554 [M + H]+ 61 MS 587 [M + H]+ 62 MS 582 [M + H]+ 63 MS 542 [M + H]+ 64 MS 549 [M + H]+ 65 MS 484 [M + H]+ 66 MS 616 [M + H]+ 67 MS 522 [M + H]+ 68 MS 584 [M + H]+ 69 MS 570 [M + H]+ 70 MS 538 [M + H]+ 71 MS 570 [M + H]+ 72 MS 524 [M + H]+ 73 MS 510 [M + H]+ 74 MS 510 [M + H]+ 75 MS 652 [M + H]+ 76 MS 510 [M + H]+ -
-
-
- The general procedure described in Example 1 (Steps C-F) was followed to synthesize Example 82; however, in Step C, trichloroacetophenone was used instead of 1-bromomethylcarbonyl-2,5-bistrifluoromethylbenzene to produce the intermediate 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethylamine as a white solid, and then this intermediate was used in step F instead of 1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylamine, to provide Example 82 as a solid. MS (ES): m/z 468 [M+H]+.
-
- Compounds having the formula (Ij), wherein R3 has the values listed in Table 4, were prepared by following the procedure described above in Example 82, except different cyanothioureas were used in Step F.
TABLE 4 Example # R3 Data 83 MS 468 [M + H]+ 84 MS 468 [M + H]+ 85 MS 468 [M + H]+ 86 MS 433 [M + H]+ 87 MS 433 [M + H]+ 88 MS 433 [M + H]+ 89 MS 468 [M + H]+ 90 MS 468 [M + H]+ 91 MS 505 [M + H]+ 92 MS 427 [M + H]+ 93 MS 447 [M + H]+ 94 MS 459 [M + H]+ 95 MS 413 [M + H]+ 96 MS 417 [M + H]+ 97 MS 441 [M + H]+ 98 MS 467 [M + H]+ 99 MS 447 [M + H]+ 100 MS 449 [M + H]+ 101 MS 467 [M + H]+ 102 MS 467 [M + H]+ 103 MS 483 [M + H]+ 104 MS 492 [M + H]+ -
- The procedure described for Example 12 was followed, except 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethylamine was used in Step A to produce the intermediate N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(3-phenylpropyl)-N″-cyanoguanidine, and then that intermediate was used in Step B with 3-phenylpropylamine (instead of diphenylmethylamine) to produce Example 105.
-
- Compounds having formula (Ij), wherein R3 has the values listed in Table 5, were prepared by following the procedure described above for Example 105, except using different amines in Step B.
TABLE 5 Example # R3 Data 105 MS 441 [M + H]+ 106 n-Bu— MS 379 [M + H]+ 107 HO(CH2)3— MS 381 [M + H]+ 108 EtOEt— MS 395 [M + H]+ 109 HO(CH2)4— MS 395 [M + H]+ 110 MS 381 [M + H]+ 111 MS 496 [M + H]+ 112 MS 461 [M + H]+ 113 MS 473 [M + H]+ 114 MS 551 [M + H]+ 115 MS 414 [M + H]+ 116 MS 439 [M + H]+ 117 MS 459 [M + H]+ 118 MS 471 [M + H]+ 119 MS 520 [M + H]+ 120 MS 470 [M + H]+ 121 MS 484 [M + H]+ 122 MS 447 [M + H]+ 123 MS 465 [M + H]+ 124 MS 489 [M + H]+ 125 MS 427 [M + H]+ 126 MS 487 [M + H]+ 127 MS 517 [M + H]+ 128 MS 485 [M + H]+ -
- Steps B to E of Example 1 were followed, starting with 2,5-dichlorophenylmethyl-carbonylbenzene in Step B, to produce after Step E the intermediate 1-(2,5-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine; and then this amine was used as Compound E in Step F of Example 1 to obtain the titled compound as a solid. MS (ES): m/z 467 [M+H]+.
-
-
-
- The procedure of Example 1 was followed, except in Step B, 2-chlorophenylmethylketone was used as Compound A (instead of 2,5-bistrifluoromethyl-1-methylcarbonylbenzene), to produce after Step E 1-(2-Chlorophenyl)-2-(imidazol-1-yl)ethylamine. Then in Step F, this ethylamine was used to obtain Example 136 as a solid. MS (ES): m/z 433 [M+H]+.
-
-
-
- The procedure of Example 1 was followed, except 2,3-Dichlorophenylmethylketone was used in Step B instead of 2,5-bistrifluoromethyl-1-methylcarbonylbenzene, to produce after Step E 1-(2,3-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine, and then step F was followed with this ethylamine to obtain Example 148 as a solid. MS (ES): m/z 433 [M+H]+.
-
-
-
- The procedure of Example 1 was followed, except 2,4-bistrifluoromethyl-phenylmethylketone was used as Compound A in Step B to produce 1-(2,4-Bistrifluoromethylphenyl)-2-(imidazol-1-yl)ethylamine (after Step E), and then Step F was followed with this ethylamine to obtain Example 155 as a solid. MS (ES): m/z 535 [M+H]+.
-
- Compounds having the formula (In) were prepared wherein R3 has the values listed in Table 9, following the procedure as described for Example 155, except different N-aryl-N′-cyanothioureas were used in Step F.
TABLE 9 Example # R3 Data 156 MS 500 [M + H]+ 157 MS 500 [M + H]+ 158 MS 500 [M + H]+ 159 MS 535 [M + H]+ 160 MS 535 [M + H]+ 161 MS 535 [M + H]+ 162 MS 535 [M + H]+ 163 MS 558 [M + H]+ 164 MS 514 [M + H]+ 165 MS 506 [M + H]+ 166 MS 498 [M + H]+ 167 MS 494 [M + H]+ 168 MS 514 [M + H]+ 169 MS 559 [M + H]+ 170 MS 472 [M + H]+ 171 MS 528 [M + H]+ -
- Example 172 was synthesized following the procedure described for Example 155, except triazole was used instead of imidazole (i.e., as per Example 1, Step C), to produce 1-(2,4-Bistrifluoromethylphenyt)-2-[1-(1,2,4-triazolyl)]ethylamine, and this ethylamine was used in the last step to make the titled compound as a solid. MS (ES): m/z 536 [M+H]+.
-
-
-
- The procedure described for Example 172 was followed using benzimidazole instead of triazole to produce 1-(2,4-Bistrifluoromethylphenyl)-2-(benzimidazol-1-yl)ethylamine, and then this ethylamine was used in the last step to make Example 176. MS (ES): m/z 585 [M+H]+.
-
- Example 177 was prepared in the same manner as for Example 176, except N-(indan-7-yl)-N′-cyanothiourea was used in the last step. MS (ES): m/z 556 [M+H]+.
-
-
-
-
-
- A. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(4-chlorophenyl)carbonyl thiourea. To a stirred solution of 4-chlorobenzoyl chloride (175 mg, 1.0 mmol) in anhydrous acetone was added KNCS (100 mg, 1.0 mmol) at rt. The reaction mixture was heated at reflux for 40 min, then cooled to rt, and 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethylamine (250 mg, 1.0 mmol) was added. The reaction was allowed to proceed for 2 h. The precipitate was filtered and the filtrate concentrated to give Compound A, which was used in the next step without further purification.
- B. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-diphenylmethyl-N″-(4-chlorophenyl)carbonylguanidine Hydrochloride. To a stirred solution of Compound A in CH2Cl2 was added diphenylmnethylamine (150 mg), followed by TEA and mercuric chloride (270 mg). The mixture was allowed to stir at rt for 3 h. The reaction mixture was diluted with EtOAc. The precipitate was filtered, the filtrate concentrated, and the residue purified by column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give, after conversion to HCl salt with HCl solution in ether, the titled compound a solid. MS (ES): m/z 602 [M+H]+.
-
- A. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-phenyl)carbonyl thiourea. Compound A was prepared by following the procedure of Example 190, Step A, except benzoyl chloride was used instead of 4-chlorobenzoyl chloride.
- B. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]—N′-phenyl-N″-phenylcarbonylguanidine. Step B of Example 190 was followed using Compound A, above, and aniline (instead of diphenylmethylamine) to obtain Example 191. MS (ES): m/z 478 [M+H]+.
-
- Compounds having the formula (If) wherein R3 has the values listed in Table 13, were prepared by following the process described in Example 191 except using different arylamines in step B.
TABLE 13 Example # R3 Data 192 MS 512 [M + H]+ 193 MS 492 [M + H]+ 194 MS 512 [M + H]+ 195 MS 526 [M + H]+ 196 MS 547 [M + H]+ 197 MS 503 [M + H]+ 198 MS 547 [M + H]+ 199 MS 536 [M + H]+ 200 MS 546 [M + H]+ 201 MS 557 [M + H]+ 202 MS 526 [M + H]+ 203 MS 520 [M + H]+ 204 MS 560 [M + H]+ 205 MS 571 [M + H]+ 206 MS 554 [M + H]+ 207 MS 562 [M + H]+ 208 MS 520 [M + H]+ 209 MS 556 [M + H]+ 210 MS 557 [M + H]+ 211 MS 570 [M + H]+ 212 MS 644 [M + H]+ 213 MS 528 [M + H]+ 214 MS 536 [M + H]+ 215 MS 506 [M + H]+ 216 MS 580 [M + H]+ 217 MS 562 [M + H]+ 218 MS 528 [M + H]+ 219 MS 524 [M + H]+ 220 MS 627 [M + H]+ 221 MS 517 [M + H]+ 222 MS 518 [M + H]+ 223 MS 557 [M + H]+ 224 MS 522 [M + H]+ 225 MS 581 [M + H]+ 226 MS 520 [M + H]+ 227 MS 569 [M + H]+ -
-
-
- A. N-(4-Chlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethyl] thiourea. To a stirred solution of 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethylaruine (255 mg, 1.0 mmol) in acetonitrile was added 4-chlorophenylisothiocyanate (170 mg, 1.0 mmol). The reaction mixture was allowed to stir at rt for 18 h. The solvent was evaporated to give Compound A as a solid, which was used directly in the next step.
- B. N-(4-Chlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethyl]guanidine. Compound A was mixed with a solution of ammonium hydroxide (10 mL, 7M) in MeOH. To this stirred solution was added mercuric oxide (red, 1.5 mmol). The suspension was allowed to stir at rt for 18 h. The mixture was filtered, and the filtrate concentrated and partitioned between aqueous NaOH solution and EtOAc. The organic layer was separated, dried, and concentrated to give Compound B as an oil.
- C. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(4-chlorophenyl)-N″-(4-cyanophenyl)carbonylguanidine hydrochloride. To a stirred solution of 4-cyanobenzoic acid (43 mg, 0.3 mmol) in 5 mL of anhydrous THF was added carbonyl diimidazole (48 mg, 0.3 mmol). This was allowed to stir at rt for 2 h. A solution of Compound B (120 mg, 0.3 mmol) in anhydrous THF (1 mL) was added, and the mixture was allowed to stir at rt for 18 h. The solvent was removed, and the residue partitioned between EtOAc and NaHCO3 solution. The organic layer was separated, dried, and concentrated. The residue was purified by silica gel column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give an oil, which was dissolved in MeOH. HCl solution in ether was added, and the solvent was removed to give the title compound as a solid. MS (ES): m/z 537 [M+H]+.
-
- Compounds having the formula (It) wherein R9 has the values listed in Table 15, were prepared by following the process described for Example 231 except instead of 4-cyanobenzoic acid, different carboxyclic acids were used in Step C.
TABLE 15 Example # R9 Data 232 MS 478 [M + H]+ 233 MS 518 [M + H]+ 234 MS 537 [M + H]+ 235 MS 548 [M + H]+ 236 MS 677 [M + H]+ 237 MS 557 [M + H]+ 238 MS 526 [M + H]+ 239 MS 530 [M + H]+ 240 MS 592 [M + H]+ 241 MS 526 [M + H]+ 242 MS 513 [M + H]+ 243 MS 581 [M + H]+ 244 MS 547 [M + H]+ 245 MS 570 [M + H]+ 246 MS 530 [M + H]+ 247 MS 569 [M + H]+ 248 MS 502 [M + H]+ 249 MS 502 [M + H]+ 250 MS 518 [M + H]+ 251 MS 580 [M + H]+ 252 MS 565 [M + H]+ 253 MS 590 [M + H]+ 254 MS 563 [M + H]+ 255 MS 555 [M + H]+ 256 MS 569 [M + H]+ 257 MS 537 [M + H]+ 258 MS 537 [M + H]+ 259 MS 532 [M + H]+ 260 MS 496 [M + H]+ 261 MS 464 [M + H]+ 262 MS 518 [M + H]+ 263 MS 494 [M + H]+ 264 MS 493 [M + H]+ 265 MS 504 [M + H]+ 266 MS 490 [M + H]+ 267 MS 476 [M + H]+ 268 MS 542 [M + H]+ 269 MS 542 [M + H]+ 270 MS 555 [M + H]+ 271 MS 556 [M + H]+ -
- Example 272 was prepared by following the procedure of Example 190, except 3-cyanobenzoyl chloride was used instead of 4-chlorobenzoyl chloride in Step A to obtain N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(3-cyanophenyl)carbonyl thiourea, and tert-butylcyclohexylamine was used in Step B instead of diphenylmethylamine to obtain the titled compound. MS (ES): m/z 565 [M+H]+.
-
- Compounds having the formula (Iu) wherein R3 has the values listed in Table 16, were prepared by following the process described for Example 272 except different amines were used in Step B.
TABLE 16 Example # R3 Data 273 MS 571 [M + H]+ 274 MS 531 [M + H]+ 275 MS 561 [M + H]+ 276 MS 498 [M + H]+ 277 MS 538 [M + H]+ 278 MS 534 [M + H]+ 279 MS 524 [M + H]+ 280 MS 579 [M + H]+ 281 MS 508 [M + H]+ 282 MS 562 [M + H]+ 283 MS 528 [M + H]+ 284 MS 549 [M + H]+ 285 MS 596 [M + H]+ 286 MS 571 [M + H]+ 287 MS 544 [M + H]+ 288 MS 559 [M + H]+ 289 MS 587 [M + H]+ 290 MS 560 [M + H]+ 291 MS 585 [M + H]+ 292 MS 550 [M + H]+ 293 MS 565 [M + H]+ 294 MS 677 [M + H]+ 295 MS 553 [M + H]+ 296 MS 522 [M + H]+ 297 MS 574 [M + H]+ 298 MS 550 [M + H]+ 299 MS 591 [M + H]+ 300 MS 550 [M + H]+ 301 MS 570 [M + H]+ 303 MS 551 [M + H]+ 304 MS 587 [M + H]+ 305 MS 622 [M + H]+ 306 MS 538 [M + H]+ -
- The procedure described in Example 1, Steps A-E, was followed except in Step C, trichloroacetophenone was used for Compound B and 2-methylimidazole was used instead of imidazole to prepare (after Step E), 1-(2,4-dichlorophenyl)-2-(2-methylimidazol-1-yl-yl)ethylamine. Then this ethylamine and 3-cyanobenzoic acid were used in the procedure described in Example 231, Steps A to B, to prepare the titled compound as a solid. MS (ES): mnz 551 [M+H]+.
-
-
-
- A. 2-Chloro-5-trifluoromethylphenylethylene oxide. To a stirred solution of 2-chloro-5-trifluoromethylbenzalhyde (2.05 g, 10 mmol) in acetonitrile (50 mL) at rt was added trimethylsulfonium iodide (2.04 g, 10 mmol) and 0.5 mL of water, followed by powdered KOH (1.05 g). The suspension was heated on an oil-bath at 70° C. under argon for 6 h. The reaction mixture was cooled, ether was added, and the suspension was filtered. The filtrate was concentrated and the residue purified by flash column chromatography (hexanes/EtOAc, 9:1) to give Compound A as a yellow oil (1.8 g).
- B. 1-(2-Chloro-5-trifuoromethylphenyl)-2-(imidazol-1-yl)ethanol. To a stirred solution of Compound A (600 mg, 2.7 mmol) and imidazole (550 mg, 8 mmol) in DMF at rt was added sodium hydride (200 mg, 8 mmol) in one portion. This was allowed to stir at rt for 2 h. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated, washed with saturated ammonium chloride solution, dried, and concentrated to give Compound B as an oil, which was used directly in the next step.
- C. N-(2,4-Dichlorophenyl)-N′-[1-(2-chloro-5-trifluoromethylphenyl)-2-(imidazol-1-yl)-ethyl]-N″-cyanoguanidine. Step E of Example 1 was followed with t-(2-chloro-5-trifuoromethylphenyl)-2-(imidazol-1-yl)ethanol to prepare 1-(2-Chloro-5-trifuoromethylphenyl)-2-(imidazol-1-yl)ethylamine, and then this ethylamine was used in Step F of Example 1 to produce Example 307. MS (ES): m/z 501 [M+H]+.
-
- The procedure described for Example 307 was followed except in Step A, 2,5-bistrifluoromethylbenzadehyde was used to give 2,5-Bistrifluoromethylphenylethylene oxide. Step B gave bistrifuoromethylphenyl)-2-(benzimidazol-1-yl)ethanol, which was used in Step C to give 1-(2-Chloro-5-trifuoromethylphenyl)-2-(benzimidazol-1-yl)ethylamine and Example 308. MS (ES): m/z 585 [M+H]+.
-
- A. N-(4-Trifluoromethylphenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethyl]thiourea. Compound A was prepared by following the procedure of Example 231, except 4-trifluoromethylphenylisothiocyanate was used.
- B. N-(4-Chlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(irmdazol-1-yl)-ethyl] guanidine. Compound B was prepared by following the procedure of Example 231, Step B, except the thiourea used was Compound A.
- C. N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(4-trifluoromethylphenyl)-N″-(pyridin-3-ylamino)carbonylguanidine dihydrochloride. To a stirred solution of 3-aminopyridine (200 mg, 2.2 mmol) in 5 mL of anhydrous acetonitrile was added carbonyl diimidazole (330 mg, 2.2 mmol). This was allowed to stir at rt for 2 h. A solution of Compound B (700 mg, 1.5 mmol) in anhydrous acetonitrile (1 mL) was added. This was allowed to stir at rt for 18 h. The solvent was removed and the residue partitioned between EtOAc and NaHCO3 solution. The organic layer was separated, dried, and concentrated; the residue was purified by silica gel column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give an oil. The oil was dissolved in MeOH, and to this was added HCT solution in ether. The solvent was removed to give the titled compound as a solid. MS (ES): nmz 562 [M+H]+.
-
-
-
- To a stirred solution of N-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(4-chlorophenyl)guanidine of Example 231 (step B) in THF was added carbonyldimidazole. The reaction mixture was allowed to stir at rt for 2 h, then 4-chlorophenylmethylamine was added. This was allowed to stir at rt for 18 h. The solvent was removed and the residue partitioned between EtOAc and ammonium chloride solution. The organic layer was separated, dried, concentrated, and purified by silica gel column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give an oil. The oil was dissolved in MEOH, and to this was added HCl solution in ether. The solvent was removed to give the title compound as a solid. MS (ES): r/z 576 [M+H]+.
-
- Compounds having the formula (1×) wherein R9 has the values listed in Table 19 were prepared by following the procedure described for Example 314 except instead of 4-chlorophenylmethylamine, different amines were used.
TABLE 19 Example # R9 Data 315 MS 517 [M + H]+ 316 MS 575 [M + H]+ 317 MS 641 [M + H]+ 318 MS 547 [M + H]+ 319 MS 639 [M + H]+ 320 MS 628 [M + H]+ 321 MS 624 [M + H]+ 322 MS 573 [M + H]+ 323 MS 547 [M + H]+ 324 MS 533 [M + H]+ 325 MS 609 [M + H]+ 326 MS 628 [M + H]+ 327 MS 627 [M + H]+ 328 MS 567 [M + H]+ 329 MS 569 [M + H]+ 330 MS 631 [M + H]+ 331 MS 591 [M + H]+ 332 MS 613 [M + H]+ 333 MS 640 [M + H]+ 334 MS 605 [M + H]+ 335 MS 575 [M + H]+ 336 MS 569 [M + H]+ 337 MS 549 [M + H]+ 338 MS 589 [M + H]+ 339 MS 611 [M + H]+ 340 MS 618 [M + H]+ 341 MS 612 [M + H]+ 342 MS 569 [M + H]+ 343 MS 593 [M + H]+ 344 MS 539 [M + H]+ 345 MS 623 [M + H]+ 346 MS 585 [M + H]+ 347 MS 584 [M + H]+ 348 MS 519 [M + H]+ 349 MS 535 [M + H]+ 350 MS 559 [M + H]+ 351 MS 555 [M + H]+ 352 MS 665 [M + H]+ 353 MS 691 [M + H]+ 354 MS 577 [M + H]+ 355 MS 559 [M + H]+ 356 MS 547 [M + H]+ 357 MS 648 [M + H]+ 358 MS 541 [M + H]+ 359 MS 547 [M + H]+ 360 MS 567 [M + H]+ 361 MS 598 [M + H]+ 362 MS 585 [M + H]+ 363 MS 585 [M + H]+ 364 MS 545 [M + H]+ 365 MS 651 [M + H]+ 366 MS 556 [M + H]+ 367 MS 601 [M + H]+ 368 MS 624 [M + H]+ 369 MS 678 [M + H]+ 370 MS 551 [M + H]+ 371 MS 625 [M + H]+ 372 MS 592 [M + H]+ 373 MS 565 [M + H]+ 374 MS 535 [M + H]+ 375 MS 562 [M + H]+ 376 MS 581 [M + H]+ 377 MS 545 [M + H]+ 378 MS 576 [M + H]+ 379 MS 556 [M + H]+ 380 MS 556 [M + H]+ 381 MS 559 [M + H]+ 382 MS 578 [M + H]+ 383 MS 556 [M + H]+ 384 MS 523 [M + H]+ 385 MS 562 [M + H]+ 386 MS 550 [M + H]+ -
- A. (R) and (S)-2-Chloro-1-(2,4-dichlorophenyl)ethanol. To a stirred solution of DIP-Cl (15 g, 46.8 mmol) in THF (100 mL) at −78° C. under argon atmosphere was added chloroacetophenone (5.5 g, 24.6 mmol) in THF (10 mL) via an additional funnel. This was allowed to stir at −78° C. and slowly warmed to rt for 18 h. To the resulting mixture was added MeOH (10 mL) followed by saturated NaHCO3 solution. The mixture was concentrated and the residue partitioned between EtOAc and saturated NaHCO3 solution. The organic layer was separated, dried, and concentrated, and the residue was purified by silica gel column chromatography (8:1, hexanes/EtOAc) to give Compound A as an oil (5 g, 90%). The R-enantiomer was made by starting with (−) DIP-Cl (to give Ex. 387), and the S-enantiomer with (+) DIP-Cl (Ex. 388).
- B. (R) and (S)-1-(2,4-Dichlorophenyl)-(imidazol-1-yl)ethanol. To a stirred solution of Compound A (5.0 g, 22.2 mmol) in DMF was added imidazole (2.0 g, 29.4 mmol). This was cooled to 0° C., and sodium hydride (1.0 g, 42 mmol) was added. The resultant mnixture was allowed to stir at 0° C. for 2 h and at rt for 18 h. The reaction was quenched with water (10 mL), and resultant mixture was partitioned between water and EtOAc. The organic layer was separated, dried, concentrated, and the residue was purified by column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give Compound B as a solid (4.0 g, 70%).
- C. (S) and (R)-1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine. Step E of Example 1 was followed to obtain Compound C except 1-(2,4-dichlorophenyl)-(imidazol-1-yl)ethanol was used.
- D. (S) and (R)-N-[1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)-ethyl]-N′-(4-chlorophenyl)-N″-(4-cyanophenyl)carbonylguanidine hydrochloride. Steps A-C of Example 231 were followed to obtain the Compound of Examples 387 and 388 as a white solid, except in Step A, 1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine was used and in Step C1-3-cyanobenzoic acid. The S-enantiomer was made by starting with (−) DIP-Cl, and the R-enantiomer with (+) DIP-Cl. MS (ES): m/z 537 [M+H]+.
-
- To a stirred solution of 2-aminothiazole (100 mg) in acetonitrile (3 mL) was added thiocarbonyl dimidazole (180 mg, 1.0 mmol). The mixture was allowed to stir at rt for 2 h and at 65° C. for 5 h, and then 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethylamine (250 mg, 1.0 mmol) was added. This was allowed to stir for 5 h at 65° C. The mixture was cooled to rt, and diphenylmethylamine was added, followed by TEA and mercuric chloride. The suspension was allowed to stir at rt for 3 h and filtered. The filtrate was concentrated and the residue purified by column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give after conversion to HCT salt, the title compound as a yellow solid (100 mg). MS (ES): m/z 547 [M+H]+.
-
- To a stirred solution of isoniconamide (150 mg, 1.2 mmol) in DMF (3 mL) at rt was added sodium hydride (60% in oil, 120 mg, 3.0 mmol). After the mixture was allowed to stir at rt for 2 h, 4-chlorophenylthioisocyanate was added, and then it was allowed to stir for an additional 2 h. 1-(2,4-Dichlorophenyl)-2-(imidazol-1-yl)ethylamine (200 mg, 0.78 mmol) was added, followed by mercuric chloride (300 mg). The suspension was allowed to stir at rt for 3 h, diluted with EtOAc, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography (EtOAc, MeOH, NH4OH; 90:10:0.1) to give, after conversion to HCl salt, the title compound as a yellow solid (190 mg). MS (ES): m/z 513 [M+H]+.
-
-
-
- The titled compound was prepared by following the procedure of Example 390 except 4-nitrophenylsulfonamide was used instead of isoniconamide. MS (ES): m/z 593 [M+H]+.
-
- The titled compound was prepared by following the procedure of Example 390 except N,N-dimethylurea was used instead of isoniconamide and 2,4-dichlorophenyliso-thiocyanate was used instead of 4-chlorophenylthioisocyanate. MS (ES): m/z 513 [M+H]+.
-
- A. N-(2,4-Dichlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethyl] guanidine. Compound A was prepared by following Example 231, Step A, except 2,4-dichlorophenylisothiocyanate was used.
- B . N-(2,4-Dichlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethyl] N″-(n-butylaminocarbonyl)guanidine. The title compound was prepared by following the procedure of Example 314, except N-(2,4-dichlorophenyl)-N′-[1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethyl] guanidine was used as the guanidine source and n-butylamine was used in place of 4-chlorophenylmethylamine. MS (ES): m/z 541 [M+H]+.
-
-
-
- A. 1-(2,5-Bistrifuoromethylphenyl)-2-(benzimidazol-2-yl)ethylamine. To a stirred solution of 1,1,1,3,3,3-hexamethyldisilazane (2.91 mL, 13.8 mmol, 1.11 equiv) in 13 mL anhydrous THF at 0° C. was added n-butyllithium (5.20 mL of a 2.5 M solution in hexane, 13.0 mmol, 1.05 equiv). After 15 min, 2,5-bistrifluoromethylbenzaldehyde (2.04 g, 8.43 mmol) in anhydrous THF (4 mL) at 0° C. was slowly added, followed by chlorotrimethylsilane (1.73 mL, 1.6 mmol, 1.10 equiv). The mixture was partitioned between EtOAc and water, and the organic layer was washed with brine (3×50 mL), dried (Na2SO4), and concentrated to give Compound A as a solid.
- B. N-(2,4-Dichlorophenyl)-N′-[1-(2,5-bistrifluoromethylphenyl)-2-(imidazol-1-yl)-ethyl]-N″-cyanoguanidine. To a stirred solution of 1-(2,5-bistrifuoromethylphenyl)-2-(imidazol-1-yl)ethylamine (1.1 g, 3.4 mmol) in DMF at rt, N-cyano-N′-(2,4-dichlorophenyl)thiourea (1.1 g, 4.1 mmol) was added, followed by N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (800 mg, 4.1 mmol). The mixture was allowed to stir at rt for 18 h and then partitioned between EtOAc and saturated ammonium chloride solution. The organic layer was separated and washed with saturated ammonium chloride solution (3×50 mL). The organic layer was dried and concentrated, and the residue was purified by silica gel column chromatography (EtOAc, MeOH, NH4OH; 95:5:0.1) to give a solid (350 mg). MS (ES): m/z 535 [M+H]+.
-
- Compounds having the formula (Iaa) wherein R9 has the values listed in Table 22 were prepared following the same or similar procedure as for Example 390, except instead of isoniconamide, different ureas were used.
TABLE 22 Exam- ple # R9 Appearance Data 402 White solid 1H NMR (400 MHz, MeOD) δ 1.4 (1H, m), 1.50 (3H, m), 2.15 (1H, dd, J = 16.0, 8.0 Hz), 4.7 (2H, m), 6.0 (1H, m), 7.2-7.7 (9H, m), 8.95 (1H, s). 403 White powder MS 532 404 Yellow oil MS 496 405 MS 464 406 MS 518 407 MS 494 408 MS 493 409 MS 504 410 MS 490 411 MS 476 412 MS 542 413 MS 542 414 MS 555 415 MS 555 416 MS 556 417 White solid MS 506 418 White solid MS 492 419 Pale yellow oil MS 508 420 Colorless oil MS 501 421 White solid MS 490 422 White solid MS 490 423 White solid MS 490 424 Yellow oil MS 574 425 Yellow oil MS 532 426 Yellow oil MS 586 427 Yellow oil MS 558 428 White solid MS 544 429 White solid MS 591 430 White solid MS 558 -
-
-
-
-
- Compounds having the formula (Iad) wherein the phenyl group Ar and R9 have the values listed in Table 25 were prepared following the same or similar procedure as Example 390, except instead of isoniconamide, different ureas were used, and and the ethylamines used were different 1-(Dihalosubstitutedphenyl)-2-(benzimidazol-1-yl)ethylamines.
TABLE 25 Example # Ar R9 Data 457 MS 608 458 MS 556 459 MS 558 460 MS 542 461 MS 568 462 MS 540 463 MS 526 464 MS 592 465 MS 592 466 MS 592 467 MS 555 468 MS 522 469 MS 524 470 MS 525 471 MS 509 472 MS 509 473 MS 518 474 MS 576 475 MS 536 476 MS 507 477 MS 493 478 MS 560 479 MS 560 480 MS 560 -
- Compounds having the formula (Iae) wherein R21 and R9 have the values listed in Table 26 were prepared following the same or similar procedure as Example 390, except instead of isoniconamide different ureas were used, and instead of 4-chlorophenylthioisocyante, different benzylisothiocyanates were used.
TABLE 26 Example # R21 R9 Appearance Characterization 481 Colorless oil MS 572 482 Colorless oil MS 520 483 Colorless oil MS 504 484 Colorless oil MS 600 485 Colorless oil MS 490 486 Colorless oil MS 591 487 White solid MS 606; 1H NMR (500 MHz, MeOD) δ 1.3-1.4 (1H, m), 1.51 (3H, d, J =15.0 Hz), 2.16 (1H, d, J =10.0 Hz), 4.4-4.8 (4H, m), 6.0-6.3 (1H, m), 7.0-7.3 (2H, m), 7.3-7.7 (7H, m), 8.96 (1H, s). 488 Colorless oil MS 538 489 White solid MS 554 490 White solid MS 634 -
- A. 4-tert-Butylphenylsulphonylamine.
-
- B.
- To 1.60 g of Compound A in 30 mL DMF at 0° C. in a 250-mL round-bottomed flask was added NaH (0.72 g, 25 mmol, 3.5 equiv). This mixture was allowed to stir at 0° C. for 30 min and then p-chlorophenylisothiocyanate (1.70 g, 10 mmol, 1 equiv) was added. The mixture was slowly warmed to rt over 24 h. The mixture was poured into ice-water and the solution acidified to pH 2. The precipitate was collected to give 2.76 g (72%) of Compound B as a white solid.
- C. Example 491. To a stirred solution of compound B (1.91 g, 5 mmol) in DMF was added 1-(2,4-dichlorophenyl)-2-imidazol-1-yl)ethylamine (1.35 g, 5 mmol, 1 equiv), followed by 1 mL diisopropylethylamine. The mixture was allowed to stir at rt for 15 min, and then HgCl2 was added (2 g, 7.5 mmol, 1.5 equiv). After stirring at rt for 20 h, the mixture was poured into 1N HCl solution, and then filtered by Buchner funnel. The aqueous solution was neutralized to pH 9-10, extracted with EtOAc, and then purified using preparative HPLC, giving 2.0 g (63%) of Example 491 as a white solid. 1H NMR (400 MHz, MeOD) δ 1.30 (9H, s), 4.63 (2H, d, J=8.0 Hz), 5.7 (1H, m), 6.98 (2H, d, J=8.0 Hz), 7.4-7.6 (I IH, m), 8.9 (1H, s). MS (ES): m/z 604 [M+H]+.
-
- The same procedure of Example 491 was followed, except in step A, t-butyl sulfonyl chloride was used in place of 4-(t-butyl)phenyl sulfonyl chloride to give 50% yield of Example 492 as a white solid.1H NMR (400 MHz, MeOD) δ 1.15 (6H, d, J=4.0 Hz), 2.98 (1H, m), 4.60 (2H, d, J=4.0 Hz), 5.82 (1H, t, J=4.0 Hz), 7.13 (2H, d, J=8.0 Hz), 7.4-7.6 (7H, m), 8.91 (1H, s). MS (ES): m/z 514 [M+H]+.
-
- A. 1-[2,5-Bis(trifluromethyl)phenyl]-2-(benzimidazol-2-yl)-ethylamine.
- To a flame-dried 200-mL round-bottomed flask containing hexamethyldisilazane (2.91 mL, 13.8 mmol, 1.11 equiv) in 13 mL THF at 0° C. was added n-butyllithium (5.20 mL of a 2.5 M solution in hexanes, 13.0 mmol, 0.95 equiv). After 10 minutes, 2,5-bis-(trifluoromethyl)benzaldehyde (3.00 g, 12.4 mmol) was added as a solution in 5 mL THF. After 5 minutes, chlorotrimethylsilane (1.73 mL, 13.6 mmol, 1.10 equiv) was added, and the mixture was allowed to stir at 0° C. for an additional 20 minutes. During this time, to a separate flame-dried 200-mL round-bottomed flask containing 2-methylbenzimidazole (1.63 g, 12.3 mmol, 1.05 equiv) in 45 mL THF at 0° C. was added n-butyllithium (9.91 mL of a 2.5 M solution in hexanes, 24.8 mmol, 2.00 equiv), and the mixture was stirred 20 minutes. To the N-silylimine generated in the first flask was then added BF3.OEt2 (1.65 mL, 12.4 mmol, 1.00 equiv) all at once, followed by the dianion of 2-methylbenzimidazole generated in the second flask (transferred via cannula). The combined reaction mixture was then allowed to stir, warming to rt overnight. The mixture was then poured into a 500-mL separatory funnel containing 100 mL saturated NH4Cl solution, and the resultant biphasic mixture was extracted with CHCl3 (2×100 mL). The combined organics were washed with 100 mL brine, dried over Na2SO4, and concentrated under reduced pressure. Purification by flash chromatography (silica gel, 10% MeOH in CH2Cl2) provided 1.61 g (35%) of the desired benzylic amine as an off-white solid. HPLC: 97% at 2.12 min (retention time) (YMC ODSA column 4.6×50 mm eluting with 10-90% aqueous MeOH over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm) MS (ES): m/z 374 [M+H]+.
- B. N-[1-(2,4-Dichlorophenyl)]-N′-[1-(2,5-bistrifluoromethylphenyl)-2-(benzimidazol-2-yl)-ethyl]-N″-cyanoguanidine.
- This compound was prepared from 1-[2,5-bis(trifluromethyl)phenyl]-2-(benzimidazol-2-yl)-ethylamine and N-cyano-N′-(2,4-dichlorophenyl)thiourea in a manner similar to that previously described for Example 1. HPLC: 99% at 1.75 min (retention time) (YMC S5 ODS column 4.6×33 mm eluting with 10-90% aqueous MeOH over 2 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm) MS (ES): m/z 585 M+.
-
- Example 494 was prepared from 1-[2,5-bis(trifluromethyl)phenyl]-2-(benzimidazol-2-yl)-ethylamine and N-cyano-N′-(4-chlorophenyl)thiourea in a manner similar to that previously described for Example 1, providing the desired cyanoguanidine as an off-white solid. HPLC: 99% at 3.16 min (retention time) (YMC ODSA column 4.6×50 mm eluting with 10-90% aqueous MeOH over 4 min containing 0.1% TFA, 4 mL/min, monitoring at 220 nm) MS (ES): m/z 551 [M+H]+.
Claims (23)
1. A compound having the formula (I):
or a pharmaceutically-acceptable salt, hydrate, or prodrug thereof, wherein:
R1 is cyano, —SO2R8, —C(═O)R9, or heteroaryl;
R2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R3 forms a heterocyclo;
R3 is (i) independently alkyl, substituted alkyl, alkylthio, aminoalkyl, carbamyl, A-aryl, A-heterocyclo, A-heteroaryl, or A-cycloalkyl, or (ii) taken together with R2 forms a heterocyclo;
Z is heteroaryl provided that when R1 is cyano, Z is not 2-pyridinyl;
A is a bond, C1-4alkylene, C2-4alkenylene, substituted C1-4alkylene, substituted C2-4alkenylene, —C(═O)NR19—, —C1-4alkylene-C(═O)NR9—, or substituted C1-4alkylene-C(═O)NR19—;
R4 at each occurrence is selected independently of each other R4 from the group consisting of halogen, alkyl, substituted alkyl, haloalkyl, nitro, cyano, haloalkoxy, OR25, SR25, NR25R26, NR25SO2R27, SO2R27, SO2NR25R26, CO2R26, C(═O)R26, C(═O)NR25R26, OC(═O)R25, —OC(═O)NR25R26, NR25C(═O)R26, NR25CO2R26, aryl, heteroaryl, heterocyclo and cycloalkyl;
R8 is alkyl, substituted alkyl, aryl, or heteroaryl;
R9 is —NR10R11, alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or —CO2R12;
R10 and R11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl;or (ii) taken together form a heterocyclo or heteroaryl;
R12 and R19 are hydrogen or alkyl;
R25 and R26 are independently selected from hydrogen, alkyl, or substituted alkyl, or taken together form a heterocyclo or heteroaryl ring;
R27 is alkyl or substituted alkyl, and
q is 0, 1, 2, or 3.
2. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which Z is an optionally-substituted bicyclic heteroaryl.
3. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which:
Z is triazolyl optionally substituted with one to two R7 or imidazolyl optionally substituted with one to two R7 and/or having fused thereto a benzene ring in turn optionally substituted with one to two R7; and
R7 is alkyl, carbamyl, or substituted alkyl.
3. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which
R1 is cyano or —C(═O)R9.
4. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which
R1 is cyano, —SO2R8, —C(═O)R9, or thiazolyl;
R8 is C1-4alkyl or phenyl optionally substituted with alkyl, halogen, haloalkoxy, cyano, nitro, or trifluoromethyl;
R9 is
a) NR10R11;
b) C1-8alkyl optionally substituted with one to two of:
i) SR13, OR13, NR13aR13b, halogen, trifluoromethyl, CO2R13a, and C(═O)NR13aR13b;
ii) cycloalkyl optionally substituted with one to two of C(═O)H, C1-4acyl, alkenyl, carbamyl, and/or phenyl in turn optionally substituted with halogen;
iii) phenyl or napthyl optionally substituted with one to two of halogen, nitro, amino, alkyl, hydroxy, C1-4alkoxy, or having fused thereto a five or six membered heterocyclo;
iv) pyridinyl, thiophenyl, furanyl, tetrahydrofuranyl, or azepinyl, optionally substituted with alkyl or having fused thereto a five to six membered carbocyclic ring optionally substituted with keto or C1-4alkoxy;
c) C1-4alkoxy;
d) C1-4alkylthio;
e) CO2alkyl;
f) 3 to 6 membered cycloalkyl optionally having up to four substituents selected from alkyl, halogen, cyano, alkenyl, acyl, alkylthio, carbamyl, phenyl in turn optionally substituted with halogen; or having an aryl fused thereto;
g) phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C1-4alkoxy, haloalkoxy, C1-6alkyl, CO2alkyl, SO2alkyl, SO2NH2, amino, NH(C1-4alkyl), N(C1-4alkyl)2, NHC(═O)alkyl, C(═O)alkyl, and/or C1-4alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto;
h) pyridinyl, thiazolyl, furanyl, thiophenyl, and pyrrolyl optionally substituted with one to two of halogen, alkyl, and phenyl in turn optionally substituted with halogen or trifluoromethyl;
R10 and R11 are—
a) independently selected from:
i) hydrogen, C1-4alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl; and
ii) C1-8alkyl optionally substituted with one to two of —CO2alkyl, —C(═O)NH(aryl), NH(aryl), cycloalkyl, phenyloxy, phenyl in turn optionally substituted with C1-4alkyl, hydroxy, C1-4alkoxy, halogen, amino, nitro, tetrahydrofuranyl, and/or five or six membered heterocycle, or having a five or six membered heterocycle fused thereto; pyrrolidinyl optionally substituted with keto; napthyl, anthracenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, benzimidazolyl, or indolyl in turn optionally substituted with C1-4 alkyl or C1-4alkoxy; or
b) R10 and R11 taken together form a heterocycle selected from pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, tetrahydropyridinyl, and imidazolidinyl, wherein said heterocycle formed by R10 and R11 is optionally substistuted with one to two of keto, CO2H, C1-4alkoxy, CO2alkyl, C1-4carbamyl, benzyl; phenyl in turn optionally substituted with alkyl, halogen, or C1-4 alkoxy; tetrahydropyridinyl in turn optionally substituted with keto and/or phenyl; alkyl optionally substituted with amino or NHR21 wherein R21 is alkyl or phenyl optionally substituted with alkyl; and/or has a benzene ring fused thereto in turn optionally substituted with one to two of alkyl, C1-4alkoxy, CO2alkyl, and/or C1-4carbamyl;
R13 is hydrogen or alkyl; and
R13a and R13b are selected from hydrogen, alkyl, and aryl.
5. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which
R2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R3 forms a heterocyclo optionally substituted with alkyl or substituted alkyl;
R3 is (i) independently selected from C1-4alkyl, alkylthio, aminoalkyl, -A-aryl, -A-heterocyclo, -A-cycloalkyl, and -A-heteroaryl, optionally having one to three substituents selected from R3a; and/or having fused thereto a five or six membered carbocyclic ring, or (ii) taken together with R2 forms a heterocyclo optionally substituted with alkyl or substituted alkyl;
R3a at each occurrence is selected independently from alkyl, substituted alkyl, halogen, haloalkoxy, cyano, nitro, keto, trifluoromethyl, —NR17R18, —SR17, —OR17, —SO2R17a, —SO2NR17R18, —NR17C(═O)R18, —CO2R17, —C(═O)R17, cycloalkyl, aryl, heterocyclo, and heteroaryl, wherein when R3a is cycloalkyl, aryl, heterocyclo or heteroaryl, said cycloalkyl, aryl, heterocyclo and heteroaryl in turn is optionally substituted with alkyl or substituted alkyl;
A is a bond, C1-4alkylene, substituted C1-4alkylene, —C(═O)NH—, —C1-4alkylene-C(═O)NH—, or substituted C1-4alkylene-C(═O)NH—;
R17 and R18 are independently selected from hydrogen, alkyl, substituted alkyl, and aryl; and
R17a is alkyl or substituted alkyl.
6. The compound of claim 5 , or a pharmaceutically-acceptable salt thereof, in which
A is —(CHR14)m—(CR15R16)n— or —(CHR14)p—C(═O)NH—;
R14, R15 and R16 at each occurrence are independently selected from hydrogen, alkyl, hydroxy, hydroxyC1-4alkyl, C1-4alkoxy, and phenyl, and/or one of R15 and one of R16join together to form a 3 to 6 membered cycloalkyl;
m and n are 0, 1 or 2; and
p is 0, 1, 2, or 3.
7. The compound of claim 5 , or a pharmaceutically-acceptable salt thereof, in which
R17 and R18 are independently selected from hydrogen, alkyl, phenyl, or benzyl wherein the phenyl or benzyl is optionally substituted with alkyl, hydroxy, or hydroxyalkyl.
8. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which
R1 is cyano;
R2 is hydrogen, alkyl, or benzyl;
R3 is phenyl optionally substituted with C1-4alkyl, halogen, trifluoromethyl, OCF3, cyano, nitro, amino, hydroxy, or methoxy; and
R4 is halogen, alkyl, trifluoromethyl, or OCF3.
9. The compound of claim 1 , or a pharmaceutically-acceptable salt thereof, in which
R1 is C(═O)R9;
R2 is hydrogen, alkyl, or benzyl;
R3 is phenyl optionally substituted with C1-4alkyl, halogen, trifluoromethyl, OCF3, cyano, nitro, amino, hydroxy, or methoxy;
R4 is halogen, alkyl, trifluoromethyl, or OCF3; and
R9 is —NR10R11, alkyl or phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C1-4alkoxy, haloalkoxy, C1-6alkyl, CO2alkyl, SO2alkyl, SO2NH2, amino, NH(C1-4alkyl), N(C1-4alkyl)2, NHC(═O)alkyl, C(═O)alkyl, and/or C1-4alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto.
10. A compound having the formula:
or a pharmaceutically-acceptable salt thereof, wherein:
R1 is cyano, —SO2R8, —C(═O)R9, or heteroaryl;
R2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R3 forms a heterocyclo;
R3 is
(i) independently selected from
(a) alkyl optionally substituted with one to two of hydroxy and alkoxy;
(b) alkylthio or aminoalkyl optionally substituted with hydroxy or alkoxy;
(c) -A1-aryl, wherein the aryl is optionally substituted with up to four substituents selected from alkyl, substituted alkyl, halogen, haloalkoxy, cyano, nitro, —NR17R18, —SR17, —OR17, —SO2R17a, —SO2NR17R18, —NR17C(═O)R18, —CO2R17, —C(═O)R17, cycloalkyl, aryl, heterocyclo, and heteroaryl, and/or has fused thereto a five or six membered cycloalkyl ring;
(d) -A2-heteroaryl wherein the heteroaryl is a five or six membered monocyclic ring having 1 to 3 heteroatoms selected from N, O, and S, or an eight or nine membered bicyclic ringed system having at least one aromatic ring and 1 to 4 heteroatoms selected from N, O, and S in at least one of the rings, said heteroaryl being optionally substituted with halogen, alkyl, alkoxycarbonyl, sulfonamide, nitro, cyano, trifluoromethyl, alkylthio, alkoxy, keto, —C(═O)H, acyl, benzyloxy, hydroxy, hydroxyalkyl, or phenyl optionally substituted with alkyl or substituted alkyl;
(e) -A2-heterocyclo wherein the heterocyclo is optionally substituted with one to two groups selected from alkyl, keto, hydroxy, hydroxyalkyl, —C(═O)H, acyl, CO2H, alkoxycarbonyl, phenyl, and/or benzyl, and/or has a bridged carbon-carbon chain or fused benzene ring joined thereto;
(f) -A2-cycloalkyl wherein the cycloalkyl is optionally substituted with one to two groups selected from alkyl, keto, —C(═O)H, acyl, CO2H, alkoxycarbonyl, and/or benzyl, and/or has a bridged carbon-carbon chain or fused benzene ring joined thereto; or
(ii) taken together with R2 forms a heterocyclo;
R4 at each occurrence is selected independently of each other R4 from the group consisting of halogen, alkyl, haloalkyl, nitro, cyano, and haloalkoxy;
R7a, R7b and R7c are alkyl, carbamyl, or carbamylalkyl, or R7a and R7, join to form an aryl or heteoraryl;
R8 is alkyl, arylalkyl, or aryl;
R9 is —NR10R11, alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocycle, or CO2R12;
R10 is independently hydrogen, alkyl, or alkoxy; and
R11 is independently hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, or heteroaryl; or
R10 and R11 taken together form a heterocyclo or heteroaryl optionally substituted with alkyl, keto, CO2H, alkoxycarbonyl, hydroxy, alkoxy, alkyl, carbamyl, aryl, or substituted alkyl, wherein when the R10 and R11 group comprises a phenyl ring, said phenyl ring is optionally substituted with one to two of alkyl, halogen, and alkoxy;
R12 is hydrogen or alkyl;
A1 is —(CHR14)m-V-(CR15R16)n— or —(CHR14)p—C(═O)NH—;
A2 is —(CHR14)m-V-(CR15R16)n;
V is a bond, S, or —NR22—;
R14, R15 and R16 at each occurrence are independently selected from hydrogen, alkyl, hydroxy, hydroxyC1-4alkyl, C1-4alkoxy, and phenyl, and/or one of R15 and one of R16join together to form a three to six membered cycloalkyl;
R17 and R18 are independently selected from hydrogen, alkyl, phenyl, and benzyl, wherein the phenyl and benzyl is optionally substituted with alkyl, hydroxy, or hydroxyalkyl;
R17a is alkyl or substituted alkyl;
R22 is hydrogen or alkyl;
m and n are 0, 1, 2, or 3;
p is 0, 1, 2, or 3; and
q is 0, 1,2, or 3.
11. The compound of claim 10 , or a pharmaceutically-acceptable salt thereof, having the formula:
in which
R7a, R7b and R7, are alkyl, carbamyl or carbamylC1-4alkyl, or R7a and R7, join to form a fused phenyl ring;
R23 is selected from hydrogen, alkyl, hydroxyalkyl, or phenyl;
R24 is selected from alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF3, methoxy, phenyloxy, benzyloxy, cyano, acyl, or two R24 groups join to form a fused cycloalkyl or benzene ring; and
x is 0, 1, or 2; and
y is 0, 1, 2, or 3.
12. The compound of claim 11 , or a pharmaceutically-acceptable salt thereof, in which R1 is cyano or —C(═O)R9.
13. The compound of claim 12 , or a pharmaceutically-acceptable salt thereof, in which R9 is —NR10R11, alkyl or phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C1-4alkoxy, haloalkoxy, C1-6alkyl, CO2alkyl, SO2alkyl, SO2NH2, amino, NH(C1-4alkyl), N(C1-4alkyl)2, NHC(═O)alkyl, C(═O)alkyl, and/or C1-4alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto.
14. A non-peptidic organic compound having less than 1000 molecular weight that is effective for inhibiting F1F0-ATP hydrolase.
15. A compound according to claim 14 having less than 750 molecular weight.
16. A method of inhibiting F1F0-ATP hydrolase by administering to a mammal a non-peptidic organic compound according to claim 14 .
17. The method of claim 16 , comprising administering to the mammal the non-peptidic organic compound in combination with a second compound selected from an anti-arryhthmic agent, anti-hypertensive agent, anti-platelet agents, anti-thrombotic agent, anti-thrombolytic agent, beta blocker, calcium channel blocker, cardiac glycoside, diruetic, mineralocorticoid receptor antagonist, phospodiesterase inhibitor, lipid lowering agent, anti-inflammatory agent, HMGcoA-reductase inhibitor, platelet inhibitor, and NHE inhibitor.
18. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically-acceptable carrier or diluent.
19. The pharmaceutical composition of claim 18 further comprising at least one additional therapeutic agent selected from one or more of an anti-arryhthmic agent, anti-hypertensive agent, anti-platelet agents, anti-thrombotic agent, anti-thrombolytic agent, beta blocker, calcium channel blocker, cardiac glycoside, diruetic, mineralocorticoid receptor antagonist, phospodiesterase inhibitor, lipid lowering agent, anti-inflammatory agent, HMGcoA-reductase inhibitor, platelet inhibitor, and NHE inhibitor.
20. The pharmaceutical composition of claim 19 wherein the additional therapeutic agent is selected from (a) an anti-arryhthmic agent selected from sotalol, dofetilide, amiodarone, azimilide, ibutilide, diltiazem, verapamil and K+ channel openers; (b) an anti-hypertensive agent selected from ACE inhibitors, AT-1 receptor antagonists, ET receptor antagonists, dual ET/AII receptor antagonists, and vasopepsidase inhibitors; and (c) a platelet inhibitor selected from one or more of aGPIIb/IIIa blocker, P2Y12 antagonist, thromboxane receptor antagonist, aspirin, and plavix.
21. A method of treating an ischemic condition comprising administering an effective amount of at least one compound of claim 1 to a patient in need thereof.
22. The method according to claim 21 wherein the ischemic condition is an acute coronary syndrome selected from myocardial infarction, congestive heart failure, and cardiac arrhythmias.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/315,818 US6916813B2 (en) | 2001-12-10 | 2002-12-10 | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33910801P | 2001-12-10 | 2001-12-10 | |
US10/315,818 US6916813B2 (en) | 2001-12-10 | 2002-12-10 | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040039033A1 true US20040039033A1 (en) | 2004-02-26 |
US6916813B2 US6916813B2 (en) | 2005-07-12 |
Family
ID=23327531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/315,818 Expired - Lifetime US6916813B2 (en) | 2001-12-10 | 2002-12-10 | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
Country Status (4)
Country | Link |
---|---|
US (1) | US6916813B2 (en) |
EP (1) | EP1450901A4 (en) |
AU (1) | AU2002357137A1 (en) |
WO (1) | WO2003050261A2 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220233A1 (en) * | 2003-02-06 | 2004-11-04 | John Hynes | Thiazolyl-based compounds useful as kinase inhibitors |
US20040248853A1 (en) * | 2003-05-01 | 2004-12-09 | Dyckman Alaric J. | Pyrazole-amine compounds useful as kinase inhibitors |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
WO2006117534A2 (en) * | 2005-04-30 | 2006-11-09 | Astrazeneca Ab | New use |
EP1976839A2 (en) * | 2006-01-26 | 2008-10-08 | Foldrx Pharmaceuticals, Inc. | Compounds and methods for modulating protein trafficking |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2012078869A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2012078874A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2013185046A1 (en) * | 2012-06-08 | 2013-12-12 | Lycera Corporation | Saturated acyl guanid1ne for inhibition of f1f0-atpase |
WO2013185045A1 (en) * | 2012-06-08 | 2013-12-12 | Lycera Corporation | Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2013185048A3 (en) * | 2012-06-08 | 2014-01-30 | Lycera Corporation | Heterocyclic guanidine f1f0-atpase inhibitors |
US8962612B2 (en) | 2011-02-02 | 2015-02-24 | Astellas Pharma Inc. | Tetrahydroisoquinoline derivative |
US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9266839B2 (en) | 2013-12-10 | 2016-02-23 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9421267B2 (en) | 2010-11-15 | 2016-08-23 | Neuroderm, Ltd. | Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same |
US9815791B2 (en) | 2013-12-10 | 2017-11-14 | Lycera Corporation | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9914706B2 (en) | 2013-12-10 | 2018-03-13 | Lycera Corporation | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9993451B2 (en) | 2009-05-19 | 2018-06-12 | Neuroderm, Ltd. | Continuous administration of dopa decarboxylase inhibitors and compositions for same |
US10022320B2 (en) | 2014-03-13 | 2018-07-17 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
JP5127096B2 (en) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Use of benzodiazepines to treat autoimmune diseases induced by apoptosis |
US7572788B2 (en) * | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
DE102004008141A1 (en) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidine compounds and their use as binding partners for 5-HT5 receptors |
JP5697296B2 (en) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Method for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia with minimal side effects |
US20090275099A1 (en) * | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
CA2593019A1 (en) | 2005-01-03 | 2006-07-13 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
EP1893218A4 (en) | 2005-06-01 | 2011-01-12 | Univ Michigan | Unsolvated benzodiazepine compositions and methods |
WO2007047724A2 (en) * | 2005-10-18 | 2007-04-26 | Aegerion Pharmaceuticals | Compositions for lowering serum cholesterol and/or triglycerides |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
EP2604269B1 (en) | 2005-11-01 | 2014-09-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
CA2659549C (en) | 2006-06-09 | 2013-07-30 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
WO2008079398A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor |
EP2139331B1 (en) | 2007-03-09 | 2013-02-20 | The Regents of the University of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7884244B2 (en) * | 2007-04-12 | 2011-02-08 | Allergan, Inc. | Therapeutic fluoroethylcyano guanidines |
CN101855203B (en) * | 2007-09-14 | 2014-03-19 | 密执安州立大学董事会 | F1F0-ATPase inhibitors and related methods |
AU2008323945B2 (en) | 2007-11-06 | 2013-11-28 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
EP2352724B1 (en) * | 2008-09-11 | 2015-04-22 | The Regents of the University of Michigan | Aryl guanidine f1f0-atpase inhibitors and their medical use |
US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
US8673897B2 (en) | 2009-09-18 | 2014-03-18 | The Regents Of The University Of Michigan | Benzodiazepinone compounds and methods of treatment using same |
CA2780333C (en) | 2009-11-17 | 2016-05-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
AU2010322287B2 (en) | 2009-11-17 | 2014-04-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
WO2012078867A2 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
DE102014201651A1 (en) * | 2014-01-30 | 2015-07-30 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Isoxazole derivatives for use in the treatment and / or prophylaxis of heart disease |
AU2018209175B2 (en) * | 2017-01-17 | 2021-11-25 | Michael David FORREST | Therapeutic inhibitors of the reverse mode of ATP synthase |
WO2018183701A1 (en) | 2017-03-29 | 2018-10-04 | The George Washington University | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors |
SG11202000331YA (en) * | 2017-07-13 | 2020-02-27 | Michael David Forrest | Therapeutic modulators of the reverse mode of atp synthase |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
EP4341246A1 (en) * | 2021-05-17 | 2024-03-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478845A (en) * | 1993-05-26 | 1995-12-26 | Novo Nordisk A/S | Piperidine derivatives |
US5482948A (en) * | 1991-12-14 | 1996-01-09 | Dr. Karl Thomae Gmbh | Pyridyl derivatives and pharmaceutical compositions comprising these compounds |
US5521177A (en) * | 1992-10-06 | 1996-05-28 | Dr. Karl Thomae Gmbh | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them |
US5532258A (en) * | 1991-12-06 | 1996-07-02 | Fujisawa Pharmaceutical Co., Ltd. | H2 -receptor antagonist thiazoles |
US6162790A (en) * | 1995-12-20 | 2000-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9205222A (en) | 1991-09-11 | 1993-03-01 | Smithkline Beecham Corp | PEPTIDE ISOESTERS CONTAINING A HETERO CYCLE |
US5602155A (en) | 1995-01-17 | 1997-02-11 | G. D. Searle & Co. | Platelet aggregation inhibitors |
WO2000035449A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU3348700A (en) | 1999-01-25 | 2000-08-07 | American Home Products Corporation | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
DE60213958T2 (en) * | 2001-02-27 | 2007-08-30 | Migenix Corp., San Diego | ARYL-N-CYANOGUANIDINE DERIVATIVES AND THEIR USE |
-
2002
- 2002-12-10 EP EP02804765A patent/EP1450901A4/en not_active Withdrawn
- 2002-12-10 WO PCT/US2002/039478 patent/WO2003050261A2/en not_active Application Discontinuation
- 2002-12-10 AU AU2002357137A patent/AU2002357137A1/en not_active Abandoned
- 2002-12-10 US US10/315,818 patent/US6916813B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5532258A (en) * | 1991-12-06 | 1996-07-02 | Fujisawa Pharmaceutical Co., Ltd. | H2 -receptor antagonist thiazoles |
US5482948A (en) * | 1991-12-14 | 1996-01-09 | Dr. Karl Thomae Gmbh | Pyridyl derivatives and pharmaceutical compositions comprising these compounds |
US5521177A (en) * | 1992-10-06 | 1996-05-28 | Dr. Karl Thomae Gmbh | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them |
US5478845A (en) * | 1993-05-26 | 1995-12-26 | Novo Nordisk A/S | Piperidine derivatives |
US6162790A (en) * | 1995-12-20 | 2000-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169771B2 (en) | 2003-02-06 | 2007-01-30 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
US7323482B2 (en) | 2003-02-06 | 2008-01-29 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
US20040220233A1 (en) * | 2003-02-06 | 2004-11-04 | John Hynes | Thiazolyl-based compounds useful as kinase inhibitors |
US20070093537A1 (en) * | 2003-02-06 | 2007-04-26 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
US20080004278A1 (en) * | 2003-05-01 | 2008-01-03 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
US20040248853A1 (en) * | 2003-05-01 | 2004-12-09 | Dyckman Alaric J. | Pyrazole-amine compounds useful as kinase inhibitors |
US7151113B2 (en) | 2003-05-01 | 2006-12-19 | Bristol Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
US7592338B2 (en) | 2003-05-01 | 2009-09-22 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
US20060247247A1 (en) * | 2003-05-01 | 2006-11-02 | Dyckman Alaric J | Pyrazole-amine compounds useful as kinase inhibitors |
US7253170B2 (en) | 2003-05-01 | 2007-08-07 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
US7923556B2 (en) | 2005-02-04 | 2011-04-12 | Bristol-Myers Squibb Company | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US20100029649A1 (en) * | 2005-02-04 | 2010-02-04 | Bristol-Myers Squibb Company | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
WO2006117534A2 (en) * | 2005-04-30 | 2006-11-09 | Astrazeneca Ab | New use |
WO2006117534A3 (en) * | 2005-04-30 | 2007-01-25 | Astrazeneca Ab | New use |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
EP2266981A2 (en) | 2005-08-01 | 2010-12-29 | Bristol-Myers Squibb Company | Benzothiazole compounds useful as kinase inhibitors |
US7994337B2 (en) | 2005-08-01 | 2011-08-09 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
EP1976839A2 (en) * | 2006-01-26 | 2008-10-08 | Foldrx Pharmaceuticals, Inc. | Compounds and methods for modulating protein trafficking |
EP1976839A4 (en) * | 2006-01-26 | 2011-06-15 | Foldrx Pharmaceuticals Inc | Compounds and methods for modulating protein trafficking |
US9993451B2 (en) | 2009-05-19 | 2018-06-12 | Neuroderm, Ltd. | Continuous administration of dopa decarboxylase inhibitors and compositions for same |
US9421267B2 (en) | 2010-11-15 | 2016-08-23 | Neuroderm, Ltd. | Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same |
US9139532B2 (en) | 2010-12-08 | 2015-09-22 | Lycera Corporation | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof |
US9932313B2 (en) | 2010-12-08 | 2018-04-03 | Lycera Corporation | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
CN103458886A (en) * | 2010-12-08 | 2013-12-18 | 莱斯拉公司 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
CN103476252A (en) * | 2010-12-08 | 2013-12-25 | 莱斯拉公司 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
WO2012078869A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2012078874A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
US9000014B2 (en) | 2010-12-08 | 2015-04-07 | Lycera Corporation | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
AU2011338304B2 (en) * | 2010-12-08 | 2016-10-27 | Lycera Corporation | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9580388B2 (en) | 2010-12-08 | 2017-02-28 | Lycera Corporation | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
CN103476252B (en) * | 2010-12-08 | 2017-02-22 | 莱斯拉公司 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
CN103458886B (en) * | 2010-12-08 | 2016-06-08 | 莱斯拉公司 | Pyriconyl guanidine F1F0-atpase inhibitor and therapeutical uses thereof |
US9370507B2 (en) | 2010-12-08 | 2016-06-21 | Lycera Corporation | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US8962612B2 (en) | 2011-02-02 | 2015-02-24 | Astellas Pharma Inc. | Tetrahydroisoquinoline derivative |
US9580391B2 (en) | 2012-06-08 | 2017-02-28 | Lycera Corporation | Saturated acyl guanidine for inhibition of F1F0-ATPase |
US9920012B2 (en) | 2012-06-08 | 2018-03-20 | Lycera Corporation | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9221814B2 (en) | 2012-06-08 | 2015-12-29 | Lycera Corporation | Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof |
WO2013185045A1 (en) * | 2012-06-08 | 2013-12-12 | Lycera Corporation | Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2013185048A3 (en) * | 2012-06-08 | 2014-01-30 | Lycera Corporation | Heterocyclic guanidine f1f0-atpase inhibitors |
WO2013185046A1 (en) * | 2012-06-08 | 2013-12-12 | Lycera Corporation | Saturated acyl guanid1ne for inhibition of f1f0-atpase |
US9815791B2 (en) | 2013-12-10 | 2017-11-14 | Lycera Corporation | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US10392350B2 (en) | 2013-12-10 | 2019-08-27 | Lycera Corporation | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9266839B2 (en) | 2013-12-10 | 2016-02-23 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9707211B2 (en) | 2013-12-10 | 2017-07-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US9914706B2 (en) | 2013-12-10 | 2018-03-13 | Lycera Corporation | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US10085972B2 (en) | 2013-12-10 | 2018-10-02 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
US10022320B2 (en) | 2014-03-13 | 2018-07-17 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
US10624839B2 (en) | 2014-03-13 | 2020-04-21 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
US10813902B2 (en) | 2014-03-13 | 2020-10-27 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11458115B2 (en) | 2020-11-17 | 2022-10-04 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Also Published As
Publication number | Publication date |
---|---|
WO2003050261A2 (en) | 2003-06-19 |
AU2002357137A8 (en) | 2003-06-23 |
US6916813B2 (en) | 2005-07-12 |
AU2002357137A1 (en) | 2003-06-23 |
WO2003050261A3 (en) | 2004-02-26 |
EP1450901A2 (en) | 2004-09-01 |
EP1450901A4 (en) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6916813B2 (en) | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | |
US20040009972A1 (en) | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | |
US6534535B1 (en) | Inhibitors of factor Xa | |
KR100837420B1 (en) | 5-Hydroxyindole-3-carboxylates derivatives and their use | |
US9161924B2 (en) | Factor IXa inhibitors | |
EP1048652A1 (en) | Aromatic compounds having cyclic amino or salts thereof | |
TW200403058A (en) | Heterocyclo inhibitors of potassium channel function | |
US7446210B2 (en) | Factor Xa compounds | |
JP2013121919A (en) | Plasma kallikrein inhibitor | |
JP2003500383A (en) | Factor Xa inhibitor | |
IL143303A (en) | Substituted benzimidazoles and their use as parp inhibitors | |
US6846836B2 (en) | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase | |
JP2008513387A (en) | Medicaments containing carbonyl compounds and uses thereof | |
US7429611B2 (en) | Indole inhibitors of 15-lipoxygenase | |
PL204898B1 (en) | Substituted benzene derivatives or salts thereof | |
SK8662000A3 (en) | Triazine angiogenesis inhibitors | |
ZA200300998B (en) | Compounds inhibiting factor Xa activity. | |
CA2822787C (en) | Substituted isoquinoline derivative | |
US7432271B2 (en) | Pyrazolyl inhibitors of 15-lipoxygenase | |
TW201041583A (en) | 2,5-disubstituted arylsulfonamide CCR3 antagonists | |
US20040204412A1 (en) | Phenylglycine derivatives useful as serine protease inhibitors | |
US7144895B2 (en) | Benzene acetamide compounds useful as serine protease inhibitors | |
US7317032B2 (en) | Imidazolyl inhibitors of 15-lipoxygenase | |
JP2004531494A (en) | Biurethane derivatives | |
JP2009530323A (en) | Substituted 1-amino-4-phenyl-dihydroisoquinolines, processes for their preparation, their use as drugs, and drugs containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ATWAL, KARNAIL S.;GROVER, GARY J.;DING, CHARLES Z.;AND OTHERS;REEL/FRAME:013981/0001;SIGNING DATES FROM 20030318 TO 20030408 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |